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SYNOPSIS
An Early Synovitis Clinic - Differentiating Persistent 
from Self-Limiting Synovitis
Background
My interest in differentiating between persistent and self-limiting 
synovitis (PS and SLS) developed from the Bath experience, where 
Professor Bacon and Dr Blake ran an early synovitis clinic. A 
proportion of the patients were noted (in an epidemic year) to have 
had Human Parvovirus B19 (B19) infection coinciding with the start of 
their synovitis (White DG et al. Lancet 1985; 1: 419-22). A minority 
of the B19 patients had persisting symptoms a year later adding to 
speculation on the possible role of viruses in the aetiology of 
chronic rheumatic diseases.
The other cornerstone of this work is the difficulty in diagnosing 
rheumatoid arthritis (RA) in very early disease. This is revealed in 
the requirement of the standard diagnostic criteria for symptoms to 
be persistent and was hinted at in the Bath study where the pattern 
of joint involvement in B19 patients was very similar to RA. Thus 
viral arthritis might offer itself as a (usually) self-limiting model 
of RA, permitting a search for variables predictive of persistence 
which might also be relevant in understanding the pathogenetic 
mechanisms of persistence.
Aims
An early synovitis clinic was established with a view to:
- identifying clinical or laboratory variables which might 
predictively distinguish at an early stage those with RA from those
22
with self limiting disease.
- considering the pathogenetic relevance of any such variable, with 
particular reference to the role of virus in early synovitis.
Methods
Target patients were those with less than six months of synovitis, 
recruited by means of circular letter to General Practitioners.
Clinical and laboratory variables were recorded on a standard 
proforma designed for computer analysis. Selected variables were 
monitored at subsequent visits, patients being followed until either 
symptoms disappeared or until a definite diagnosis declared itself.
The proforma includes an itemised clinical history, examination and 
routinely available laboratory tests. In addition, serum was banked 
at each visit and, where appropriate, lymphocytes were stored on 
freeze dried slides for surface marker studies. Analysis was by 
applying non-parametric tests to single variables, comparing PS with 
SLS. Analysis was extended to Stepwise Variable Selection, a form of 
multiple logistic regression, applied to the clinical variables in 
the search for the most predictive combination of the least number of 
variables.
Results:
These refer to data obtained at first visit only, analysed on the 
basis of subsequent outcome.
Clinical
Analysis of 114 patients reveals three approximately equal sized 
groups: Persistent Synovitis (PS), and self-limiting synovitis (SLS), 
both with patients having symmetrical, peripheral, polyarthritis 
similar to RA, and "Others" (having nothing by history or examination
23
to suggest RA, and including patients with psoriatic arthritis, 
ankylosing spondylitis, osteoarthritis and the like). Clinically the 
PS and SLS were found to be similar (by onset, pattern of joint 
involvement, duration of symptoms, even ARA criteria) at first visit 
to the clinic but by around three months symptom duration the SLS 
patients had all undergone spontaneous remission. Although 
differences (severity, height of acute phase response, rheumatoid 
factor et al) can be observed retrospectively between these two 
groups, they would be difficult to apply to a new cohort of patients 
because of overlap between the groups. The main conclusion is that 
although traditional variables eventually separate the groups, in the 
early stages the similarities are greater than the differences.
T-Lymphocytes
I collaborated with colleagues in this department to study T- 
lymphocyte subsets in SLS and PS. We measured CD4:CD8 ratios both in 
the whole blood and within the activated (transferrin receptor 
bearing, TFR+) cell population. Within the whole peripheral blood, 
the ratio did not differ between the two groups but the number of 
TFR+ cells was higher in PS than in normals or in SLS. Within the 
activated, TFR+ population the ratio in PS was higher than in SLS.
This increase in the ratio was due to higher numbers of CD4+, TFR+ 
cells in PS with no overlap with SLS. There was no difference in the 
numbers of CD8+, TFR+ cells between the two groups.
Rheumatoid factor: the antibody and its antigen.
Rheumatoid factors (RF) are seen in RA but also during the course of 
many infections. I have collaborated with colleagues in the 
Department of Immunology to define quantitative and qualitative 
variation in RF between SLS and PS. An overall quantitative
difference was found with PS patients as a group having higher RF 
levels, irrespective of the IgG subclass used in the assay. In these 
patients with very early disease, however, quantitation of RF is of 
limited predictive value because of the overlap between the groups In 
PS we also found greater diversity of idiotypic expression, inviting 
speculation on the role and control of gene rearrangement and somatic 
mutation. These qualitative observations may enhance our 
understanding of the pathogenesis of persistence of synovitis.
We also looked at fluorescent IgG as a possible marker of damaged IgG 
but the results showed no difference between SLS, PS and normal 
subjects.
Virology
Simple viral serology was performed, to be evaluated in relation to 
disease duration at first visit. Interestingly, in a non-epidemic 
year, Human Parvovirus B19 (B19) accounts for very few cases of acute 
arthritis. Six patients were identified as having had B19 near the 
start of their arthritis, of whom five were allocated to the SLS 
group and one to PS. In single patients it has been possible to send 
tissue to colleagues for molecular probing, seeking the persistence 
of virus but none was found.
Discussion
The similarity in symptoms between the two groups indicates elements 
of inflammation in common, suggesting that the SLS group of patients 
might offer themselves as a model for the study of PS and hence for 
the study of RA. There are also differences between the groups, 
particularly in the numbers of activated T-helper lymphoctyes and in
the apparent somatic mutation underlying the IgMRF results: the 
possible underlying mechanisms are discussed. I have shown that in 
turn B19 arthritis is representative of the SLS group of patients and 
thus B19 offers itself as a human model for the study of RA. I have 
discussed the implications for further work based on the use of B19, 
with its defined protein structure, to study the responses of the 
immune system to specific antigens, in individuals of defined Human 
Leukocyte Antigen phenotype.
CHAPTER 1 
INTRODUCTION AND HISTORICAL REVIEW
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CHAPTER 1
INTRODUCTION AND HISTORICAL REVIEW
1.1 Aims
The aim of this thesis is to study patients afflicted with 
symmetrical peripheral polyarthritis within the first 6 months of 
their disease. The hope is to find ways of predicting those who will 
recover spontaneously (Self Limiting Synovitis, SLS) and those whose 
disease will become persistent (Persistent Synovitis, PS).
1.2 Introduction: SLS versus PS
Rheumatoid Arthritis (RA) is a disease of unknown aetiology and is 
probably heterogeneous in its manifestation. At its simplest it is a 
disease defined by its persistence and recognized by its crippling 
sequelae. There is much interest in seeing RA early because it may be 
during the onset of the disease that definable pathogenetic 
mechanisms will be separable from phenomena which, although well 
recognized in established disease, may be a consequence of the 
disease rather than its cause. This however leads to a potentially 
circular difficulty because the interest is in the initiation of a 
disease whose definition requires persistence. One way out of this is 
to study during initiation all of those diseases which may 
potentially evolve into RA. Depending on how widely one initially 
casts the net this approach is likely to reveal three groups of 
patients. The first is eventually recognisable as RA: to avoid 
pedantic debate about the timing of applying the label of RA, I shall 
in this study refer to patients in this evolving group as having 
"Persistent Synovitis" (PS). The second group includes diseases which 
also persist but evolve into recognisable diagnoses distinct from RA
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"Others". Previous studies have shown that a third.group of patients 
evolves from those presenting with symptoms initially suggestive of 
RA but which resolve spontaneously within a sufficiently short time 
to traditionally preclude them from being defined as having RA. I 
will refer to these patients as having "Self-limiting Synovitis" 
(SLS). While many of the latter group never have a definitive 
diagnosis made, recent studies have revealed a significant proportion 
of them have suffered a recent viral infection. Consequently, much 
interest has been shown in trying to confirm.the association of 
specific viruses with definable patterns of arthritis. As discussed 
below, most arthritis convincingly associated with viral infection is 
both of the self-limiting type and initially mimics the earliest 
stages of RA. Thus virus induced SLS might offer a human disease 
model of some aspects of RA but with the crucial absence of 
persistence. A comparative study of SLS and PS in their earliest 
stages offers the potential for finding variables which will 
discriminate between the two groups. Such discriminant variables 
would offer the opportunity to predict persistence and might even 
offer insights into the pathogenesis of persistence.
Since it is crucial to the concept of comparing two groups of 
patients, I will now briefly review the way in which the definition 
of RA has evolved in an effort to define a reasonably homogeneous 
entity. I will also review the justification for associating viruses 
with arthritis, particularly SLS.
29
1.3 Historical review
1.3.1 Rheumatoid arthritis
Over the last 30 years we have gradually come to accept that it is 
easy to make a diagnosis of RA in a patient suffering a symmetrical 
peripheral polyarthritis in association with subcutaneous nodules and 
erosive joint damage. This confidence has been due mainly to the 
international acceptance of two sets of diagnostic criteria for the 
diagnosis of RA, that from the American Rheumatism Association (ARA)1 
and that named after a symposium held in New York2. However those 
publications are but recent highlights at point time in the still 
evolving understanding and definition of RA and its close mimics.
There is debate about how far back in time can be traced the origins 
of the disease which would meet our current definition of RA' .
Bearing in mind that failure to find written or skeletal evidence 
does not prove that it did not previously exist, the earliest
3a.descriptions of RA are believed to have begun in the 17th century .
It was more than a century later that the disease resurfaced in the 
literature in a detailed case history30. Perhaps the gap in time 
reflects the relatively poor communications and indeed the priorities 
of physicians before the advent of sanitation, antiseptics and 
antibiotics. It was later in that 19th century that the term 
"Rheumatoid Arthritis" was introduced4 but even then this may have 
arisen mainly because of its importance in the differential diagnosis 
of Rheumatic Fever: in that context RA could be regarded as having a 
relatively benign prognosis.
There is, of course, an important distinction to be drawn between the 
strength of descriptions of individual cases and the reliability of
prognostication based on observations of wider populations of 
patients with arthritis. In order to understand a single disease, it 
is necessary to try to describe a population of patients with a 
homogeneous pattern of clinical features. The passage of time tends 
to increasingly refine a diagnostic label and earlier populations are 
seen to include more than one disease. Thus gout diluted early 
descriptions of RA3a. Ankylosing Spondylitis was, as recently as 
1957, regarded as a variant but nevertheless real part of RA5. The
-I
acceptance a year later of the ARA criteria for the diagnosis of RA 
set the currently recognized picture of RA, with the symmetrical and 
peripheral characteristics being emphasised. Although pre-dating our 
understanding of the human leukocyte antigen (HLA) system the 
seronegative, asymmetrical, axial and oligo-arthritides (eg 
ankylosing spondylitis, psoriatic arthritis) were able to be excluded 
on clinical grounds. Those exclusions were later justified when their 
association with the HLA B27 phenotype was recognized6 and then the 
association of RA with HLA DR4 was noted7. In an attempt to improve 
the still emerging picture of RA, the New York criteria were 
introduced2.
The relative strengths of the ARA and New York criteria are 
sensitivity and specificity respectively. One effect of this 
polarisation is to lead to the prevalence of RA differing according 
to which criteria are used to define the afflicted within the study 
population. In a proper population study (as opposed to a report on 
hospital attenders) both the ARA and New York criteria were used to 
define the prevalence of RA in the community of Sudbury, 
Massachusetts8. Both sets of criteria were applied at the start of 
the study and again at follow-up examination 3 to 5 years later. Of 
the 4552 subjects {lit of the possible subjects aged between 15 and
31
75 years) RA was initially diagnosed in 3.8% of the women and 1.3% of 
the men by ARA but in only 0.5% and 0.1% respectively by the New York 
criteria. The follow-up concentrated on those in whom RA had been 
diagnosed by either system. For those initially with RA by ARA, some 
70% no longer satisfied the criteria. In contrast, of those initially 
diagnosed RA by New York criteria, nearly 70% still had the disease 
by the same criteria at the later assessment. Those authors concluded 
that the New York criteria identified a more meaningful disease.
Looked at from the opposite viewpoint, that study places in sharp 
focus those patients with initial symptoms who then recovered: 
arguably similar to the SLS group in this thesis. A number of 
interesting questions are raised.
The SLS patients recover: is this not desirable, and why can those 
with PS not do so? Is there an absolute difference between those with 
SLS and those with PS, or is it a gradient? "What is SLS? Where 
exactly does RA fit: as well as PS, can RA behave in the SLS manner?
When is SLS not RA: only when there is an identified viral infection? 
Would that exclusion be valid if eventually RA was shown to be caused 
by a virus?
Most early synovitis clinic reports concentrate on the persistent 
diseases such as RA. I would now like to review what is known about 
the aetiology of SLS, in particular the viral arthritides, to see 
whether any information can be gleaned to help the understanding of 
RA where the aetiology is unknown. That done I will then review the 
information about RA which has been gleaned from early synovitis 
studies.
/
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1.3.2 Viruses and arthritis
In this part of the historical review it is intended to: 1) establish 
that viral arthritis is a reasonable model for RA with the crucial 
distinction that viral arthritis is not (usually) persistent.
2) review the evidence for the implication of individual viruses in 
causing arthritis, with particular attention to the strength of the 
techniques used.
What clinical patterns of arthritis can viruses produce?
Leaving aside those demonstrably due to intra-synovial bacteria and 
possibly to crystals, the inflammatory arthritides irrespective of 
aetiology can initially be allocated to one of two groups: either the 
symmetrical peripheral polyarthritides, such as sero-positive RA; or 
the asymmetrical oligo-arthritides, classically sero-negative for 
rheumatoid factor and associated with an over-representation in 
sufferers of the HLA B27 positive phenotype6. Although the virus- 
associated arthritides are usually sero-negative, the clinical 
picture (detailed below) is usually different to the classical sero­
negative spondylo-arthropathies. High prevalence of HLA B27 subjects 
in the post viral arthritides has not been found: one small study 
hinted at a possible association when 4 out of 5 patients with 
chronic arthritis after Chikungunya infection were found to be B27 
positive9. However, this was not confirmed in a larger study of 
similarly afflicted subjects10. In addition the prevalence of 
arthritis occurring after a viral epidemic or vaccination program is
much greater than the prevalence of the B27 phenotype in the 
11population and the B27 phenotype was not over-represented in 
patients with viral arthritis12. Those limited reports of viral 
identification in the presence of, for example, ankylosing
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spondylitis13, will be evaluated in more detail below. Those
arthritides which are known to follow virus infections, typically in
epidemics, tend to be symmetrical, peripheral, self-limiting and
without enthesitis or spondylitis. An example would be those
associated with the Togavirus infections discussed in detail below.
Genetic factors in the viral arthritides should not be dismissed
since there is emerging evidence that within those who do develop a
post-viral arthritis, eg human parvovirus, severity and persistence
12of the arthritis may be associated with specific HLA DR phenotypes 
and it may be that studies at or near the DR~locus will prove 
helpful. Thus the pattern of arthritis associated with viral 
infection is more akin to that seen in RA than in the B27 
asymmetrical oligoarthritides.
Do viruses cause arthritis?
Great caution is required in evaluating the evidence of viral 
involvement in any arthritis. Simply identifying viral proteins in a 
joint by immunofluorescence does not prove the presence of intact, 
viable, functioning and infectious virion. Even identifying virion by 
electron microscopy and showing its infectivity by co-cultivation 
experiments, thus demonstrating presence in a joint, does not prove a 
pathological role for that virus in that joint. The virus may simply 
be an irrelevant passenger if it is using as host a cell (eg a 
macrophage) which has been called to the site by other signals. Thus 
the hypothesis that an arthritis may be the result of virus-host 
interaction, will require careful evaluation of temporal association, 
specificity of host response and biology of the implicated virus.
Rubella is one of the most studied of the viruses implicated in
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arthritis and the evidence for its implication will be reviewed in 
detail and then the evidence for other viruses will be outlined.
1.3.3 Togaviruses - Rubella. Chikungunya, etc.
The Togaviruses are enveloped, single stranded RNA viruses. The 
family includes the genera: Alphavirus, Flavivirus, Rubrivirus and 
Pestivirus. The Alphaviruses (group A arboviruses) include 
chikungunya (CHIK), 0 ’nyong-nyong and Ross River. The Rubrivirus 
genus includes Rubella. These named viruses are all implicated in 
human arthritis syndromes and are now discussed further to illustrate 
the current state of knowledge of mechanisms of virus induced 
arthritis. They are of course not the only viral agents described in 
relation to arthritis.
Rubella - clinical evidence:
Acute arthritic syndromes following wild Rubella infection are well 
described and are probably common - but because of the frequently 
mild nature of the musculo-skeletal manifestations and the occurrence 
of sub-clinical Rubella infection, it is difficult to arrive at a 
reliable figure for the frequency of this post-viral complication. In 
one study of those who had clinically apparent Rubella, the incidence 
of objective arthritis was reported as 30% with a further 30% having 
arthralgia14. Figures for post Rubella-vaccination (women only) are 
probably more accurate; the same study observed arthritis in 14% and 
arthralgia in 41% of vaccine recipients. Care should be taken with 
such figures since post-Rubella joint symptoms are rare in children 
and increase in frequency in adulthood. However, the mean age in the 
wild and vaccine groups was similar (19 and 23 years). The study also 
highlighted a feature of many studies of viral arthritis, that women 
are more severely affected than men. The wild group contained equal
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numbers of men and women but objective arthritis was seen more often 
in women (52% versus 9% in men). Symptoms were observed to start 9 to 
27 days post vaccination and it is suggested that in wild infection 
the onset of arthritis occurs within one week of the appearance of 
the rash. The duration of joint symptoms was variable. Although most 
settled within 2 months, continued symptoms were seen at 18 months in 
5% of the (all female) vaccine group and in 30% of the women and 9% 
of the men in the wild group. Thus for the great majority of those 
who develop post Rubella arthralgia or arthritis this is short lived, 
ie SLS.
However, if this thesis is to regard viral arthritis as short lived 
then it is important to evaluate the very small amount of evidence, 
derived from a small number of cases, which is used to implicate 
viruses in more chronic arthritis. Chronic polyarthritis following 
Rubella or Rubella vaccination has been described, lasting up to 6 
years15. The severity of symptoms is not easy to assess from these 
papers. The usual pattern seems to be one of relapse and remission
1 fi 17but in two other reported cases ' the clinical picture was 
sufficiently severe and persistent to meet the ARA definition of RA. 
Although both of these cases were well documented as having severe 
persistent disabling symmetrical peripheral polyarthritis and became 
sero-positive for Rheumatoid Factor, neither had subcutaneous nodules 
or erosions on X-ray, perhaps suggesting the diagnosis belonged to a 
sub-group of "RA".
In addition to epidemiologic observations, measurement of host 
response is widely used to seek evidence of viral causation.
Rubella - antibodies:
The B-lymphocytes may be producing specific anti-viral antibody. The 
anti-Rubella antibody profiles immediately following an acute Rubella 
infection are conventional irrespective of whether the subject 
develops arthritis18: as measured by the conventional 
Haemagglutination Inhibition (HAI) titres the IgM antibody shows a 
transient rise, falling back to pre-exposure levels by 6 months. The 
IgG rise is long-lived. The ability of virus to persist despite 
circulating antibody has been shown in the congenital Rubella 
syndrome19. In the two clinical cases of severe post-Rubella 
polyarthritis described above16,17, although persistent virus was not 
seen (not sought in one, limited search in the other), there were 
persistently high HAI titres, including high levels of the IgM class. 
This finding of persistently high titres of anti-Rubella antibody 
raised two initial questions: (1) might this suggest persistence of 
the Rubella antigen in post-viral arthritis? (2) Could such high 
titres be found in other patients with persistent arthritis without 
any apparent temporal relationship to a recognized Rubella infection? 
The attempts to answer these have served to increase the confusion.
One serological survey showed no increased Rubella HAI antibody 
levels in RA compared with other arthritis including 
osteoarthritis20. The significance of the antibody titres was further 
challenged by another study15 of 7 patients with post-Rubella (1 
wild, 6 vaccination) persistent arthritis. Each had increased 
Rubella-specific cell-mediated immunity and indeed Rubella virus was 
isolated from each patient (see below) but despite this the Rubella 
HAI titres were not elevated in any of the patients. These negative 
HAI results are in marked contrast to those reported13 in 6 patients 
with persistent inflammatory oligo- or polyarthritis (and from each
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of whom Rubella virus was isolated* see below), where the HAI titres
were elevated (to Rubella but not to other micro-organisms tested)
but there was no apparent history of recent Rubella. It may be
relevant that in these patients the Rubella specific IgM was usually
absent, even at times when virus could be isolated. Perhaps the
answer to the relevance of antibody titres . to arthritis lies in a
18prospective immunological study of post-Rubella arthritis , where 
although HAI titres were elevated to levels comparable with those of 
the previous study, there was no difference between those who did and 
those who did not develop arthritis. Whilst it may be invidious to 
compare results from clinically different arthritides, it is clear 
that for the study of mechanisms (including possible persistence) of 
arthritis induced by a given virus, the simple study of antibody 
levels will provide more questions than answers. Thus, in a patient 
at point time, a high titre of a specific anti-viral IgM antibody may 
indicate recent infection OR some form of persistence. A low titre 
may indicate no recent infection with that virus OR that the IgM rise 
and fall has already been completed.
Of potentially greater importance than observations on post­
infection/vaccination serology are the findings in the pre-
18vaccination serology. In the study mentioned above patients had 
been selected for vaccination on the traditional basis of HAI 
negativity. A separate Enzyme Linked Immunosorbent Assay (ELISA) 
technique for anti-Rubella antibody was also employed pre-vaccination 
(together with lymphocyte reactivity). The ELISA results suggested 
that 732 of these HAI negative women had some pre-vaccination 
immunity to Rubella (or to a similar antigen?). Moreover, such status 
appeared to confer an increased risk of post vaccination arthritis 
(although the numbers developing arthritis were small). It is
interesting to note that one of the patients who developed a 
transient arthralgia post vaccination, did not sero-convert as judged 
by HAI but did produce high levels of the ELISA detected antibody. It 
was therefore suggested that the arthritogenic infection in these 
patients was a second meeting of the virus. Since in the ELISA the 
antigen was fixed to plastic, concern may be expressed that the 
quaternary structure of the antigen may be altered in the process: 
this in turn might question the in vivo relevance or specificity of 
an antibody detected in this manner. However there is corroborating 
evidence for the role of second exposure in generating arthritis from 
the goat model of symmetrical proliferative erosive arthritis 
produced by a retrovirus, the caprine arthritis encephalitis virus 
(CAEV). Essentially the production of arthritis in goats given live 
virus is enhanced in those animals previously exposed to the virus, 
either naturally (live, wild virus) or by vaccination with 
inactivated virus21.
Rubella - Immune Complexes:
If simple antibody levels do not discriminate between SLS and PS (or 
even select for those who do develop arthritis), is it possible that 
there are some qualitative differences in the antibodies formed as 
the pre-immunity ELISA data would hint? For example, do some patients 
more readily produce immune complexes (IC)? When the Vancouver group 
examined this question in their acute post-Rubella (wild or 
vaccination) arthritis subjects22 they were able to detect IC, using 
both Clq binding and Raji cell assays, in both those who did and 
those who did not develop arthritis. Although the levels tended to be 
higher in the arthritis group (as opposed to arthralgia or no 
symptoms), this reached statistical significance only for the Raji 
cell assay at 6 and 12 weeks post immunization. However, "clearly
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raised circulating IC levels" were seen in entirely asymptomatic 
individuals, so the biological relationship of circulating IC to the 
arthritis is not clear.
Tissue deposition of IC might be more relevant in pathogenesis. This 
is not easy to study in SLS after viral infection since, by 
definition, it is short-lived and usually too benign to merit 
invasive investigation. Immunofluorescent studies of synovial fluid 
cells and synovial biopsies were performed as part of an
13investigation of chronic seronegative inflammatory oligo-arthritis .
In addition to identifying Rubella antigen (see below), the sections 
stained positively for IgG and, in some, also for IgM. C3 could also 
be detected in some sections and the synovial fluid C3 levels were 
low compared to those in serum, suggesting Complement consumption by 
IC. It was not exactly clear where (in or around which cells) the 
antigen and immunoglobulins were found but the authors concluded from 
the staining pattern that the virus particles were predominantly 
extracellular; that the immunoglobulin and Complement findings were 
consistent with local IC deposition; and suggested that these IC 
might block receptors on phagocytic cells, preventing the uptake of 
the virus.
Rubella: T-lymphocyte reactivity:
T-cells are also used as tools in the hunt for the virus in chronic 
arthritis. Several authors have used the technique of challenging 
peripheral blood lymphocytes (PBL) or synovial fluid (SF) cells with 
specific antigen and found that in some patients, their lymphocytes 
respond to the test antigen by proliferation. Most control their 
studies by showing negative responses to other antigens. The 
attractive deduction is that the observed responses are antigen
specific. This leads on to models of foreign antigen persistence with
chronic immune stimulation; or of molecular mimicry between viral and
auto-antigens. How strong are the data on which such discussions are
based? The group in Vancouver have produced a series of related
publications. These support the existence but not the relevance of
pre-vaccination immunity. In contrast to their data on ELISA detected
antibodies, no increased lymphocyte reactivity could be demonstrated
pre-vaccination in recipients who subsequently developed arthritis
18compared with recipients who did not . Indeed lymphocyte responses 
were judged to be positive in around half of the patients in each of 
their three outcome groups: arthritis, arthralgia or no symptoms. 
Post-vaccination, those with arthritis or arthralgia had higher 
"stimulation indices" than the asymptomatic group at 6 weeks but not 
at 6 months. That prospective study makes it difficult to interpret 
the same group’s more anecdotal observations on 7 women with post 
Rubella arthritis who were found to have high lymphocyte 
responsiveness to Rubella antigen (compared with 5 symptomless 
vaccine recipients) up to 6 years after infection15. In a further 
detailed case report23 these authors followed the lymphocyte 
stimulation index over time in one patient with a sero-negative 
inflammatory arthritis (which began at least 12 years after a 
possible episode of Rubella). A correlation was seen between the 
presence of Rubella virus (blood and synovial fluid), synovial 
lymphocyte (but not PBL) reactivity to Rubella antigen and the 
clinical severity of the synovitis. Despite the fascination this begs 
the question: does the Rubella virus have an aetiopathologic role in 
this context or is Rubella simply utilising for its replication 
metabolically active cells - including eg those involved in 
synovitis? A high stimulation index to Cytomegalovirus was also found 
in this patient and questions the specificity of the Rubella data, as
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does the further work of that group on other viruses ’ . In these
studies lymphocyte responsiveness, expressed as a stimulation index, 
was measured over up to three years in patients with RA. Increased 
responsiveness was reported to a number of viruses including 
adenovirus, mumps and cytomegalovirus perhaps with some differences 
between sero-positive and sero-negative RA. Interestingly, these 
patients did not have increased responsiveness to Rubella! Perhaps 
these RA results say more about the control of B-cells in sero­
positive disease than about viral involvement.
The difficulty in interpreting much of the Vancouver data has been 
well reviewed recently26. The main problem is that the lymphocyte 
responses reported were not shown to be specific for a given virus, 
either within a given patient or across a group.
Rubella - Isolation of the virus:
If anti-viral antibody levels and lymphocyte reactivities serve to 
heighten interest in virus-associated chronic arthritis but fail to 
prove the association or define the markers or mechanisms of the 
problem, then is viral identification more specific? Clear 
distinction must be drawn between isolation of virus as intact 
infectious virion (as from co-cultivation with permissive cell lines, 
possibly visualizing by electron microscopy) - and identification of 
viral antigen (eg by immunofluorescence) which may or may not 
represent intact virion. In addition distinction should be made 
between identification sites: ie peripheral blood versus synovial 
fluid or cells. Even if whole virus is identified distinction has to 
be drawn between replicative forms indicating synthesis of the virus 
in that particular cell as against intact virus which may have been 
made by that cell but could simply have been sequestered, as might
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happen with a phagocytic cell. Finally a clinical distinction: some 
reports refer to acute arthritis after Rubella (acquired naturally or 
by vaccination) but others refer to patients with chronic arthritis, 
some apparently unrelated to Rubella by history.
That the virus can persist in the congenital Rubella syndrome has 
already been mentioned19. It tends to be assumed that Rubella virus 
does not persist in normal subjects after an acute infection: this is 
supported by the negative isolation attempts in normal subjects
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quoted as controls by some authors ’ .
Beginning with acute post Rubella arthritis, there are very few cases 
of isolation of the virus in the synovial fluid, reflecting the 
usually mild or transient clinical course. The first report was in a
97child with naturally acquired disease and this was followed by the
no
report in an adult post vaccination . In a detailed report on three 
patients with arthritis after naturally acquired Rubella29 the virus 
was detected (by cytopathic effect in co-cultivated target cells,
CPE) in the synovial fluids at 1 to 5 days after the first Rubella 
symptoms. It is interesting to note that, in one of these cases, the 
synovial fluid cell count was elevated: Rubella antigen was 
identified by immunofluorescence in 45% of the cells but electron 
microscopy failed to find any Rubella virion.
Turning to chronic arthritis and firstly to that which can be 
temporally related to Rubella: 7 patients with arthritis subsequent 
to infection (natural in 1 case, vaccination with the attenuated but 
live virus in 6 cases) have previously been mentioned in regard to
1 Htheir lymphocyte studies . Rubella virus was isolated, as defined by 
CPE, from their peripheral blood lymphocytes in 6 of the 7 cases, up
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to 6 years post infection/vaccination. (It will be recalled that 
these were the patients who had normal serum Rubella antibody levels 
by HAI but increased lymphocyte responsiveness to Rubella). Those 
authors were unable to isolate Rubella from the peripheral blood 
lymphocytes from non-arthritic antibody-positive adults or from 3 
cases of congenital Rubella. However they did find that in the above 
6 patients in whom Rubella virus could be identified, this was 
possible even during periods when their arthritis was in remission. 
This finding does not entirely support their conclusion that the 
ability to identify virus was related to the pathogenesis of the 
arthritis.
Rubella virus has also been identified in a very small number of 
patients with chronic arthritis not apparently related to any history 
of Rubella13,23. The former presented 6 cases of seronegative, 
inflammatory oligoarthritis and apparently identified Rubella virus 
on at least one occasion in each patient. The viral antigen was 
detected in synovial fluid cells (mainly lymphocytes) by 
immunofluorescence. In one of their cases electron microscopy 
revealed intracellular Rubella-like particles though the phylogeny of 
the cells was not given. It is interesting that a control group of 
patients with other rheumatic diseases did not have evidence of 
Rubella virus persistence; however it was not indicated whether those 
included patients with active inflammatory synovitis. On the other 
hand, any dismissive suggestion that Rubella might be found in the 
synovial fluid of any inflamed joint would have to.be tempered by the 
finding, in the virus-bearing patients, of coexisting high anti- 
Rubella titres (with negative serology for control viruses). The 
second paper23 detecting Rubella virus in chronic arthritis 
(temporally discrete from any apparent Rubella) was the single case
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report previously mentioned as showing a correlation between the 
appearance of virus, lymphocyte responsiveness and clinical severity 
of synovitis. Here the virus was identified by co-cultivation of 
donor cells with target cells; in the targets CPE was not seen but 
viral antigen was identified by immunoperoxidase method; in addition 
the culture medium contained "plaque forming virus". This was true 
for donor cells from both peripheral blood and from the synovial 
fluid mononuclear cells: it must be difficult to ensure that no blood 
contaminates synovial fluid.
Rubella - Discussion of the evidence:
There is little doubt that the above publications contain positive 
observations. There is good evidence to link to Rubella with some 
cases of acute, self-limiting synovitis (SLS): by clinical 
association, by acute response antibody levels and by virus 
isolation. The problem lies in the interpretation of the data 
relating to chronic arthritis. Rubella virus has been identified in a 
small number of patients with chronic arthritis, at least in 
peripheral blood and possibly in synovium. Whether virus is 
identified in synovial fluid as a result of contamination with blood 
during sampling remains contentious. Specificity is not a strong 
virtue of much of the host response data and it is apparent that 
there is a range of different arthritides encompassed by some of the 
phenomena described. This might suggest that viral identification or 
implication could be a secondary phenomenon of inflammation rather 
than its cause. It would appear that Rubella has a special place in 
this context even though some of the lymphocyte data would point also 
at other viruses. This may reflect the position of Rubella as the 
commonest Togavirus in European or European emigrant populations and
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should be viewed in the light of information.on arthritis and other 
Togaviruses in Africa and Asia (see below).
Chikungunya (CHIK)
The Rubella data is enhanced by some remarkable parallels in other 
Togaviruses such as CHIK.
CHIK - Clinical association:
This arbovirus is mosquito borne and can cause sporadic or more 
commonly epidemic disease in man. There are close similarities with 
the diseases caused by other arboviruses of the Togaviridiae 
including O ’nyong-nyong and Ross River. First described in Tanganyika 
in 195530, the acute illness, of about 10 days duration, is 
characterised by fever, rash and joint pains. In addition there may 
be lymphadenopathy, headache, conjunctivitis and gastrointestinal 
symptoms. In the acute phase the joint pains are accompanied by 
objective symmetrical polyarthritis including swelling. Because of 
the absence of asymptomatic controls it is not certain what 
proportion of those who are infected with CHIK will develop 
arthritis. Of those who have (any) symptoms and have the disease 
proven by rising titres of specific antibody, 732 have 
musculoskeletal manifestations9. Although "short-lived" in most, the 
joint symptoms resolve slowly (months) in some patients and in around 
52 arthritis including swelling was still present after 3 years31.
Like Rubella, the symptoms tended to be more severe and persistent in 
adults than in children, although one of those with symptoms lasting 
3 years was aged 16y. These reports drew attention to the 
similarities between a few patients with severe persisting symptoms 
and RA: the assertion that they closely mimicked RA is of interest
46
but not beyond dispute. There are no reports of association of this 
virus with chronic arthritis without a history of infection.
CHIK - Antibodies and Virus Isolation:
CHIK virus specific antibody is identified by rising HAI titres, with 
high values persisting in those with persisting arthritis in one 
small series31. This might suggest that the CHIK virus can persist in 
the human host but those authors were unable to culture the virus 
from either the serum or synovial fluid of these particular patients. 
The virus has been cultured from the serum of patients with arthritis 
in the acute phase after CHIK infection but not from those with
qi
chronic arthritis . As yet there are no reports of it being cultured 
from either circulating lymphocytes or from synovial fluid.
1.3.4 Parvovirus
One can conclude from the above Togavirus studies that the clinical 
data implicating these viruses in inflammatory arthritis is stronger 
than the data arising from the laboratory investigations. It will be 
interesting to see whether the laboratory investigation of newly 
implicated viruses, such as the human Parvovirus B19 (B19), will 
provide clearer answers. This small, naked, single stranded DNA virus 
is becoming quite well characterised with the cloning33,34 and 
sequencing35 of the genome. Its association with the childhood 
exanthem Erythema Infectiosum (Fifth Disease) and with aplastic 
crises is now well known36.
The possibility that the virus may persist in the host long after the 
initial infection, is currently being explored. Only one case of 
persistence of B19 has been reported in a child with severe combined
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immunodeficiency37. One further case report purported to show (by 
dot-blot DNA hybridisation) B19 persistence in the synovium of a
OO
patient with synovitis but the report lacked such details as the 
duration of the symptoms and whether there was concurrent viraemia. 
The virus could persist either free in the infected cell (primarily 
the erythroid stem cell in the case of B1939 or incorporated into the 
host genome. Those Parvoviruses whose genomic structure includes 
palindromic terminal sequences (characterised by formation of 
"hairpin ends") are theoretically capable of persistence by 
incorporation into the host genome40. The human Parvovirus B19 genome
qr
has such a structure but incorporation has not yet been shown.
The association of B19 with arthritis is at the stage of clinical
description. An inflammatory polyarthritis is seen post infection and
as with Rubella, the arthritis is probably commoner in adults than
children41 - most studies42,43 are not controlled for this variable
and have a reporting bias towards adults. The arthritis is clearly
11 42 43commoner in women than in men ’ ’ and is usually transient but 
symptoms may persist for some months in a small and diminishing 
percentage of patients. There are reports of this virus being 
associated temporally with the onset of RA based on the finding of a 
specific IgM antibody response in serum from patients with RA 
examined retrospectively44. However, evidence (detectable levels of
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specific IgG) of past infection is seen in at least 60% of adults 
and during epidemics the virus is widespread. Therefore it would be 
surprising if we did not find a few adults suffering a B19 infection 
coincident with the notoriously insidious onset of RA. Furthermore, 
it is difficult to assess from published data whether a B19 infection 
confers an increased risk of persistent arthritis. Although in one 
often quoted study42 incidence of persistent joint symptoms after a
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B19 infection was high: 3/19 ie 16%, these were patients already 
selected for having joint symptoms and furthermore, this percentage 
was not controlled by a figure for persistent arthritis in those not 
having recent B19 infection. It is not appropriate to compare the 
figures with those for RA since in the case of the three patients 
mentioned above, although they could initially have been diagnosed as 
RA according to ARA criteria1, by 3 years "persistence... was not 
associated with any long term damage or functional incapacity".
1.3.5 Viruses - In Conclusion
It is clear that the most commonly recognized articular manifestation 
of the above virus infections is a brief episode of symmetrical 
peripheral poly- arthralgia or arthritis, ie SLS. There is debate 
about the role of viruses in longer lasting arthritis, ie PS. The 
most commonly recognized form of RA (almost by definition) is a 
persistent arthritis, although it can be argued that an unknown 
percentage of SLS might have been abortive RA. While the data 
analysis which follows is based on the hypothesis that the groupings 
(PS/RA versus Viral/SLS) are broadly correct, it will be important 
during the interpretation of the analysis to consider that some 
overlap may be present. Notwithstanding the constraints on data 
interpretation, virus related arthritis may offer a human model for 
the study of those chronic and crippling arthritides whose aetiology 
remains elusive.
It is quite clear that the studies cited above, which looked at 
viruses in arthritis, used assays which had difficulty discriminating 
between infected patients with and without joint symptoms. It seems 
unlikely that those same methods would act within the arthritis group
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at an early stage to sort those destined to have PS from those with 
SLS. What methods might be used to distinguish between PS and SLS and 
thus select for early interventive treatments those with PS?
1.4 Clinical studies in identifying PS (or RA)
Why is it important to predict persistent synovitis at an early stage 
of the disease?
1.4.1 The therapeutic problem
The available treatments for RA are of limited efficacy and have 
significant cost, particularly in terms of side-effects.
First Line Drugs:
Non-steroidal anti-inflammatory drugs (NSAIDs) produce a limited
reduction in pain and stiffness on a day-to-day basis but do not
result in a reduction in serological markers of inflammation - the
acute phase proteins47. Although the common serious side-effect of
gastro-intestinal upset including bleeding is well recognized, their
ability to reduce renal blood flow has recently caused additional 
46concern .
Second Line Drugs:
These are slow-acting with the onset of any benefit not arising until 
the patient has been taking the drug for several weeks or months and 
they are defined by their ability to produce a reduction in the serum 
levels of acute phase proteins in some patients47. By inference the 
hope is that this in turn means a reduction in the disease severity
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and consequences. Certainly there is evidence showing a correlation
48between reduction in acute phase proteins and clinical well-being . 
Unfortunately, by the end of one year approximately one third of all 
patients started on such drugs will have discontinued because of 
inefficacy and an additional one third will have discontinued the 
drug because of side effects of which the two most serious are the 
marrow suppression and the protein losing nephropathy49.
In addition the best time to start treatment remains uncertain. 
Traditionally, in view of their side effects, the "second-line" drug 
treatments are reserved for patients with severe persistent disease. 
Although there is debate about the correlation between the two main 
"outcome measures" in RA ie functional capacity and joint damage seen 
on X-ray50, there is enthusiasm for attempting to preserve the former 
by reducing the latter. The evidence supporting the case for a role 
for Second Line Drugs in reducing the progression of joint damage is 
scanty indeed51. One proffered explanation is that in most patients 
the drug is started too late: it has been shown that some 45Z of 
patients have already begun to develop erosive joint damage by the 
end of their first year of symptoms, rising to 90X by the end of the
cp
second year . There is some evidence that those in whom the acute 
phase proteins have been lower (by nature or treatment?) tend to have 
less joint damage53. If joint damage correlates best with the area 
under the curve of "acute phase protein level versus time" then 
perhaps even an imperfect treatment applied early enough might reduce 
the progression of joint damage. The pursuit of this strategy 
requires the earliest possible distinction between PS and SLS since 
otherwise, at worst, those with PS will receive, too late, treatment
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which will not help and those with SLS will suffer side-effects 
unnecessarily.
1.4.2 The diagnostic problem
Unlike the mathematically discrete description of dead or not dead, 
in the rheumatic diseases the diagnosis is a continuous variable. 
Arguably the most important criterion for the traditional diagnosis 
of RA is the persistence of synovitis, which in turn depends on the 
passage of time, this in turn mitigating against optimal early 
treatment suggested above. There have been a number of studies of 
relatively early disease but before discussing those it is worth 
reviewing the two major sets of criteria used in an effort to bring a 
degree of homogeneity to the classification of patients described in 
epidemiological and therapeutic publications. It has to be borne in 
mind that these criteria were established with a view to describing 
RA and since they directly or implicitly require the passage of time 
they might not be expected to cope with the subtly different task of 
predicting persistence in very early disease.
New York Criteria2:
In addition to a history and positive examination, the diagnosis of 
RA requires either erosions or positive serology (Table 1.1). Since 
only 45% of patients have begun to show erosions by the end of the 
first year52 this criterion will fail to find at least 55% (probably 
more) of patients with RA of, for example, 6 months duration. This 
then puts pressure on the rheumatoid factor (RF) which is itself only 
positive in 70% of established RA54. Review of all of the above 
publications on viral arthritis reveals no case of viral arthritis 
with typical RA erosions except for a very few instances (single
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figures) where a virus was thought to have been present at the start 
of otherwise typical RA. As discussed below (page 60 , 54), while RF 
are found in infectious diseases these are not usually in significant 
titres. In short, in the context of synovitis of less than 6 months 
duration, these criteria will be specific but not sensitive.
Pain in three or more joints. (Proximal 
interphalangeal, metacarpophalangeal or 
metatarsophalangeal joints of one side counting 
as single joints).
Swelling, limitation of movement or subluxation 
of at least three limb joints, two of which 
should be symmetrical. (The exclusions do not 
help in the current context).
evidence of erosion of specified severity, in 
hands or feet.
positive for rheumatoid factor.
Table 1.1 New York Criteria for the diagnosis of RA (abridged) 
RA present if 1 and 2 plus either 3 or 4 are met.
American Rheumatism Association (ARA) criteria1:
In the discussion of a report on parvovirus arthritis42 the authors 
commented that 3 patients could have fulfilled the diagnosis of 
"definite RA" by the ARA criteria (Table 1.2). Perusal of that text 
and that of a simultaneous report43 suggests that even more of the 
patients might have done so. Thus these criteria are sensitive at the 
expense of specificity. The optimistic exclusion criterion "history 
suggestive of infection.." is itself insensitive42,43 and fails to 
help. To improve the specificity it has been necessary for the 
original criteria to be revised (and indeed simplified)55. These will 
be further examined in the present study.
1 History:
2 Examination:
3 X-ray:
4 Serology:
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1 Morning stiffness, more than 60 mins.
2 Pain on motion or tenderness in one joint..
3 Swelling in at least one joint for at least 6 weeks.
4 Swelling of at least one other joint.
5 Symmetrical joint swelling
6 Subcutaneous nodules
7 X-ray changes (at least peri-articular osteoporosis) typical of RA.
8 Positive rheumatoid factor
9 Poor mucin clot
10 Characteristic synovial histology
11 Characteristic nodule histology
Table 1.2 ARA criteria for diagnosis of RA (Abridged)
Number of criteria met define category: classical
RA(7);
definite RA (5); probable RA (3).
Relevant exclusions: see text
Previous early arthritis studies:
Prognostication in recent onset arthritis has been addressed in 
previous studies but the aim of those most often cited was generally 
to predict severity of outcome in cohorts of patients referred to 
hospital and selected for having RA, as distinct from taking from the 
wider community any patient with polyarthritis and trying to predict 
eventual evolution into persistent synovitis (which approximates to 
RA). Indeed Short5 specifically stated "No doubtful case was included 
in the series until, through follow-up, the passage of time had made 
clear the true nature of the patient’s illness" and "....designed to 
be representative of RA severe enough to warrant hospitalisation". 
Duthie studied the value of hospitalisation on the course of RA. 
Ragan in a retrospective study57 sought prognostic indices in 
patients presenting to hospital clinic who already had classical or 
definite RA by the original ARA criteria at the first clinic visit.
Furthermore, each of the above three studies had a definition of
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"early" which differed from this thesis. Although some of their cases 
were within 3 years of onset, they each included significant numbers 
of patients with disease durations of up to and beyond 10 years. Even 
those studies of first visit disease durations of less than one 
year58'60 refer to patients with sufficiently severe disease to 
present to hospital and again address prognosis in those with RA.
Two studies of very early disease, while addressing the question of 
prognostic indicators, have highlighted the concept of short-lived,
RA-like polyarthritis, ie SLS. The first61 deals mainly with disease 
sufficiently severe to present to hospital but included only patients 
with less than 6 months disease duration. Despite the severity, 
around half of the patients had recovered by the end of the first 
year. The second62 specifically addressed the question of the outcome 
of early synovitis: persistent or transient. Interestingly the 
conclusions are broadly in agreement with those studying established 
disease. The best predictor of persistence was the presence of a 
positive RF; the best predictor of transience was a positive 
diagnosis of the specific viral infection, B19 parvovirus. However 
the value of these variables is arithmetic and not absolute: it will 
be recalled that B19 may be involved in persistent synovitis (page 
47) and RF is not always detected by routine methods ab initio .
Despite the reservations, the prognostic indicators derived from the 
above studies will be relevant to this study-since they will (if 
detectable early enough) define those with most severe disease, ie 
define a subset of PS. They may also point the way to more sensitive 
tests for use in very early disease. There is broad agreement on some
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of their suggested prognostic indicators, dispute on others:(Table 
1.3)
GOOD BAD
Acute onset Joint erosions
Disease of < lyr Continuous disease activity
Age < 40yrs Extra articular manifestations
Male Rheumatoid nodules
Rheumatoid factor
Poor grip strength
Many joints affected
Many ARA criteria positive
Raised ESR
Poor functional status
Table 1.3 Prognostic features in RA: summary
From the table it is clear that many of these prognostic criteria are 
interdependent. It would seem that within those patients diagnosed as 
having RA, a poor prognosis is likely for the those who already have 
severe, persistent disease. In the context of patients with 
polyarthritis of very recent (less than 6 months) onset arthritis, 
the first 4 criteria on the BAD list are likely to be rare, ie more 
specific than sensitive. The discriminatory value of these listed 
variables will be considered in this study.
1.5 T-Cells
1.5.1 Introduction
Thymus derived T-lymphocytes have been implicated in the pathogenesis 
of RA by many authors using a number of techniques. Furthermore the 
apparent association of severity and persistence of viral arthritis 
with specific HLA Class II phenotypes12, suggests involvement of the 
T-helper lymphocytes to which Class II molecules present antigen .
In patients with RA, increased numbers of activated lymphocytes are 
found in the peripheral blood as shown by the increased numbers of 
circulating immunoblasts64. The circulating lymphocytes in RA 
patients show increased incorporation of tritiated thymidine 
(indicating increased nucleic acid synthesis) compared with normal 
control subjects65 and increased levels of low-density lymphocytes 
(with unfolded chromatin and hence activated) are also found66. At 
the local site of inflammation, the synovium, there is infiltration 
with lymphocytes which are predominantly activated CD4 helper/inducer 
cells67. Removal of recirculating lymphocytes by either thoracic duct 
drainage68 or by lymphopheresis69 produces significant, if transient 
clinical improvement in patients with RA. A study of the activated 
lymphocytes in the peripheral blood of patients with very early 
synovitis might reveal patterns predictive of persistence of disease.
The methods mentioned above all have disadvantages when attempts are 
made to use them to look at sub-populations of activated cells. It is
difficult to use radiolabelled nucleic acid precursors to study 
individual cells. Low density lymphocytes in the peripheral blood are 
a heterogeneous group of cells, not all of which are activated70. 
Clearly, neither of the above methods of lymphocyte removal is 
selective for subpopulations.
1.5.2 Transferrin receptor bearing cells (TFR+)
All cells by virtue of their requirement for iron, express
71 73transferrin receptors on their surface during activation .
Lymphocytes express this activation marker from soon after the
activation signal is received and throughout the cycle of division, 
with peak density of receptor expression being during S-phase, in 
close temporal association with DNA synthesis74. The transferrin
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receptor can be labelled either with a monoclonal antibody to the 
receptor, 0KT975 or by loading the receptor with transferrin and
7labelling that carrier protein with an antibody . Thus if smears of 
circulating lymphocytes are made on glass slides, the numbers of 
transferrin receptor bearing (TFR+) cells can be enumerated and, 
using double labelling techniques, can be further characterised.
In keeping with the earlier information about circulating activated 
lymphocytes, raised levels of TFR+ cells have been shown in the 
peripheral blood of some patients with RA particularly during the 
onset of flares in disease activity. High levels of TFR+ cells are 
also found in patients with viral infections such as acute upper 
respiratory tract infection77.
1.5.3 Further characterising TFR+ cells
It it not possible to characterise the TFR+ cells for normal subjects 
because their number of such cells is too small to allow the double 
labelling necessary to establish subsets. TFR+ cells (in elevated 
numbers) in the peripheral blood of patients with RA have been 
characterised using cell surface markers and the subsets so obtained 
were compared with those in the whole peripheral blood mononuclear 
population (ie including resting cells) from the same subjects77. In 
keeping with their activated state, 90% of the TFR+ cells co­
expressed HLA DR antigens as compared with only 30% in the total 
peripheral blood population. The finding of 70% T-cells (T3+) and 9% 
B-cells (Ig+) was similar for both TFR+ and whole blood. Of the 
remaining 20% (null cells; T3-,Ig-) some were NK cells (Leu-7+). Thus
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T-cells form the bulk of the TFR+ cells and TFR labelling is a useful 
tool in their study.
1.5.4 Subdividing activated, TFR+ cells
The activated, TFR+ T-cells have been further subdivided and compared
7R
with the subsets in the whole blood populations . In patients with 
RA, a chronic disease, the CD4:CD8 ratios were significantly higher 
within the TFR+ population due to increased numbers of activated CD4+ 
cells. Interestingly, in patients with acute self-limiting viral 
infections the CD4:CD8 ratios have been found to be lowered, both in 
the whole blood79 and in the TFR+ population, due to increased 
numbers of CD8+ cells78.
Since some of the cases of acute self-limiting synovitis seen in an 
early synovitis clinic are virus induced, the CD4:CD8 ratio 
particularly within the TFR+ population may be an early marker of 
disease persistence. The ratio might be expected to be raised in PS 
and reduced in SLS.
1.6 B-CELLS
1.6.1 Introduction
The importance of rheumatoid factors has been discussed above (page 
51-55) purely in terms of RF as a useful predictive variable. Does 
pathogenetic relevance underlie its clinical prominence? Here the 
study of the B-lymphocytes is of peculiar interest since, as a group, 
these cells have the capacity to produce both of the 
opposing/complimentary facets of the globulin - antiglobulin system.
That is, this cell group can produce both the Rheumatoid Factor (RF) 
and its antigen, the Fc portion of IgG. If indeed this, system is
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relevant to the persistence of inflammation, then its closer study in 
early synovitis, with the opportunity to compare PS with SLS, may not 
only refine the predictive value of RF but also offer insights into 
fundamental disease mechanisms.
1.6.2 The antibody (RF)
RF - History:
Serendipity surrounded the discovery of rheumatoid factors on each of 
the almost independent occasions when the phenomenon came to light.
Waaler was in the process of testing sera from patients suspected of 
having syphilis using a complement consumption assay involving sheep 
red cells sensitized with a sub-agglutinating concentration of 
rabbit-anti-sheep IgG. When serum from a patient with RA but not 
syphilis was tested, instead of haemolysis there occurred 
haemagglutination80,81 and he repeated the observations in several 
patients with RA. He demonstrated the requirement for the sensitizing 
rabbit antibody in the agglutination: this was to eliminate as 
candidate explanation the possibility that non-specific agglutinins 
in the tested sera were directly responsible for the reaction. That 
complement was not necessary for the reaction and that the 
"agglutinating activating factor" resided in the globulin fraction of 
the serum was also shown in the sajne work. After the Second World 
War, while testing the serum of a patient with Rickettsial Pox using 
a haemolysis assay (to confirm the infection) there was observed 
instead haemagglutination: the patient was known to suffer also with 
RA82. Again the observations were extended to and repeated in other 
RA patients and were compared with other diseases: they showed that
83high titres of rheumatoid factors (as they were later designated 
were found in RA but not in healthy controls or in other inflammatory 
arthritides. The demonstration that the RF activity resided in the
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19S fraction of centrifuged serum84 revealed it to consist of what 
are now known to be antibodies of the IgM class and the same paper 
showed that a 22S fraction could be dissolved to yield RF activity in 
a 19S fraction leaving a 7S fraction, the IgG. Although 
immunoglobulins with RF activity from the G and A classes are found 
in RA85 their assay presents difficulties54, the resolution of which 
was not the primary objective of this thesis. Accordingly, this study 
will concentrate on RF of the IgM class (IgMRF).
Why cannot IgMRF be used as a simple, reliable predictor of 
persistence in very early synovitis? The short answer is that any 
predictive value of RF is arithmetic and not absolute. This is true 
both when considering titres of RF in serum and when applied across 
disease groups. That RF is not specific to RA has been well 
reviewed54. Among the many conditions in which RF may appear are 
included infections and of particular relevance this includes viral 
diseases. Thus there is the possibility that RF may be detected in 
some virally induced SLS. Conversely, in PS, even those who become 
seropositive for RF do so at differing times after disease onset 
and furthermore, of those with otherwise undoubted RA, only some 70% 
become seropositive . Interestingly one recent study has helped to 
quantify the specificity and sensitivity of RF by applying it to
ep
synovitis of less than 6 months duration : of those with the 
eventual classification of "persistent" 502 were seropositive for RF 
at presentation compared with 112 of "transient" synovitis. So 
although its value is not absolute, RF does have a limited predictive 
value in very early disease which reflects its more common 
application in prognostication once RA has become established. The 
use of RF in very early disease might be enhanced by considering that 
the RF - IgG interaction is not a homogeneous phenomenon. The IgMRF
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in RA sera have numerous specificities and react differently with IgG
pe
according to the isotype .
Although the occurrence of RF in high titresin the serum and
Q7
synovial fluids of patients with RA has been suggested as being of
QQ
fundamental pathogenetic significance , the finding of RF in benign 
conditions such as short lived infections suggests.the possibility 
that RF have a physiological role89. This apparent contradiction 
would in part be explained if the RF produced in RA were different 
from the physiological response. Such differences are hinted at by 
the in vitro observation that the specificity of a positive RF test 
is enhanced according to the test antigen used: hence the test is 
more specific for RA if positive with both human and rabbit IgG54. RF 
can be further characterised by considering the structure and 
antibody specificity of the variable parts of the molecule.
IgMRF - Structure:
The pentameric form of IgM derives from the association of its 
subunits, each of which has the classic Ig structure: 2 heavy (H)
chains of subclass and 2 light (L) chains either^ or^, each chain
/
having a "constant" (C) region and a "variable" (V) region. For IgM 
the heterogeneity is located in the V regions of the H and L chains 
ie VH and VL. Amino acid sequencing reveals much homology between 
antibodies of different specificities90 with some homologies being 
closer than others permitting those with the closest homologies to be 
ascribed to the same sub-groups (Table 1.4).
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CHAIN V-REGION SUBGROUP
L
¥
Vfcl
V*II
VfcHI
X VXI
VXLI
VXIII
VXIV
vxv
H VH VHX
v h ii
VHIXI
Table 1.4 Subgroups of V-regions of light (VL) and heavy (VH) chains
However, the sequence of a protein can only be defined if there is a 
manipulable quantity. The above classification is based on the 
analysis of paraproteins, that is monoclonal'(Me) proteins produced 
in large amounts. The RF occurring in RA is polyclonal86 and any 
individual RF will be in quantity to small for this kind of analysis. 
To study the RF of RA and its close mimics alternative strategies 
have to be employed.
RF antigen binding site specificity (idiotypy):
Previous studies of RF idiotypy used polyclonal rabbit antisera to 
examine the IgM in those 10%91 of patients with Waldenstrom’s 
macroglobulinaemia whose (IgM) paraprotein has RF activity92. This 
and similar work on other naturally occurring Me RF93 revealed that 
there are idiotypic similarities in the proteins produced by 
unrelated individuals, falling into 2 main cross-reactive groups, Wa- 
and Po. That within such a group there may occur extremely high 
amino-acid homology94 argues for these specificities arising from
63
germ-line coding rather than from gene rearrangement and somatic 
mutation. The existence of such highly conserved "primitive" 
specificities invites speculation on their evolutionary benefit but 
it must be recalled that these refer to "malignant" clonal protein 
production and the focus is therefore being turned on the polyclonal 
RF in RA and similar conditions.
To do this the "malignant" monoclonal RF are used to inoculate mice 
in order to raise and select mouse hybridoma (ie monoclonal) 
antibodies which have specificity for epitopes in the V-region of the 
RF. Some of the hybridoma antibodies have specificity for epitopes 
within the antigen binding site of the V-region of the inoculum RF 
(anti-idiotopic). Others may have specificity for epitopes at other 
parts of the V-region but if they bind close to the antigen binding 
site of the RF they can alter its shape (ie exert a conformational 
influence). These hybridoma antibodies can then be used to explore 
the pattern of idiotope expression on RF within human serum in SLS 
and PS. The source and nature of the hybridoma antibodies used in the 
present study are outlined in Methods (Chapter 3). Thus there is 
exciting possibility that to the limited arithmetic value of simple 
RF titres in the prediction of persistence, we may be able to find 
qualitative differences in the RF produced in SLS and PS. This may be 
particularly relevant in very early disease before the simple titres 
are high enough to be reliable.
1.6.3 The antigen (IgG)
Introduction:
RF are now defined as immunoglobulins with specificity for the Fc 
fragment of IgG and do not include those antibodies with specificity
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for other parts of the IgG molecule95. In view of the discussion 
below (page 64) about altered ^antigenicity of IgG, the defining of 
sites on the Fc fragment of IgG, antigenic for RF, is of pivotal 
importance. Early work concentrated on the genetically defined 
markers antigenic for RF, the Gm antigens in the heavy chain96,97. In
QQ
addition it was realised that the specificity of IgMRF was often 
not for Gm. The Ga antigen is an isotypic marker on the Fc fragment 
at or near the C152/C)£>3 junction of human IgG subclasses 1,2 and 4 but 
not 3"'100. rf has specificity for IgGl, 2 and 4 but usually not for 
IgG3 and Ga is held to be important in conferring upon IgG its 
antigenicity for IgMRF86. This is reinforced by the finding101 that 
seropositive RA sera all had antibody activity directed against Ga.
It is interesting to note that IgG3 has at amino acid position 435 
(consistent with C^l2/C^3 junction) an arginine with its long side 
chain, instead of a histidine as in subclasses 1,2 and 4. A 
particular variant of IgG3 actually has histidine at this position 
and it does bind some R F 102.
Even allowing for the IgG sub-class variations the binding constants 
of RF for IgG Fc are considerably lower than those for other defined 
Ag/Ab systems54, and so theoretically IgG may not be the primary Ag 
for RF. Even so, these low avidity interactions may be sufficient for 
the RF to perform a putative physiological role. In addition, 
however, there are conditions under which RF/IgG binding is enhanced 
and these may be highly relevant to synovitis and in particular to 
its persistence.
IgG in inflammation: increased affinity for RF:
IgG can exist in rheumatoid synovial sera in aggregated form. That 
aggregates can link to IgMRF and form stable complexes as a result of
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stearic stability without change in the individual RF-Fc bonds has 
been discussed by Carson54. Further to this mechanism there is 
evidence that as a result of inflammation IgG can undergo structural 
changes which enhance its binding of RF.
Oxygen derived free radical species have the potential to denature 
proteins including IgG 103. Exposure to free radicals in-vitro 
produces changes in IgG which can be visualised in a number of 
waysl04,105 detailed below (page 65). This altered IgG binds at. least 
IgG and IgA RF with two or threefold increased avidityl06. Similarly 
altered IgG can be visualised in vivo, in RA synovial fluids and 
seruml07. Still under investigationl08 are the relative contributions 
(to the increased antigenicity) of damage to the usual Fc sites for 
binding RF versus damage exposing new sites for binding (eg at the 
hinge region, rich in aromatic amino-acids). Certainly damage 
uncovering new sites might partly explain the apparently 
contradictory finding that in synovial fluid there is RF-IgG3 
interactionl09 although it has to be admitted that that particular 
study used a plaque assay and hence the IgG3 being studied may have 
been undamaged. Before seeking radical-damaged IgG in the present 
study it is necessary to evaluate the techniques for visualising such 
damage.
Detecting oxygen-derived-radical damaged IgG;
Fluorescence: One method utilises the development of characteristic 
auto-fluorescence (excitation 360nm, emission 454nm). It has been 
suggested that such fluorescence is due at least in part to damage to
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and loss of aromatic amino acids in IgG, particularly in the hinge 
region of the molecule107.
Aggregation: In the same work it was also shown that in addition to 
fluorescent monomer, increasing exposure to oxygen derived radical 
species so alters IgG that it can aggregate into polymers.
Some deductions can be made about which free radicals are responsible 
for the damage observed, since scavengers are available that 
preferentially remove particular radicals. It has been shown that 
catalase, which preferentially scavenges hydrogen peroxide (H202), 
greatly reduced resultant IgG damage in the above study106. However 
the concurrent finding that desferrioxamine (a chelator of metal 
ions) also almost completely protects, suggests that H202 is not the 
direct mediator of the damage. Rather, through the Fenton reaction:
Fe2+ + H202 ---> OH- + -OH'
it suggests that iron catalyses the conversion of H202 to the 
hydroxyl radical (OH') and it is this which is responsible for the 
fluorescence and aggregation. Superoxide dismutase, which reduces the 
level of the superoxide anion (by converting it to H202), had less 
protective effect.
Relevance of altered IgG to persistence of synovitis:
It has been shown in vitro that artificial stimulation of neutrophils
(using phorbol myristate acetate) results in the production of oxygen
derived free radical species, resulting in alteration to IgG in the
medium, visualised as aggregation, fluorescence and reactivity with 
106RF . It has been shown that similar neutrophil activation results 
from the presence, at their cell surface membrane, of immune
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complexes110,111. It has been suggested106 that a cycle of self­
perpetuation could arise in the joint with its high local 
concentration of neutrophils: inflammation, however initiated, 
includes the production of oxygen derived free radicals from 
neutrophils; the free radicals then damage the IgG, resulting in its 
aggregation and its more avid complexing with RF; the complexes could 
then further stimulate neutrophils and complete the cycle. Thus with 
or even without invoking local production of RF in the joint, 
fluorescent IgG has a theoretical role to play in the persistence of 
inflammation. That the aggregated IgG can also stimulate RF 
production54 is an additional justification for its study.
If the above mechanism has anything to do with persistence of 
inflammation it would be important to seek differences in the 
measured products (eg fluorescent IgG) between those patients with 
persisting versus those with self-limiting synovitis. Specifically it 
would be important to study each of these groups as early in the 
course of the disease as possible, in order to try to circumvent the 
ever present problem that an observed disorder can be the consequence 
rather than the cause of the larger abnormality.
1.7 Summary of introduction
Patients with Rheumatoid Arthritis (RA) may benefit from disease 
modifying treatment being introduced as early in the disease as 
possible. Because of the high incidence of serious side effects with 
established treatments, it will be necessary to distinguish patients 
with RA from those with more benign, self-limiting arthritis. For the 
present study patients were recruited as early in their disease as 
possible.
A number of variables may help to predict those who will have 
persistent disease, and for this study the clinical pattern of 
disease was studied in detail. In addition, patterns of T-cell and B- 
cell activity which are found in established RA were sought in the 
study patients. Finally, evidence of specific viral infection was 
sought.
The results will be discussed primarily for their predictive value 
but where opportunities to elucidate underlying pathogenetic 
mechanisms arise, these will be explored.
CHAPTER 2
METHODS
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CHAPTER 2 
METHODS
This chapter presents an outline of the methods used in each part of 
the work for this thesis.
2.1 Clinical studies
2.1.1 Recruitment
Patients were recruited to the study by means of a letter circulated 
to General Practitioners in the South and Central health districts of 
Birmingham inviting them to refer those with a history of synovitis 
of up to six months duration. The letter indicated that although the 
main objective was to see patients with Rheumatoid Arthritis (RA) as 
early in its evolution as possible, it acknowledged that such 
diagnosis was difficult and not necessary before referral. The 
letter offered to see referrals within days, as opposed to the 
routine waiting time of three months.
2.1.2 Intervention
The data being presented was all taken at the patient’s first clinic 
visit. It is relevant to comment on intervention, however, since the 
allocation to diagnostic groups was made retrospectively on the basis 
of eventual outcome. Many patients had been started on non-steroidal 
anti-inflammatory drugs (NSAIDs) prior to being seen in clinic. To 
minimise the possibility of altering the natural history of an 
arthritis, patients were managed only by NSAIDs plus simple analgesia 
plus physiotherapy. They did not receive "second-line" drugs such as 
gold or penicillamine unless their disease was persistent, severe and
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not responding to "first-line" therapy, by which stage data 
collection and diagnostic categorisation had been completed.
2.1.3 Clinical and routine laboratory variables
An Early Synovitis Clinic was established and held once weekly to 
screen and follow patients at six weekly intervals, until either a 
diagnosis became apparent or their symptoms resolved. The patients 
were seen exclusively by myself and a standard proforma was completed 
at each visit.
The proforma was designed by myself to ensure uniform data collection 
and to facilitate its subsequent transfer to computer for analysis. 
Although the proforma was to be used primarily for eventual formal 
statistical analysis, it was also a clinical management tool. To 
avoid duplication of effort, the proforma was designed to include, 
within a full clinical history, the variables of particular interest 
to the thesis. An abbreviated version of the proforma was also 
completed at subsequent visits to determine progress. A copy of the 
full proforma is included in appendix 1 , and-the variables extracted 
for analysis are listed below. I am grateful to Dr A Silman, Senior 
Lecturer in Clinical Epidemiology at the London Hospital, for his 
helpful comments on the proforma design.
The variables to be measured were grouped under three main headings: 
Clinical, derived from the patient history and examination; Routine 
Laboratory, performed on blood sent to the hospital service 
laboratories; and Research, performed on blood taken at each visit 
and stored for later analysis in the research laboratories.
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History:
Name and Number
Sex
Age
Onset date
Date of first visit
Duration of symptoms (at first visit)
Type of onset (rate: hours, days or weeks)
Pain severity (5 point scale)
Morning stiffness (duration in minutes)
Morning stiffness (severity, 5 point ordinal scale)
Joint stiffness } yes/no
Joint pain } for
Joint swelling } each joint (i)
Prodromal symptoms
Family history
Examination:
Rheumatoid nodules
Rash
Reduced range of movement } yes/no
Tenderness } for
Swelling } each joint
Ritchie articular index112
Number of inflamed joints (ii)
Mean grip strength (iii)
Table 2.1 Clinical variables
Notes:
i) see text for grouping of joints
ii) "inflamed" = tender or swollen
iii) mean, 3 pairs of readings with standard bag and manometer
Grouping of joints;
The joints examined were: temporo-mandibular (TMJ), neck, shoulder, 
elbow, wrist, metacarpo-phalangeal (MCP), proximal inter-phalangeal 
(PIP), distal interphalangeal (DIP), back, hip, knee, ankle, 
metatarso-phalangeal (MTP). Paired joints or groups of joints were 
recorded separately on the proforma but at analysis were recorded 
together. Thus although in the analysis (chapter 3) MCP swelling 
means involvement of any of the left and/or right MCP joints,
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patients with asymmetric disease were specifically excluded from the 
groups under study.
Haemoglobin114
White blood cell count
Platelets
Erythrocyte sedimentation rate115 
RA latex 
Rose Waaler
Anti-nuclear antibody116
. . 117C-reactive protein 
X-rays of hands and feet
Table 2.2 Routine laboratory tests
RA latex and Rose Waaler tests:
These two assays were routinely available in the local service 
laboratories. The RA latex slide test (RA80 Eiken, Tokyo, Japan) is 
simple to perform and, having human IgG as the antigen, has the 
advantage of sensitivity and was used to screen all patients. Those 
with positive results were tested by the Rose-Waaler assay118 which 
uses rabbit IgG as the antigen, and has increased specificity for RA 
(at the expense of sensitivity). The results of these assays will be 
presented with the clinical and routine laboratory variables in 
chapter 3.
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T-lymphocytes:
Number CD4+ 
Number CD8+ 
Number TFR+ 
Number TFR+ also 
Number TFR+ also
CD4+
CD8+
B-lymphocytes:
Quantitation of IgM RF 
Quantitation of IgM RF idiotype 
Ratio: fluorescent IgG / whole IgG
(ELISA capture assay) 
(ELISA inhibition assay)
Virology:
Anti- B19 Human Parvovirus antibody (IgM and IgG) 
Anti- Rubella virus antibody (IgG and IgM)
Table 2.3 Research variables
Details of the methods for the 
assays: see text.
research variable
2.2 T-Lymphocyte studies
Dr M Salmon, Dr G Kitas and Mr D Pilling taught me the cell 
separation technique and smear preparation but they also performed 
these operations for most of the patients and did the monoclonal 
antibody staining, blind to the diagnostic coding. They also offered 
constructive criticism of my analysis and interpretation of the data.
2.2.1 Cell separation
At each visit and at the same time of day, lOsto 20 ml of venous
blood was collected into a heparinised tube, and transported to the
laboratory immediately. The blood was layered onto Ficoll-hypaque
and centrifuged for 30 min at 300G118. The harvested mononuclear
cells were smeared onto glass slides which had been previously been
120coated with high molecular weight polymers of L-lysine . The 
slides were dried and foil wrapped before storing at -20°C. Duplicate 
slides were made for each sample. The slides were later labelled in
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batches with monoclonal antibodies to cell surface markers.
2.2.2 Single labelling
Smears were incubated for 60 min with monoclonal antibodies: UCHT-1 
pan-T cell, anti-T3 121; 0KT4-helper/inducer T cells122; 0KT8- 
suppressor/cytotoxic T cells123; 0KT9-anti-TFR75. After incubation 
smears were washed in phosphate buffered saline (PBS) pH 7.4 for 10 
min and labelled with fluorescein conjugated goat-anti-mouse IgG 
(Ortho Diagnostics, Raritan, New Jersey, USA) for 30 min. Smears 
were then counterstained with ethidium bromide and mounted in 
phosphate buffered (pH 8 .6) glycerol containing p-phenylamine diamine
124to retard photobleaching during microscopy .
2.2.3 Double labelling
The problem with double labelling a smear of cells is that if the 
same species is used to raise both marker antibodies, then the dye- 
conjugated detecting antibody will label all positive cells 
indiscriminately. To circumvent this, smears were double labelled for 
TFR according to the method developed by Dr Salmon in this 
laboratory77. Smears were labelled with fluorescein-conjugated 
monoclonal antibodies to T-cell surface antigens as above, but 
without the ethidium bromide counter stain. They were then incubated 
with normal human serum (as a source of transferrin) for 15 min and 
washed for 40 min in three changes of PBS. Smears were then exposed 
to rabbit anti-transferrin IgG (DAKOPATTS, Weybridge, UK) for 25 min. 
To visualise the TFR+, labelled cells, the smears were incubated with 
swine-anti-rabbit IgG conjugated to rhodamine (DAKOPATTS, Weybridge, 
UK) for 30 min. Since 0KT9 does not compete with transferrin for 
binding sites on the receptor, it was used to control for the 
sensitivity and specificity of the transferrin - anti-transferrin
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binding system. As a negative control transferrin was removed from 
the smears by incubation with acid desferrioxamine (pH 5.5) for 10 
min and then stained with rabbit-anti-human transferrin followed by 
sheep-anti-rabbit IgG: these controls were all negative.
Smears were examined using a Zeiss fluorescence microscope equipped 
for incident illumination and using separate filter sets for 
fluorescein and for rhodamine/ethidium bromide.
2.3 B-Lymphocyte studies
At each visit, during routine venipuncture, ten to twenty ml of blood 
was taken into a plain tube, allowed to clot and the serum stored in 
aliquots at -70°C. Most assays were done using serum thawed only 
once: no aliquot was used for more than three freeze - thaw cycles.
Two principle groups of assays were performed: those looking at
Rheumatoid Factors and those studying their antigen, IgG.
2.3.1 IgG as an antigen for RF
For the purposes of these experiments, no stored serum had been 
thawed more than once previously. Serum proteins were separated by 
size using high performance liquid chromatography (HPLC) on a TSK 
3000 SW column at room temperature (pH 7.4). lOmicroL of serum were 
diluted 1:2 in phosphate buffer (0.067M KH2P04 + 0.1M KCl) containing 
lOOmicroM cytochrome C. The proteins were eluted at 1ml/min with the 
phosphate buffer as the mobile phase. The protein at the eluate 
volume (and hence molecular weight) characteristic of IgG was 
measured in two ways:
1. Total protein was measured by optical densitometry (Uvicord 
spectrophotometer, Pye Unicam) at wavelength 280nm (OD 280).
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2. The fluorimeter (Gilson Instruments Ltd, Villiers le Bel, France)
using an excitation wavelength of 360nm measured fluorescent protein
by use of filters to read emission at 460nm. Emission at 460nm is
characteristic of oxygen derived free-radical species induced damage
to IgG104,105. Thus the quantity of fluorescent IgG could be compared
to the total IgG. This relationship was expressed as a ratio and
related to the internal standard, the height (intensity) of the
cytochrome C peak in the eluate107:
Fluorescent-IgG 
Ratio =   x 100%
Total IgG
2.3.2 Rheumatoid factors
These were assayed using a number of different, complimentary 
techniques. The RA Latex and the Rose-Waaler tests have been 
described above.
The following methods describe work performed by Dr R Mageed and Dr R 
Jefferis, Dept of Immunology, University of Birmingham, using serum 
samples from 40 age and sex matched patients (SLS n = 20, PS n = 20), 
drawn from the full cohort of 65 patients studied for this thesis.
The samples were taken at the patient’s first visit to the early 
synovitis clinic, stored as described above and analysed later, once 
the diagnostic allocation to SLS or PS had been made. These assays 
were performed by persons blind to the patient’s diagnostic grouping.
1 PRThe following techniques have been described previously and are 
described here in outline.
Direct binding Enzyme Linked Immunosorbent Assay (ELISA)
i) Total IgMRF: Polystyrene microtitre plates (Flow, UK) were 
sensitized with Fc-Per (an IgGl Fc fragment) at a concentration of 20 
microg/ml in PBS, pH 7.4 (50microL/well) by incubation at 37°C for 
2hrs then washing the plates three times with PBS containing 0.05% 
Tween 20 (PBS/Tween). Sera from the study patients were titrated 
1:100, 1:250, 1:1000 in PBS/Tween across the plates and incubated at 
37°C for 2hrs. The plates were washed three times with PBS/Tween. 
Binding of RF was revealed with peroxidase-conjugated sheep anti­
human IgM (The Binding Site, Birmingham Research Institute, UK).
Bound peroxidase-conjugated antibody was revealed by peroxidase 
substrate (O-phenylene diamine) and the results were recorded as OD 
values at 492nm using a Titertek multiscan reader (Flow Labs, UK).
The quantity of RF bound to the plate was obtained by comparing the 
optical density obtained with the standard curve, derived using a 
known quantity of a purified IgMRF (IgMRF Fr) as a standard.
Direct binding ELISA
ii) IgG sub-class specificity of IgMRF: Additional information may be 
gleaned from knowledge of the sub-class specificity of the 
circulating RF. Accordingly the following sensitizing antigens were 
also substituted for the Fc-Per in the above procedure: Cri (IgGl), 
Ware (IgGl), Pe (IgG2), Campbell (IgG2), Renwick (IgG3), Goe (IgG3), 
Carter (IgG4), Reeder (IgG4). The sera from 18 healthy subjects were 
also tested in these assays to determine in the normal population the 
level of IgMRF with specificity for these sub-classes of IgG.
Total IgM and idiotype positive IgM by Capture ELISA 
Introduction: Specific monoclonal antibodies (McAb) were used to 
sensitize ELISA plates (using incubation and washing as above) at an
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optimized concentration of lOmicrog/ml and a McAb of irrelevant 
specificity was used as a control. The SLS and PS patients serum 
samples were added in the same dilutions as for the direct ELISA. 
Captured IgM was again revealed by the peroxidase conjugated sheep 
anti-human IgM (specifically anti-Fc) developed with the peroxidase 
substrate as above. The concentration of captured IgM or IgMRF was 
obtained by using a standard optical density curve derived from known 
quantities of a standard IgMRF (Kok).
i) Total IgM: Using the capture ELISA the total circulating IgM (ie 
including RF and non-RF IgM) was measured. The plates were sensitized 
with a mouse anti-human ym-chain McAb (AF6) used as the intact IgG.
ii) Idiotope-positive IgM: Again using the capture ELISA, the 
patient’s serum was assayed for IgM bearing specific idiotopes (ie 
including RF and non-RF IgM). In this case the plates were sensitized 
with the F(ab’)2 fragments of the mouse McAbs listed below.
Inhibition of direct binding assay using anti-idiotypic Ab 
The above method of quantifying idiotope-positive IgM includes IgM 
with non-RF activity even though the anti-idiotypic Ab were raised 
using RF as immunogen (see below). The most interesting portion of 
the idiotope-positive IgM in the context of the Early Arthritis 
study, was that having RF activity. This was studied using the direct 
binding ELISA as described above, with Fc-Per as a bound target for 
the patient’s serum. Inhibition of that binding (ie the IgMRF 
activity) was achieved by pre-incubating the patient’s serum sample, 
diluted to twice its maximum dilution before reaching a plateau as 
measured from its binding curves (in the direct ELISA), with a 
doubling dilution series of each of the listed McAbs or polyclonal 
antisera, from 0.2mg/ml. The plates having been washed three times 
with PBS/Tween, 50microL of the mixtures were added to each well. Any
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uninhibited RF binding was revealed using peroxidase-conjugated goat 
F(ab’)2 anti-human^\-chain (Kallestad, USA) and the plates developed 
as above.
McAb Specificity for:
17-109: A light chain cross-reactive idiotope associated with RF 
from the Wa group. Immunogen Sie-IgMRF. Kindly supplied by 
Dr DA Carson
C7: A 4<III associated epitope independent of H-chain class or 
sub-class but with preferential association with IgM RF 
paraproteins. Immunogen Ko-RF, a monoclonal 
IgM-4<RF from a patient with Waldenstrom’s 
macroglobulinaemia. Ko-RF is a member of the Wa idiotype 
group .
HI: A heavy chain idiotope on a subset of RF from the Wa 
idiotype group. Immunogen Ko-RF125.
G6 : A heavy chain cross-reactive idiotope restricted to RF from 
the Wa group. Immunogen Ko-RF125.
G8 : A conformation dependent epitope expressed on some IgMRF. 
Immunogen Ko-RF. (Method:1 )
AF6 Non-idiotopic, binding to human ^ u-chain. Used to quantify 
total IgM.
Table 2.4 Antibodies used to detect cross-reactive idiotopes (CRI)
The monoclonal anti-idiotypic antibodies used In this set of 
experiments are listed above (Table 2.4). Although monoclonal 
antibodies have value in relative specificity, even allowing for some 
cross-reactivity they will detect only a limited number of epitopes 
(idiotopes) on, for example, Ko-RF. In screening populations for 
patterns of epitope expression it is useful to be able to detect a 
broader range of epitopes which can be further characterised later. 
Accordingly, we have used a polyclonal antiserum raised against Ko- 
RF.
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The above hybridoma antibodies have an additional problem in that 
they were raised using malignant clonal RF as immunogen. Therefore 
they give information only on those few selected RF idiotopes. This 
may or may not be relevant to the polyclonal RF in RA. One way 
towards circumventing this is to use hopefully more relevant 
immunogens. Accepting that the RF produced by Epstein-Barr virus
129transformed B-cells may not be entirely similar to that in RA , a 
monoclonal RF produced by EBV transformed B cells from patient with 
RA (RF-AN)130 has been used as an immunogen. The resulting polyclonal 
antiserum was used in the present study. The polyclonal antisera had 
been rendered specific for Ko-RF and RF-AN by passage on affinity 
columns with IgM^CIII, and IgM and flight chains respectively (Table 
2.5).
Polyclonal
antisera
Immunogen
Rabbit anti RF-AN: RF-AN is a monoclonal IgM \RF from an EBV
130established B cell line of a patient with RA
Rabbit anti Ko: Ko-RF as for C7, HI and G6 above.
Table 2.5
2.4 Viruses
Routine viral serology was performed by the Regional Virology Service
laboratory at East Birmingham Hospital. The specific viral antibodies 
were sought using radio-immunoassay (RIA): the ELISA plate is coated 
with anti-human IgM (or G) and then incubated with the patient’s 
serum. The viral antigen is then layered on and captured by any 
specific antibody present. Development of the plate in the case of 
Rubella is by an I125 labelled Me anti-Rubella antibody131. In the
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case of B19 Parvovirus no such labelled Me antibody exists so a mouse
19^Me anti-B19 is added before finally layering with an I labelled 
anti-mouse antibody132.
2.5 Statistical analysis
The proforma design allowed consistent data collection and systematic 
entry into a computerised database, DBase III+ 133. Data held in 
those files was manipulated and then was able to be imported directly
133into a commercial statistical analysis program, Statgraphics . This 
program permits the required range of analyses, both parametric and 
non-parametric, univariate and multivariate.
2.5.1 Differences
This thesis addresses differences between two groups of patients: 
those with persistent and those with self-limiting synovitis (PS,
SLS). Since all patients arriving in clinic who fulfilled the entry 
criteria were admitted to the study and grouping was on the basis of
later outcome, this was a cohort study rather than a case controlled
study.
Categoric variables: These were compared,using the Chi-squared 
test135, using Yates’ correction for continuity136 where the expected 
frequency of a cell was less than 5. The Relative Risk of PS for a
137given variable was obtained from :
X with PS, of population positive for variable
X with PS, of population negative for variable
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The confidence intervals (Cl) for the Relative Risk (RR) were derived
from the value of Chi135:
q j  _  +  or - z /  Chi).
where z is the value of the standard normal distribution associated 
with the desired level of confidence (taken as 952 confidence level 
giving z = 1.96).
Ordinal variables: These were compared using the Mann-Whitney U
138ranking test .
Interval variables: Differences between the groups were studied using 
the unpaired t-test, with Cl for the differences in means being given 
at the 952 level135. Since utilising biological variables often 
produces results whose distribution is not strictly Gaussian, it was 
felt important to check the results of the t-tests. Accordingly the 
distribution of values obtained for each variable used was plotted in 
a frequency histogram and these have been included in the results 
chapters where appropriate. In addition, the non-parametric ranking 
test (Mann-Whitney U test138) was used to check the t-test results.
No significant discrepancies were found but individual results have 
been presented in more detail, as appropriate.
2.5.2 Correlations
139Pearson product moment correlation coefficients are given 
particularly for the rheumatoid factor analyses. Correlations between 
variables have also been revealed in the course of conducting the 
multivariate analysis. Since the objective was the prediction of 
persistence of synovitis, the correlations have been used to explain 
how the original data set could be reduced to a few variables. The 
correlations also reveal that the many variables measured are not 
completely independent of each other. Thus in the biological setting 
the apparent risk, of a statistically significant result being found
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by chance due to many variables being admitted to univariate 
analysis, is far less than were the variables to be entirely 
independent of each other.
2.5.3 Multivariate analysis
The objective of this part of the analysis was to take the widely 
used clinical and laboratory variables and explore ways of enhancing 
the prediction of persistence of synovitis. Two contrasting outcomes 
were possible; either several variables would be combined to generate 
a scoring system more strongly predictive of persistence together 
than as individual predictors; or several variables might be shown to 
correlate so closely with each other that measuring just one of them 
would yield as much information as measuring all of them.
The steps undertaken are presented in some detail in chapter 3. 
Briefly, multiple regression was conducted using the computer based
1 ^4program Stepwise Variable Selection to construct a model for the 
prediction of the numerically coded outcome (SLS or PS). The forward 
selection mode was used, meaning that the strongest predictive 
variable was inserted into the model first and the other variables 
were invited to contribute further to accounting for the variability 
in outcome. Of the remaining variables, the strongest was again added 
to the model and the process was repeated until all variables outside 
the model failed to reach the chosen significance level (95%).
CHAPTER 3
RESULTS
CLINICAL AND LABORATORY VARIABLES
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CHAPTER 3
RESULTS - CLINICAL AND ROUTINE LABORATORY VARIABLES
3.1 AIMS
The aim of this section was to identify variables routinely available 
in the out-patient clinic which, when recorded in the earliest stages 
of Rheumatoid-like polyathritis, might identify those patients whose 
disease would become chronic. Even if the null hypothesis were proved 
and no difference could be seen between those destined for persistent 
disease and those who were to undergo spontaneous remission, then 
that would be of value in considering the latter group as a model for 
RA especially if a triggering agent were to be identified.
3.2 Patients selected
In response to the circular letter (page 70) to General Practitioners 
and to requests for referrals from other clinics within the 
Department of Rheumatology, 112 patients were admitted to the study 
for initial screening. As described above (page 71), each of these 
patients was questioned and examined by myself and the standard 
proforma completed at the first visit. The entry criteria to this 
stage of the study were deliberately lax, simply including patients 
with any history of joint symptoms of up to and including 6 months 
duration. Given that the aim was to study symmetrical peripheral 
polyarthritis, some 47 of the original 112 patients were excluded 
from further study (Fig 3.1): these included patients with, for 
example, asymmetrical oligoarthritis (eg associated with psoriasis), 
osteoarthritis, ankylosing spondylitis and even non-rheumatological 
conditions including alcoholic liver disease.
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47 others
112 patients
36 SLS
65 polyarthritis
29 PS
Figure 3.1 Patients studied, subdivisions
The remaining 65 patients were followed in the early synovitis clinic 
at 6 week intervals for at least 1 year, unless their symptoms 
resolved entirely before then. In the case of such complete 
spontaneous remission the patients were discharged from the clinic 
with instructions to report back if there was any recurrence. The 
date of remission was agreed between patient and physician and the 
total disease duration (mean 14.8 weeks) at remission was recorded 
(See Table 3.3 ii). At each follow-up visit an abbreviated proforma 
was completed by myself, this being used in an effort to standardise 
assessment and management. Thus at the end of 1 year each of these 65 
patients was allocated to one of 2 groups: Self-limiting Synovitis 
(SLS) , meaning complete remission; and Persistent Synovitis (PS) for 
those with continuing joint inflammation. Although it does not form 
part of this thesis, a 5 year recall will be conducted to check on 
the veracity of the outcome, both symptomatically and objectively.
The results presented in this chapter are derived from the data 
collected at the patients’ first visit and analysed on the basis of 
the eventual allocation to the groups SLS or PS. The results are 
presented in four stages. First the simple demographic data will be
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given; second the pattern of joint involvement (symptoms and signs) 
will be analysed; third the routine clinical and laboratory variables 
(eg duration of morning stiffness and erythrocyte sedimentation rate) 
will be presented; finally in this chapter, all of the above first 
visit variables were admitted to a process of multivariate analysis, 
to see if any combination would select those patients going on to 
persistent disease.
3.3 Demographic data
SLS PS
Men 7 12
Women 29 17.
risk of maleness for PS = 1.71
Confidence interval = 0.99
Chi Squared = 3.74
p value = 0.053
Table 3.1 Sex
Sex: The clear preponderance of women in both PS and SLS is seen in 
Table 3.1. The proportion of men is slightly higher in the PS group 
but this was not statistically significant.
SLS PS
Mean (yrs) 39.5 49.9
Range 15 - 83 23 - 71
Standard deviation 18.2 13.6
Confidence interval 
for difference in 
means
-18 to -2.5
p value (t test) 0.013
Table 3.2 Age
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Figure 3.2 Duration of disease at presentation
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Age: The mean age of the PS group was 10 years older than that of the 
SLS group (Table 3.2) and this difference did reach statistical 
significance, although the similar range of ages reduces the 
biological usefulness when applied to an individual new patient.
Duration of disease at presentation: Patients were asked at first 
clinic visit to date the onset of their joint symptoms. The aim of 
seeing patients with very early disease seems to have been met (Table
3.3). There was a slightly earlier mean presentation for the patients 
with SLS although the histogram (Figure 3.2 opposite) shows there is 
more similarity than difference.
(i) Duration of Disease at Presentation
Mean (weeks)
Range
Standard deviation
SLS
10.6
PS
14.2
2 - 3 2
7.4
1 - 2 6
5.8
Confidence interval 
for difference in 
means
p value (t test)
-6.9 to -0.17
0.034
(ii) Duration of Disease at Remission
Mean (weeks)
Range
Standard deviation
SLS
14.8
1 - 4 4
9.5
PS was defined as being present for at least 1 year
Table 3.3 Duration of disease
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3.4 PATTERN OF JOINT DISEASE
At the patient’s first visit 6 variables per joint were recorded on 
the proforma diagram (appendix 1). Three of these were subjective, 
namely stiffness, pain and swelling with the patient being asked to 
report those currently present in any given joint. Three further 
variables which were "objective" in the sense that the observer 
decided on their presence or absence in a given joint, included 
diminished range of movement, tenderness and swelling.
3.4.1 Statistics
Each of the six variables of joint disease was simply recorded as 
present or absent for a given joint. Although left and right joints 
were recorded separately, for the purposes of analysis left and right 
were grouped together: so for example a positive score for wrist 
stiffness means that for that variable either the left or the right 
or both wrists were affected. These categoric variables were analysed 
by the Chi Squared test, the number of patients with, for example, 
wrist swelling being compared between the twp groups, PS and SLS. The 
relative risk of PS was calculated for the presence of each variable 
for each joint, together with the confidence intervals for that 
relative risk (page 82). The sensitivity and specificity for each 
variable at each joint, in identifying PS was also calculated. For a 
given variable at a given joint analysis was only carried out if 
there were sufficient patients positive for that variable to give an 
expected value of greater than 2 for each cell in the Chi Squared 
table. As well as not being amenable to statistical analysis, such 
variables would be of little biological use if they were positive so 
infrequently. The raw numeric data is presented in Appendix 1 Table 
Al.l and in this section are presented in graphic form. The data 
collection for this section was complete for all patients, with no
mis sing values.
Caution: It is interesting to note (below) that shoulder pain is 
significantly different between the groups (p = 0.0132) whereas 
shoulder stiffness, although in the graph appearing to show a 
difference, did not reach statistical significance (p = 0.07). 
Similarly MTP pain is statistically different between the groups (p 
0.0265) but MTP stiffness is not (p = 0.17). Perusal of Appendix 1, 
Table Al.l reveals that the lower of the 95% Confidence Limits for 
the Relative Risk (of a positive variable for PS) for shoulder and 
MTP stiffness and pain arei very close to unity, with the limits for 
stiffness including unity but those for pain just avoiding doing so. 
This reflects the relatively small numbers of patients involved and 
even though the 95% Confidence Intervals are not particularly broad, 
it emphasises the need for cautious interpretation of a 
"statistically significant" result. The Confidence Intervals help in 
that interpretation even though in general, the lower the p - value, 
the further are the Confidence Intervals for the Relative Risk from 
including unity.
% patients affected
tmj neck shldr elbw wrist mcp pip back hip knee ankle mtp 
SLS PS p < 0.05 • ; <  0.01 0,001
Figure 3.3 Pattern of joint stiffness
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Figure 3.4 Pattern of joint pain
3.4.2 Joint Stiffness
There is remarkable similarity between the 2 groups, PS and SLS, with 
no statistically significant difference being seen in the 
distribution of symptomatic joint stiffness (Figure 3.3). The 
preponderance of peripheral joint involvement reflects the 
intentional preselection of patients with symptoms suggestive of RA. 
The question of severity of (morning) stiffness is addressed later 
(page 97) but was examined using an unvalidated and crude ordinal 
scale which revealed little useful information.
3.4.3 Joint Pain
Since the overall pattern of joint pain (Figure 3.4) is very similar 
to that recorded for stiffness, the same comments apply. At the 
shoulder and MTP there is a significant difference between the groups 
although as discussed above this is relatively weak.
% patients affected
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Figure 3.5
Pattern of subjective joint swelling
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Figure 3.6
Pattern of objectively decreased ROM
p < 0.05 * ; < 0.01 *• ; < 0.001 ***
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3.4.4 Subjective Joint Swelling
No statistically significant difference was found in the numbers of 
patients reporting joint swelling (Figure 3.5). Overall the less 
patients reported swelling than stiffness or pain. Naturally patients 
would not be expected to report swelling of joints deep in tissue and 
indeed none did for TMJ, neck, back or hip.
3.4.5 Decreased Range of Movement (ROM)
In contrast to the above three variables which were reported by the 
patients, this variable was recorded (as were the next 2 variables) 
as present or absent at the first visit by the single observer, ie 
myself. Although noted on the proforma, for the purposes of analysis 
no grading of severity of reduced ROM was made. At first clinical 
visit, diminished ROM at shoulder, MCP and.knee were significantly 
associated with an outcome of PS (Figure 3.6), the Relative Risk, its 
95% Confidence Intervals and the p - value all strongly suggesting 
this (Appendix 1, Table Al.l). Diminished ROM in the PIP joint was 
also more frequent in the PS group but although this too was 
statistically significant it was more marginal: p = 0.025, Relative 
Risk 1.86, Cl 1.08 - 3.20.
% patients affected
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Figure 3.7
Pattern of objective joint tenderness
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Figure 3.8
Pattern of objective joint swelling 
(tmj, neck, back, hip: nil recorded)
3.4.6 Joint Tenderness
As for ROM and Pain (above) tenderness (on pressure and/or joint 
movement) at the shoulder was significantly increased in the PS group 
(Figure 3.7). There were also statistically more members of the PS 
group with tenderness at wrist or at MTP but again the Confidence 
Intervals for the Relative Risk only just avoid including unity 
(Wrist Cl 1.06 - 3.04, MTP Cl 1.09 - 3.36) (Appendix 1, Table Al.l).
3.4.7 Observed Joint Swelling
Joint swelling recorded by the single observer as present at the 
first clinical visit, was significantly more frequent in the PS group 
at wrist, MCP, PIP and knee joints (Figure 3.8). The strong 
statistical values (Appendix 1, Table Al.l) support the suggestion of 
biological significance, particularly at the wrist (p < 0 .0001, 
Relative Risk 3.04, Cl 1.77 - 5.22). However, biologically relevant 
numbers of SLS patients had joint swelling recorded at first visit. 
This emphasises the clinical difficulty in predicting on the basis of 
joint swelling at first clinic visit, whether a given patient’s 
synovitis will become persistent.
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3.5 Clinical and Routine Laboratory Results
The variables included in this section of the analysis are those 
which are available from the patient history (excluding pattern of 
joint involvement), upon clinical examination or from a District 
General Hospital laboratory service. Those investigations requiring 
research laboratory facilities are analysed in later chapters. The 
values presented are those recorded at the patient’s first visit to 
the Early Synovitis Clinic.
3.5.1 Statistical Analysis
As before, the values for each variable were compared between the two 
eventual outcome groups PS and SLS.
For each categoric variable the Chi Squared test was used, and the 
Sensitivity, Specificity, Relative Risk (of PS) and its 95Z 
Confidence Interval were calculated.
For ordinal variables the Mann-Whitney test was used to assess the 
difference between the groups.
In the analysis of the interval (sometimes called continuous) 
variables, both the unpaired t-test and the Mann-Whitney test were 
used to study differences between the PS and SLS groups in this 
cohort study. This was because the distribution of values for the 
groups approached the normal distribution with varying degrees of 
closeness (histograms will be presented where illustrative). It was 
important to use the t-test in this univariate analysis since the 
variables were later used in a form of multiple linear regression, 
which relies on distributions similar to the t-test. Fortunately the 
t-test proved robust since the p - values derived from the parametric 
and non-parametric tests were very similar indeed. The only minor 
exception was haemoglobin and this will be discussed.
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3.5.2 Categoric Variables
The positive response rate for questions about recent pregnancy (n = 
2 ), and rheumatoid nodules (n = 1) was too low to permit analysis.
No
SLS
Pos
PS
Risk Conf-Int Sens
1
Spec
t
Chi2 P
Family
History
3 3 1.14 0.48 - 2.70 10 92 0.02 0.88
Rash 6 2 0.53 0.24 - 1.16 7 83 0.66 0.42
RA Latex 4 23 5.31 2.9 - 9.6 79 89 30.0 4xl0*8
Data complete for 
RA latex
first two variables: 
- one missing value:
SLS n 
PS n 
SLS n 
PS n
= 36 
= 29 
= 35 
.= 29
Table 3.4 Clinical and Laboratory: Categoric variables
Family History: Patients were asked if there was any history of 
inflammatory arthritis in their families. The clinical impression was 
that the answers were vague and very few patients could be considered 
as having a positive family history. This question did not 
discriminate between the groups (Table 3.4).
Rash: A few patients gave a positive history of a new and generalised 
rash within days of the onset of the arthritis. In all cases this was 
a mild erythematous macular rash which had resolved by the time of 
first clinic visit. A history of rash did not discriminate between 
the groups (Table 3.4).
RA Latex: Contrary to the preconception (page 61) that a simple 
positive or negative RA Latex result was sensitive but not specific 
(and so only useful as a screen leading to the Rose-Waaler test), 
this test emerged as one of the most powerful predictors of PS (Table
3.4). The Relative Risk of developing PS for patients with a positive 
test was 5.25 (Cl 2.9 - 9.5) and as can be seen from the Table the 
Specificity is actually higher than the Sensitivity when used in the 
particular setting of recent onset polyarthritis. The value of the 
test is also seen when it is admitted to the multivariate analysis 
(page 109).
3.5.3 Ordinal Variables
Whitney
n SLS 
PS
Med SLS 
PS
Range SLS 
PS
Z 2-tailed p 
Mann-
EMS
severity
36
29
2
2
0 - 3
0 - 4
2.22 0.026
Pain 36
29
2
2
1 - 3
1 - 3
0.70 0.48
ANA 29
27
0
0
0 - 1600 
0 - 400
0.12 0.90
Rose
Waaler
35
29
0
16
0 - 64 
0 - 4096
4.1 4x1 O'5
Table 3.5 Clinical and Laboratory: Ordinal variables
EMS = early morning 
ANA and Rose-Waaler
stiffness. ANA = antinuclear antibody, 
expressed as reciprocal of dilution titre.
Early Morning Stiffness (EMS) Severity: Although Table 3.5 indicates 
a statistically significant increase in the PS group, the analysis is 
based on a crude ordinal scale. It was found to be very difficult to 
decide on a grade for the patients* description of their EMS and the 
scale should be seen as very crude indeed. The identical medians and 
near-identical ranges further question the biological usefulness of 
this variable in predicting persistence when in the early stages of 
synovitis. It perhaps has a descriptive value in indicating that even 
of those patients who subsequently recovered, many described their
stiffness in terms similar to those used by the patients whose 
symptoms were to persist, emphasising similarity rather than 
difference.
Pain: The same comments apply as for EMS, since here again the score 
was based on a crude ordinal scale of pain severity, by patients’ 
description. No difference was seen between the PS and SLS groups 
(Table 3.5).
ANA: The antinuclear antibody did not predict persistence when using 
the results as the reciprocal of the dilution titre, in the ranking 
test (Table 3.5). Since this variable was to be admitted to the 
multivariate analysis, it was decided to convert it to a categoric 
variable as well: a titre of less than 100 scoring 0 and titres of at 
least 100 scoring 1. Again there was no predictive value in the 
univariate analysis (Table 3.6).
n
SLS
Pos
PS
Risk Conf-Int Sens Spec Chi2 P
RWaaler 2 14 2.8 1.7 - 4.7 48 94 15.3 9x10‘5
ANA 5 4 0.9 0.3 - 2.3 15 83 0.06 0.80
Table 3.6 ANA and Rose Waaler as Categoric Variables
Rose Waaler: There is uncertainty about the biological significance 
of single increments in the dilutional titre of the Rose-Waaler, so 
this variable was first analysed as the reciprocal of the titre by 
the ranking method and shown to be raised in the PS group (Table
3.5). It was then analysed as a categoric variable (positive titre > 
1:16) in the Chi Squared test. It was again positive statistically 
more often in the PS group (Table 3.6). It should be noted however,
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that a clinician faced with a new patient with recent onset 
synovitis, will be disappointed by the Sensitivity of only 48% in 
that stage of disease. This Sensitivity was much lower than that for 
the RA Latex (79Z), while gaining little in Specificity (94% as 
against 891 for RA Latex).
3.5.4 Interval variables
ESR: Of the interval variables, the erythrocyte sedimentation rate 
was the most clearly predictive of PS, when assayed at first visit 
(Tables 3.7 and 3.8). However the similar ranges in both groups 
(Table 3.8 and Figure 3.9 opposite) is reflected in the ESR only 
accounting for a rather small proportion of the variability in . 
outcome as will be discussed in the section on multivariate analysis.
In clinical terms it would not be possible to predict the group into 
which a patient would fall if the first visit ESR fell in the 20 to 
40 range and indeed patients with ESRs as high as 70 subsequently 
underwent spontaneous remission.
The C-reactive protein (CRP) and the Platelets behaving as acute 
phase reactants also showed a strong statistical difference (Table 
3.7) with the PS group having a higher mean level of each. This 
difference shown by the t-test was entirely supported by the non- 
parametric analysis (Table 3.8). Once again it is important to note 
from the ranges of these variables (Table 3.8 and Figures 3.10, 3.11) 
that some of the SLS patients had, at first visit, significantly 
elevated levels which reflected the clinical disease severity.
The Inflamed Joint Number included any joint (small joints grouped 
together as one, page 72) which was tender and/or hot and/or swollen.
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Since swelling was included and this has already been shown in the 
section on pattern of joint involvement (page 94 and Appendix 1) to 
be predictive of persistence, it is not surprising that looking at 
the data assembled as here also shows significantly higher scores in 
the PS. group (Tables 3.7, 3.8, Figure 3.12).
112The Ritchie Articular Index also shows statistically higher scores 
in the PS group (Table 3.7) but contrasts slightly with the Inflamed 
Joint Number in relying on joint tenderness which, in the raw joint 
data (page 94 and Appendix 1) was rather less useful than joint 
swelling. Once again however, attention is drawn to the high upper 
limit of the range of the Ritchie Index for the SLS group (Table 3.8 
and Figure 3.13) indicating the clinical disease severity in some of 
those patients.
The Grip Strength while significantly worse (ie lower) in the PS 
group (Tables 3.7, 3.8 and Figure 3.14), again indicates that 
patients from both the PS and SLS groups were affected at the time of 
first clinic visit. The observed difference between the means of the 
two groups is of clinically meaningful magnitude and would remain so 
even if the "infinitely large study" revealed a "true" value 
approaching the lower end of the 951 Confidence Interval (Table 3.7).
In contrast, for Haemoglobin the observed difference in the means of 
the two groups (both of which lie within the normal range) would not 
be clinically relevant even at the upper end of the Confidence 
Interval and in the t-test the statistics concur with clinical 
interpretation (Table 3.7). Non-parametric ranking analysis of the 
haemoglobin (Table 3.8) finds a statistically significantly lower 
level in the PS group (tending to reflect worse disease severity) but
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the clinical relevance of the difference in the medians (0.9 G/dL) is 
dubious.
The peripheral venous White Blood Cell count (WBC) did not depart 
from the laboratory’s range for the normal population and was not 
significantly different between the PS and SLS groups.
Early Morning Stiffness (EMS) duration: Both groups of patients 
reported lengthy periods of morning stiffness with no significant
difference being seen between the groups (Table 3.7, 3.8).
-
Mean
SLS
Mean
PS
SD
SLS
SD
PS
Conf-Int P
EMS
duration (mins)
177 222 305 331 -204 to 114 0.57
Ritchie 2.58 5.86 3.99 5.83 -5.8 to -0.7 0.009
Inflamed 
joint no.
2.50 6.27 3.10 4.10 -5.6 to -1.9 8xl0‘5
Grip strength 
mm Hg
201 147 86 70 11.7 to 97.9 0.0136
Haemoglobin
G/dl
13.6 13.0 0.97 1.59 -0.07 to 1.28 0.063
WBC
109/L
8.25 9.64 2.7 2.9 -2.8 to 0.04 0.056
Platelets
109/L
334 437 107 154 -172 to -34 0.0027
ESR
mm/lst hr
19 60 21.3 31.3 -54 to -26 lxl 0'7
CRP 9.6 36 10.2 39.6 -43 to -11 0.0006
mg/L
Table 3.7 Interval variables: t-test
SD = standard deviation; Conf-Int = 952 confidence interval for the 
difference in the means; Missing values, see Table 3.8 for number of 
patients included for each variable.
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n SLS Med SLS Range SLS Z 2-tailed p
PS PS PS
EMS 36 60 0 - 998 1.2 0.2
duration 28 60 0 - 998
Ritchie 36 0 0 - 1 5 2.7 0.007
29 4 0 - 2 1
Inflamed 36 1 0 - 1 3 3.8 0.0001
joint no. 29 6 0 - 1 5
Grip 32 200 38 - 300 -2.5 0.0134
mm HG 24 125 50 - 300
Haemoglobin 36 13.5 11.5 - 15.8 -2.1 0.033
G/dl 29 12.6 9.9 - 16.4
WBC 36 8.3 3.4 - 14.8 1.7 0.09
109/L 28 9.2 5.0 - 17.3
Platelets 35 290 207 - 703 2.8 0.0047
109/L 28 405 220 - 812
ESR 36 11.5 2 - 9 8 5.0 4x10-7
mm 1st hr 29 57.0 4 - 114
CRP 31 4 4 - 4 6 3.6 0.00033
mg/L 27 19 4 - 150
Table 3.8 Interval variables: Mann Whitney
Med = Median; WBC peripheral blood white cell count; ESR = 
erythrocyte sedimentation rate; CRP = C-reactive protein.
3.6 Joint Pattern. Clinical and Routine Laboratory Results: Summary 
From the apparent complexity of statistical significance, range 
overlap and clinical interpretation, a clear picture emerges. 
Irrespective of whether symptoms were to persist or remit, the 
patients in this study appeared to have very similar problems at 
their first clinical visit. The similarities resided particularly in 
those variables described subjectively by the patients. The 
similarities existed but were reduced when the patients were examined 
by the clinician, arguably a more "objective" assessment, and it was
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in those variables where the strongest statistical differences were 
found. This may be because patients unintentionally embellished with 
recent memory, their interpretation of an abnormality being 
"currently present".
Such speculation should not detract from the difficulty which the 
single clinical observer (often in consultation with colleagues) 
experienced in trying to make management decisions for these 
patients. Without the benefit of the retrospective analysis of the 
first visit data from all the patients, it was difficult to decide 
whether an individual patient’s disease would persist or remit. In 
practice, prognosis and intervention were decided over several weeks 
of observation. The univariate analysis presented above would not 
help to accelerate that process greatly because of the overlap 
between the groups. In an attempt to improve on prediction of outcome 
at the earliest opportunity for intervention, the next section 
presents the multivariate analysis which was carried out to see if a 
combination of measurements might account for a higher proportion of 
the variability in that outcome.
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3.7 Multivariate Analysis Results
This section studies the relationships between individual variables 
listed in the previous sections (pattern of joint involvement, 
clinical and routine laboratory variables) and between them and the 
patient’s outcome ie SLS or PS. From the large list of variables 
recorded it is likely that a much smaller list of variables can be 
derived to explain as much of the variability in the outcome as does 
the complete list. Whatever number of variables used, if the amount 
of variability in outcome explained by them is large then those 
variables are effective in discriminating between the groups. If the 
amount of the variability in outcome (PS or SLS) explained is small, 
then the groups are similar at first visit in terms of the variables 
used. To put that in biological context, if the variability accounted 
for by the variables in this study is small, then patients with SLS 
start out appearing very similar to those with PS.
3.7.1 Statistical Analysis
The selection of variables was carried out by a form of multiple 
linear regression analysis called stepwise variable selection using 
the statistical package Statgraphics134 on a personal computer. In 
this method the dependent variable, outcome, was called diagnosis and 
set at 1 for SLS and 3 for PS. These values were chosen for 
historical reasons and although by convention 0 and 1 might have been 
chosen, it makes no difference to interpretation. The absolute values 
of the results do have to be interpreted with caution.. The 
coefficient in the tables refers to the slope of the fitted 
regression line for that variable: a positive slope for a variable 
indicates that the patient suffering that symptom or sign is more 
likely to have PS than SLS.
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The programme conducts an analysis of linear regression on the 
dependent variable (diagnosis) for each independent variable in turn.
The variable which explains the most of the variability in diagnosis 
is selected first and entered into the model. While controlling for 
this selected variable, the regression analysis is recalculated for 
the remaining variables. In effect those remaining variables are 
invited to contribute further to explaining the variability in 
diagnosis. Many of those remaining variables will be excluded, either 
because they simply do not discriminate between the groups or 
because, although they do discriminate, they also correlate very 
closely with one of the already selected variables. That is, any 
variability which such a measure could have accounted for, has 
already been explained in the model.
A degree of caution is required in interpreting the model since in 
addition to one or two strong variables (others having been excluded 
by their close correlations) there may be selected some variables for 
which univariate analysis revealed rather weak differences between 
the groups. However they happen to measure a slightly different part 
of the variability in outcome and are accordingly added to the model.
The biological significance of such variables needs to be assessed 
carefully.
The number of candidate variables is very large and to allow the 
programme to handle them they were broken down into sections, with 
the selected, strongest variables from each section model being 
carried forward to the next modelling stage. The three preliminary 
sections were: Joint pattern, upper limb; joint pattern lower limb; 
clinical/routine laboratory variables. Particularly among the weaker 
variables there is a slight risk that the sectioning and sequence of
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the variable selection may influence the choice of variables. To 
check this the sequence of selection was varied. For example the 
"best of upper limb variables" were added to "all of lower limb 
variables" and then the model was rebuilt using "best of lower limb 
variables" and "all of upper limb variables". The effect as seen 
below was detectable but insignificant in biological terms. However, 
this does raise the important point that the variable selection 
presented below need not be the ultimate in biological usefulness.
For example, this study might select a variable which is strong in 
these particular statistical terms and yet reject another variable 
because it accounted for only slightly less of the variability in 
outcome. If the rejected variable had a lower coefficient of 
variation between observers it might actually be more clinically 
useful. Only a single observer was used in this study.
3.7.2 Stepwise Selection of Upper Limb Variables
All of the upper limb variables as listed in Appendix 1, Table Al.l 
were entered for consideration in the model. Data for all of these 
variables was complete for all 65 patients. Wrist swelling judged by 
the clinician as present or absent was the strongest of these 
variables and accounted for 24% of the variability in outcome (Table 
3.9). Its presence at the patient’s first visit was positively 
associated with an outcome in the PS group. The presence of any DIP 
involvement was negatively associated with an outcome in the PS group 
and accounted for a smaller additional fraction of the variability. 
This pattern of smaller and smaller increments in the explained 
variability continued with the addition in turn of diminished 
shoulder range of movement, TMJ pain, and PIP stiffness. The 
coefficient of determination (R2), adjusted for the number of 
independent variables in the regression, was 0.468 meaning that some
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47% of the variability in outcome (SLS or PS) was accounted for by 
this combination of variables.
Step Variables in Model Coefficient F-Remove R2 Adjusted
1 Wrist swelling 1.02 20.90 0.24
2 Wrist swelling 1.07 26.21
DIP involvement -1.12 10.14 0.33
3 Wrist swelling 0.93 20.82
. DIP involvement -1.07 10.44
Shoulder ROM 0.71 8.27 0.40
4 Wrist swelling 0.86 18.26
DIP involvement -1.01 9.74
Shoulder ROM 0.79 10.55
TMJ pain 0.97 4.60 0.43
5 Wrist swelling 0.91 21.46
DIP involvement -0.97 9.58
Shoulder ROM 0.87 13.29
TMJ pain 1.15 6.58
PIP stiffness -0.41 4.55 0.468
Table 3.9 Stepwise Variable Selection: Upper Limb
Abridged version of information available at each stage: fuller 
details for final modelling stage will be presented.
The working statistic F-Remove (and F-Enter) set at 4, to equate to 
95% significance level.
3.7.3 Stepwise Selection of Lower Limb Variables
The above procedure (3.7.2) was repeated for all of the lower limb 
variables as listed in Appendix 1, Table Al.l, with data complete for 
all 65 patients. Only diminished range of movement at the knee was 
selected and this accounted for only 15% of the variability in 
outcome (Coefficient 1.0, F-remove 12.17).
3.7.4 Combining Upper and Lower Limb Variables
The stepwise variable selection procedure was continued by offering
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to the next modelling stage all of the lower limb variables and the 
best of the upper limb variables, ie those selected above (3.7.2).
Step Variables in Model Coefficient F-Remove R2 Adjusted
7 Wrist swelling 0.87 21.28
TMJ pain 1.36 10.33
DIP involvement -0.93 10.02
Shoulder ROM 0.72 9.6
Knee ROM 0.55 5.80
Hip pain -0.57 5.23
PIP stiffness -0.93 4.49 0.540
Table 3.10 Stepwise Variable Selection: Upper and Lower Limb
Abridged analysis information showing values for last step of this 
stage of modelling.
As can be seen from the above (Table 3.10) a rather lengthy list of 
variables emerges and again during the process of selection, each 
subsequent variable recruited to the model added smaller and smaller 
increments to the amount of variability that the model accounted for. 
In all some 542 (from R2 adjusted = 0.540) of the variability in 
outcome (ie PS or SLS) was accounted for by this list of joint 
involvements. The list comprises not only the best of the upper limb 
variables (from 3.7.2) and the best of the lower limb variables (from
3.7.3) but hip pain emerged as having a negative association with PS. 
This indicates the slightly different parts of variability explained 
by differing combinations of variables. Hip pain inclusion only 
emerged because slightly more patients in the SLS group (n=6) had hip 
pain than in the PS group (n=3), and it only accounted for less than 
32 of the variability. Indeed in univariate analysis, the difference 
in numbers of patients with hip pain was not statistically different 
between the SLS and PS groups (Appendix 1, Table Al.l).
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Because of the meticulous nature of the statistical analysis, it is 
possible that some of the weaker upper limb variables which failed to 
be selected above (section 3.7.2) might have ousted the weaker lower 
limb variables, had they been given the opportunity. Even though this 
was unlikely to be of biological significance, the analysis combining 
upper and lower limb variables was repeated, this time with the best 
of the lower limb and all of the upper limb variables. The only 
difference seen was that PIP stiffness, which had been the last 
variable selected for Table 3.10, was ousted by PIP swelling as 
reported by patients. This indicates that once the other variables 
had been selected for Table 3.10, the symptom of PIP swelling 
accounted for more of the remaining variability than PIP stiffness. 
For all that statistical pedantry, the Coefficient and F-value were 
virtually identical for PIP stiffness and swelling symptoms (and were 
therefore interchangeable) and the Coefficient of Determination for 
the model remained at 0.540.
3.7.5 Stepwise Selection of Clinical and Routine Laboratory Variables 
All of the variables of section 3.5 were included in the first run of 
this analysis. From section 3.5 it can be noted that some patients 
had missing values for some of the variables, and any such patients 
with even one missing value were excluded from the first run of the 
analysis. Of the original 65 patients, only 44 patients could be 
included at this stage. The ANA and Rose Waaler results were entered 
as categoric variables, as above (section 3.5.3).
When the variables are entered into the model programme, the amount 
of variability in outcome that each individual variable accounts for 
is calculated independently of all the others (and the strongest on 
this basis is entered first into the model). For age and sex, the
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amount of variability which each could explain independently did not 
reach statistical significance: F-values 1.24 and 1.08 respectively 
(F < 4 equates to significance < 952). The RA Latex test and the EMS 
severity emerged to account for 522 of the variability in outcome 
(11) in this set of patients selected for their complete data record.
Step Variables in Model Coefficient F-Remove R2 Adjusted
1 RA Latex 1.36 36.36 0.45
2 RA Latex 1.25 33.87
EMS Severity 0.28 7.33 0.52
Table 3.11 Stepwise Variable 
44 patients included (see also
Selection: Clinical and Laboratory (a) 
Table 3.12)
It was possible to discern during the analysis that some variables 
were clearly contributing nothing to the variability either because 
they correlated closely with a selected variable (eg Rose Waaler with 
RA Latex, Pearson product-moment correlation 0.68, p<0.0001; CRP with 
ESR, 0.75, p<0.0001) or because they in any case did not discriminate 
between the groups (eg on univariate analysis WBC, ANA). These 
variables, shown to be rejected when offered to the statistical 
program, included some with many missing values so the modelling was 
retried without them. Thus CRP, ANA, Platelets, WBC and Grip strength 
were excluded for the next run of the modelling process. In view of 
its historical importance the Rose Waaler and RA Latex were included 
despite one patient having a missing value for these variables. An 
EMS duration result was also missing but only for one patient, so 
this variable was included. 63 patients (SLS 34, PS 29) were 
therefore eligible for this stage of analysis.
Variables Coeff. F-Remove Variables not in Model F-enter
in Model
RA Latex 51.80
ESR . 35.47
Rose Waaler 17.77
Inflamed Joint No. 16.11
Ritchie 6.47
EMS severity 5.63
Age 5.23
Duration at 1st visit 4.2
Sex 3.97
Step 0: Haemoglobin 2.76
Pain score 0.46
R2 Adj. = 0 EMS duration 0.29
RA Latex 1.37 51.80 ESR 5.99
EMS duration 5.06
Inflamed Jt. No. 2.59
EMS severity 2.32
Duration at 1st visit 1.1
Age 0.51
Ritchie 0.51
Haemoglobin 0.49
Step 1: Pain score 0.30
Sex 0.29
R2 Adj. = 0.45 Rose Waaler 0.10
RA Latex 0.99 17.16 EMS duration 2.85
ESR 0.009 5.99 EMS severity 2.19
Inflamed Jt. No. 1.7
Duration at 1st visit 1.5
Pain score 0.50
Age 0.25
Ritchie 0.16
Step 2: Rose Waaler 0.06
Haemoglobin 0.04
R2 Adj. =0.49 Sex 0.00
No further variables selected. Number of patients = 63
Table 3.12 Stepwise Variable Selection: Clinical and Laboratory (b)
The data presented in Table 3.12 are amongst the most revealing 
obtained from the entire study, in terms of the inter-relationships 
between individual variables. At the top of the Table, at step 0, the 
independent contribution of each variable is ranked by the F-enter
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value. Quite unexpectedly the RA Latex emerged as the strongest 
variable. When the RA Latex was entered into the model (step 1) 
accounted for 45% of the variability in outcome. This is better than 
any other single variable in this chapter and as good as a fairly 
long lists of joints in combination (see above).
As soon as the RA Latex was entered into the model, the F-enter value 
for the remaining variables fell sharply. This is because at least 
some of the variability which they might have accounted for was taken 
by the RA Latex. This is particularly true of the Rose Waaler and 
reflects its close correlation with RA Latex.(correlation coefficient 
0.68, p<0.0001). With only one further step, the insertion of ESR to 
the Model, the variability accounted for rose to 49% and the 
remaining variables failed to be selected (F < 4).
3.7.6 Combining Joint Pattern and Clinical and Laboratory Variables 
To the final modelling stage were carried forward those variables 
selected from the joint involvement data (section 3.7.4) and from the 
clinical and routine laboratory variables (section 3.7.5). From the 
latter section the variables inserted were all 12 of those from step 
0 of Table 3.12. 63 patients were entered for this stage of the 
modelling, those 2 with missing values being excluded. As might have 
been predicted from the above Models, the strongest variable was RA 
Latex, accounting for its 45% of the variability (Table 3.13). This 
time however, the next variable selected was the (diminished) knee 
range of movement, ousting the ESR. Together those two selected 
variables accounted for 52% of the variability. The subsequent 
inclusion of DIP involvement and EMS severity only increased the 
variability accounted for to 57%. Given the already stated dubious 
reliability of the measurement of EMS severity, it might be best not
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to include that variable in clinical practice. Similarly "DIP 
involvement" included patients’ subjective complaints and was only
positive in 6 of the 65 patients. Its prominence in the multivariate
analysis was because all of those 6 patients were in the SLS group.
Step Variables in Model Coefficient. F-Remove R2 Adjusted
1 RA Latex 1.37 51.81 0.45
2 RA Latex 1.25 47.22
Knee ROM 0.69 9.85 0.52
3 RA Latex 1.89 44.14
Knee ROM 0.69 10.47
DIP involvement -0.63 4.60 0.55
4 RA Latex 1.11 39.4
Knee ROM 0.71 11.50
DIP involvement -0.60 4.45
EMS severity 0.17 4.15 0.57
Table 3.13 Stepwise Selection: Joint and Clinical and Laboratory
17 variables offered to the model (see text): no further variables 
were selected. Number of patients = 63
Emphasising the marginal biological significance of DIP involvement, 
the statistical significance was also marginal: the 95% confidence 
intervals for the coefficient estimates for DIP involvement and EMS
severity were very close to including zero (Table 3.14).
Variable Coefficient 952 Conf. Interval t-value sig.level
RA Latex 1.115 0.760 to 1.471 6.28 <0.01
Knee ROM 0.709 0.291 to 1.128 3.39 <0.01
DIP inv. -0.603 -1.176 to -0.030 -2.11 0.03
EMS sev. 0.169 0.003 to 0.335 2.04 0.04
Table 3.14 Coefficient details for variables in Table 3.13
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3.7.7 Summary of Stepwise Variable Selection
For several variables, univariate analysis was able to indicate that 
there were statistically significant differences in the values 
returned at first clinic visit by patients whose synovitis was 
destined to remit (SLS), compared to the values for patients whose 
synovitis persisted (PS). However, the biological significance of 
those differences was less because of the considerable overlap in 
values obtained from the two groups. Furthermore, it can be argued 
that when conducting many univariate analyses, correction in the 
level of statistical significance has to be made for the number of 
independent variables recorded within the study. In analysing the 
pattern of joint involvement where 47 variables were recorded on each 
patient, this means that strictly only those variables showing 
difference between the groups to a p-value of 0.001 or less upon 
isolated analysis should be considered statistically significant at 
the 95% level when considered in the context of the number of 
variables recorded. However, the variables are clearly not strictly 
independent of each other with, for example an observed (by the 
clinician) joint swelling likely to be accompanied by a complaint 
(from the patient) of joint swelling. Furthermore, the presentation 
of the isolated univariate analysis results is valid if considered as 
components contributing to the understanding of pathogenesis and if 
interpreted with caution. When the routine laboratory variables are 
included and the correction is made for the number of variables, the 
essential finding in the data is not changed, with the wrist 
swelling, RA Latex, Rose Waaler, inflamed joint number, ESR and CRP 
("major variables") remaining significantly different between the 
groups. Such strict univariate analysis is only one part of the 
interpretation, however, since multivariate analysis, in seeking to
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account for variability, may recruit variables ("minor variables") 
which on their own are not significant predictors of outcome. In 
addition multivariate analysis can remove statistically significant 
but redundant variables from the selected data set.
It is likely that combining univariate and multivariate analyses 
would, from several independent groups of patients with the same 
disease process, select similar "major variables" but with 
differences in "minor variables". In that context it is interesting 
to note that the present study, in identifying for example RA Latex, 
wrist swelling and the acute phase proteins as being important in 
predicting outcome, is consistent with the ARA criteria for the 
diagnosis of RA1,55 and other studies of recent onset synovitis140 
but there is considerable divergence in the minor variables.
Multiple regression analysis, in the form of stepwise variable 
selection, has permitted a description of how much of the variability 
in outcome could be explained by the variables included in this study 
and recorded at the patient’s first clinic visit. The final Model 
selected (section 3.7.6) might be used to explain up to 571 of that 
variability, although if the two weakest of the four selected 
variables are considered too unreliable for future widespread 
clinical use, then 52% would be a more realistic working figure. The 
possibility of avoiding a variable which might be prone to inter­
observer error (eg diminished knee range of movement) should be 
considered. A combination of RA Latex and ESR (Table 3.12) would 
leave little inter-observer disagreement and still result in 45Z of 
the variability in outcome being explained.
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One possible use for these combinations of variables would be in the 
field of therapeutic intervention studies. It has been argued that 
treatment initiated in the very early stages of RA might be more 
effective than treatment which is delayed for some months (page 50). 
One of the major ethical considerations in early disease is that some 
patients may remit spontaneously and if entered into a trial, would 
be needlessly exposed to potentially toxic.drugs. From the present 
study the RA Latex alone offers 892 specificity but if a positive 
result is combined with an ESR of at least 30mm/hr or with positive 
knee ROM involvement, the specificity rises to 942 and 972 
respectively (Table 3.15). This gain is of course at the expense of 
sensitivity but until a treatment was proven to be of great benefit, 
this would be an acceptable loss at least using ESR, although the 
loss using knee ROM is probably impracticably large.
n
SLS
Pos
PS
Risk Conf-Int Sens
2
Spec
2
Chi2 P
RA Latex 
+
ESR>30mm/hr
2 20 4.33 2.52 - 7.44 69 94 28.1 lxl O'7
RA Latex 
+
Knee ROM
1 7 2.23 1.21 - 4.11 24 97 6.6 0.01
Table 3.15 Combining RA Latex with ESR or Diminished Knee ROM
A further loss shown in Table 3.15 is the reduction in relative risk 
(over RA Latex alone), whichever variable is added to "enhance" the 
usefulness of the RA Latex. This again arises because of the 
reduction in sensitivity.
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"Whichever of these combinations is used, still only around half of 
the variability in outcome is explained. This suggests that whether 
destined for SLS or for PS, patients presenting with recent onset 
polyarthritis are more remarkable for their similarities than for 
their differences. The single outstanding variable arising from this 
chapter of the study is the RA Latex. More detailed study of 
rheumatoid factors in early synovitis will be presented in chapter 5.
/
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CHAPTER 4
RESULTS - T-LYMPHOCYTE STUDIES 
4 ♦ 1 Aims
Since activated lymphocytes are a feature of established disease, the 
question was posed: would closer study of T-lymphocyte populations in 
peripheral blood help in predicting disease persistence in patients 
with recent onset arthritis, if measured on their first visit to 
clinic?
4.2 Patients selected
The patients admitted to this part of the study were drawn from those 
65 with polyarthritis of recent onset as detailed above (Section
3.2). These assays are complex and data on only 28 patients (18 SLS, 
10 PS) was available for analysis. Clearly, with small numbers such 
as these, interpretation of the results should be guarded.
The lymphocyte subsets described below were studied in two phases.
All 28 patients’ subsets were analysed in the peripheral blood, which 
includes both active and inactive cells (page 55). Of these 28 
patients, only 15 had sufficiently high numbers of activated, 
(transferrin receptor positive, TFR+) cells for the subsets to be 
measured within the activated population.
4.3 Statistical analysis
In each group values for each variable were scrutinised for equal 
variances and a statistically normal distribution. The t-test was 
then used but because of slight deviations from the normal 
distribution (histograms will be given where appropriate),.the
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results were checked using the non-parametric Mann-Whitney ranking 
test. No discrepancy was found between the results obtained with the 
parametric and the non-parametric analyses. Only univariate analysis 
was carried out for this section, particularly in view of the small 
number of subjects studied. Patients with incomplete data were 
excluded from the appropriate parts of the analysis.
4.4 Subsets of lymphocytes in whole peripheral blood PBM
4.4.1 CD4:CD8 Ratio
The ratio of CD4 positive PBM to CD8 positive PBM, when measured at 
the patients’ first visit to the clinic, was not different between 
the two outcome groups (SLS and PS) and was therefore not predictive 
of persistence (Tables 4.1, 4.2).
4.4.2 CD4 PBM
The number of CD4 positive cells in the PBM fraction of peripheral 
blood (expressed per millilitre of whole peripheral blood) also 
failed to show any difference between the SLS and PS groups (Tables
4.1, 4.2).
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4.4.3 CD8 PBM
Similarly the CD8 positive cells were not statistically different 
between the two outcome groups Tables 4.1, 4.2).
Mean Mean SD SD Conf-Int p
SLS PS SLS PS
CD4:CD8 PBM 2.54 2.79 1.77 1.17 -1.5 to 1.0 0.70
ratio
CD4 PBM 0.81 0.91 0.36 0.44 -0.4 to 0.2 0.53
106/ml
CD8 PBM 0.40 0.36 0.18 0.16 -0.1 to 0.2 0.52
106/ml
TFR+ 76 132 45.9 47.9 -95 to -19 0.005
103/ml
TFR+ 4.66 6.99 3.05 2.83 -4.7 to 0.1 0.058
% of PBM
Table 4.1 Lymphocyte Subsets in Peripheral Blood: t-test
SD = standard deviation; Conf-Int = 952 confidence interval for the 
difference in the means; n = 18 (SLS), 10 (PS). PBM = peripheral 
blood mononuclear cells.
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n SLS Med SLS Range SLS Z 2-tailed p
PS PS PS
CD4:CD8 PBM 18 2.25 0.45 - 8.66 0.96 0.34
ratio 10 2.70 0.93 - 4.67
CD4 PBM 18 0.77 0.33 - 1.59 0.55 0.58
106/ml 10 0.80 0.43 - 1.96
CD8 PBM 18 .0.42 0.06 - 0.73 -0.79 0.43
io6/ml 10 0.32 0.12 - 0.72
TFR+ 18 81.5 2 -- 147 2.76 0.0058
io3/ml 10 128.0 34 - 218
TFR+ 18 5.25 0.1 -- 9.2 1.85 0.06
% of PBM 10 6.95 2 - 12
Table 4.2 Lymphocyte subsets in peripheral blood: Mann-Whitney 
Med = Median; PBM = peripheral blood mononuclear cells.
4.4.4 TFR+ cells
The mean number of TFR positive cells was elevated above the upper 
limit of the normal range77 (95th centile of control population 
27xl03/ml, in both the SLS and the PS groups (Tables 4.1, 4.2). The 
range obtained in the SLS group included both normal and supra-normal 
values, whereas the range for PS was entirely above normal (Table
4.2, Figure 4.1). Furthermore, the TFR+ numbers were significantly 
higher in the PS group compared with SLS (p = 0.005). It was 
therefore of interest to further characterise this population of 
activated, TFR+ cells.
4.5 T-cell subsets within the activated TFR+ subpopulation of PBM 
It is not possible to know the normal values for the CD4:CD8 ratio 
and the numbers of CD4+ and CD8+ cells within the activated TFR.+
123
fraction of the PBM because healthy subjects simply do not have 
sufficiently high numbers of circulating TFR+ cells to allow the 
necessary double labelling technique. Accordingly the values obtained 
have to be compared between disease groups (here SLS and PS) and
between the values in the activated and in the heterogeneous (active
and inactive) whole PBM population.
4.5.1 CD4:CD8 ratio within the TFR+ subpopulation
The ratio of CD4+ to CD8+ cells within the activated, TFR+ population 
was significantly higher in the PS group than in the SLS group 
(Tables 4.3, 4.4). The mean ratio in the activated population was, in 
the SLS patients, not significantly different from the mean ratio in 
the whole PBM for the SLS group. However, it is interesting to note 
that for PS patients, the CD4:CD8 ratio was significantly higher in 
the activated TFR+ population compared with the ratio in the whole 
PBM preparation (p = 0.024, by unpaired t-test).
As discussed above (page 55), it might be expected that in RA any 
increased ratio would be due to a rise in the number of CD4 positive 
cells. Similarly, it was discussed that recent viral infections, with 
a fall in the ratio, were thought possibly due to a rise in the CD8 
positive population. With the working hypothesis that the PS patients 
being reported here probably had RA, and that at least some of the 
SLS patients had their disease triggered by a viral infection, the 
numbers of CD4+ and CD8+ cells within the TFR+ population, were 
therefore analysed.
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Mean
SLS
Mean
PS
SD
SLS
SD
PS
Conf-Int P
CD4:CD8 TFR+ 
ratio
2.09 4.95 1.49 2.37 -5.2 to -0.58 0.014
CD4 TFR+ 
103/ml
35.7 84.4 17.2 25.6 -73 to -23 0.0007
CD8 TFR+ 
103/ltll
27.5 19.6 18.5 8.4 -8.3 to 24.1 0.32
Table 4.3 Lymphocyte Subsets in TFR+ population in PBM: t-test
SD = standard deviation; Conf-Int = 95% confidence interval for the 
difference in the means; n = 8 (SLS), 7 (PS); PBM = peripheral blood 
mononuclear cells.
4.5.2 CD4+ TFR+
The number of CD4+ TFR+ cells was significantly higher in the PS 
group compared with SLS (Tables 4.3, 4.4). Indeed, the ranges of 
values obtained for this variable are almost unique in this study in 
that there is no overlap at all between the SLS and PS groups (Table 
4.4, Figure 4.2).
n SLS Med SLS Range SLS Z 2-tailed p
PS PS PS
CD4:CD8 TFR+ 8 1.49 0.61 - 4.33 2.37 0.018
ratio 7 4.00 3.5 - 10.2
CD4 TFR+ 8 37.0 3.12 - 58.3 3.18 0.0015
103/ml 7 75.5 59.8 - 135
CD8 TFR+ 8 23.3 0.72 - 49.7 -0.52 0.6
103/ml 7 18.7 5.88 - 34.9
Table 4.4 Lymphocyte subsets in TFR+ population in PBM: Mann-Whitney
Med = Median; PBM = peripheral blood mononuclear cells.
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4.5.3 CD8+ TFR+
In contrast to the CD4+ TFR+ results, the numbers of CD8+ TFR+ cells 
was not significantly different between the SLS and PS groups (Tables 
4.3, 4.4).
4.6 Summary of T-cell population analyses
From the studies in the whole PBM population, which includes both 
activated and resting cells, it is clear that in patients presenting 
with recent onset synovitis, the possibilities for predicting 
persistence of disease lie within the activated TFR+ subpopulation. 
Both the PS and the SLS patients had elevated numbers of these TFR+ 
cells.
Practically all of that higher number of TFR+ cells in the PS 
patients (Table 4.1) was accounted for by the higher numbers of their 
CD4+ TFR+ cells (Table 4.3). There was no correlation of the 
activated T-cell numbers with age (Table 4.5). Previous studies in 
established RA have found no correlation of the activated T-cell 
numbers with the acute phase response77 which suggests.that the two 
phenomena are not directly connected. In the present study of 
patients with early (evolving?) disease there is a weak correlation 
between the ESR and the number of TFR+ cells (Table 4.5) and a much 
stronger correlation between the ESR and the double positive 
CD4+.TFR+ cell numbers (Table 4.5, Figure 4.3). These results suggest 
that the two phenomena (acute phase response and number of activated 
CD4 cells) can occur concurrently in patients with recent onset 
synovitis.
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TFR+ CD4+,TFR+
Age
Correlation 0.29 0.41
Significance 0.13 0.13
n subjects 28 15
(SLS+PS)
ESR
Correlation 0.45 0.83
Significance 0.02 0.005
n subjects 28 15
(SLS+PS)
Table 4.5 Activated T-cell numbers: correlation with age and ESR
The most outstanding result was the finding that the ranges of 
CD4+TFR+ double positive cell numbers did not overlap at all between 
SLS and PS, unlike all the other variables in this thesis. 
Unfortunately the assay is very complex and in this form is not a 
practical proposition for routine screening. Nevertheless, the 
implications of these results for the understanding of the 
pathogenesis of persistence will be discussed in chapter 7, when they 
can be put together with the implications of the B-lymphocyte studies 
which are presented next.
CHAPTER 5
RESULTS
B-LYMPHOCYTE STUDIES
128
CHAPTER 5
RESULTS - B-LYMPHOCYTE STUDIES
5.1 Aims
The primary intention of this section of the study was once again to 
seek variables which, when measured in the earliest stages of 
synovitis, would be predictive of persistence. The variables used in 
this section are, however, all derived from assays under development, 
so the secondary intention was to see if any of them would cast light 
on mechanisms of disease persistence. Three questions were addressed:
1) Were there higher circulating levels of damaged IgG in PS, 
resulting in increased drive for the production of rheumatoid factor 
(RF)?
2) Were there quantitative differences in the levels of RF between 
the SLS and PS groups?
3) Could qualitative differences in RF production be determined by 
examining the specificity and idiotypy of the RF in the two groups?
5.2 Patients selected
For section 5.4, IgG as antigen for RF, all 65 patients were of 
interest. First visit serum samples from 52 of those patients (29 
SLS, 23 PS) were available for study in the assay which was performed 
(blind to the diagnostic coding) by Dr J Lunec.
For section 5.5, serum samples from the first clinic visits of 40 
patients (20 SLS, 20 PS) were selected from storage at -20°C, by the 
clinician (EJT) once the diagnostic outcome had been decided. The 
samples were then assayed by Dr R Mageed, who was blind to the 
diagnostic coding. If for any patient there was insufficient serum
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for a given assay, that patient was excluded from the relevant part 
of the data analysis.
5.3 Statistical analysis
The distributions for most of these variables were skewed so the non- 
parametric ranking test (Mann-Whitney) was used. The exceptions were 
the IgG Ratio and the Total IgM (see below) where the distributions 
were more normal, permitting use of the t-test.
As a consequence of the skewed distributions (for both SLS and PS) 
with most patients having low results and a few (generally PS) having 
high results, even where there was a statistically significant 
difference between the groups, interpretation of the biological 
significance needs to be guarded.
5.4 Immunoglobulin as antigen for RF: free radical altered IgG
In the fluorescent IgG assay the established normal range (the mean 
of 100 normal subjects +/- 2SD) for the ratio is 4.8 to 9.01. For 
both SLS and PS the majority of the patients were found to have 
values within the normal range (Table 5.1). Accordingly the finding 
of a statistically significant difference between the means of values 
for SLS and PS by t-test is of less biological than statistical 
significance. Using the Chi test to look at the number of patients 
in each group with ratio results above the upper limit of normal, the 
assay failed to discriminate between the two outcome groups (Table 
5.1).
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(i) t-test Mean
SLS
Mean
PS
SD SD 
SLS PS
Conf-Int P
IgG Ratio (2) 
(Normal range: 
4.8 to 9.02 )
7.67 5.71 3.29 2.58 0.25 - 3.67 0.025
SD = standard 
difference in
deviation; 
the means;
Conf-Int = 952 confidence 
n = 29 (SLS), 23 (PS).
interval for the
(ii) Above-normal values for the ratio: predictive of persistence?
Above
SLS
normal
PS
Risk Conf-Int Sens Spec Chi2 P
Ratio 8 3 0.55 0.2 - 1.4 13 72 1.6 0.20
Table 5.1 Fluorescent IgG : total IgG ratio (2)
5.5 Immunoglobulin as rheumatoid factor (IgMRF)
The RA Latex emerged in chapter 3 as the best of the rather poor 
predictors of persistence of synovitis. In an attempt to understand 
the pathogenesis and perhaps enhance the predictive value, both 
quantitative and qualitative studies of the IgMRF were performed.
5.5.1 Direct binding ELISA: quantitation of total IgMRF 
Using Fc-Per as the standard antigen for the IgMRF in the direct 
binding ELISA, levels of IgMRF were found to be significantly higher 
in the PS patients compared with either SLS or normal subjects (Table
5.2, Figure 5.1). The upper limit of normal was defined as 8.4yig/ml, 
the 90th centile of the distribution of values found in normal 
healthy volunteers (n=15). Using the Chi2 test to estimate the 
predictive usefulness in early synovitis, the finding of a supra- 
normal value carried a relative risk for developing PS of 3.43 (Table
5.3), with sensitivity and specificity comparable to the RA Latex,
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but the RA Latex remains the stronger predictor (page 96).
Clearly IgMRF was present at first clinic visit in greater than 
normal quantity for PS as a group but not in SLS as a group. However 
some individual SLS patients did have supra-normal levels of IgMRF 
and some individual PS patients did have normal IgMRF levels. As a 
result of this overlap, quantitation offers a statistical but not 
categoric ("all or nothing") distinction between the two outcomes of 
recent onset synovitis. The next question addressed was whether any 
qualitative differences in the circulating IgMRF could be found 
between the normal subjects, SLS patients and PS patients. The IgMRF 
was examined first by its specificity for IgG of differing subclasses 
and then by its expression of cross-reactive idiotopes.
5.5.2 Direct binding ELISA; IgG subclass specificity of IgMRF 
Instead of Fc-Per, the ELISA plates were sensitized with IgG from 
subclasses 1, 2, 3 and 4, two different examples of each subclass 
being used, making a total of eight potentially different target 
antigens for the polyclonal IgMRF in each patient’s serum.
Normal v. SLS: Comparison was made between the normal subjects and 
the SLS group (Table 5.2, Figures 5.2 to 5.9): both the median values 
and the Mann-Whitney analysis indicate a trend for the SLS group to 
have lower levels than normal, of IgMRF of the defined specificities. 
This trend is consistent using each IgG subclass as antigen, with the 
exceptions of the IgGl example Cri and the IgG3 Ren, where the two 
groups are essentially equal. This trend to lower than normal levels 
of IgMRF in SLS does not reach statistical significance for IgGl but 
does for both examples of IgG2 and for one example each of IgG3 and 
IgG4. This is perhaps because the normal control population were 
slightly older (Mean 49.9yrs, Std Dev 10.0, n = 14) than the SLS 
patients, (but had the same mean age as the PS group)
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Antigen n Median Range Z-value p-value
SLS SLS SLS N v SLS
PS PS PS N v PS
N N N SLS v PS
Fc-Per 19 3.4 0 - 4 6 -0.36 0.71
(IgGl) 20 90 2 - 1114 3.97 7. 0x1 O'5 k k k
18 5.1 0 - 17.7 4.06 4.8x10'5 •kick
Cri 18 2.9 0 - 7 0 0.05 0.96
(IgGl) 19 149 1 - 2598 4.29 1. 7xl0‘5 k k k
18 3.25 0 - 15.2 3.96 7. 3x1 O'5 •kick
Ware 18 3.6 0 - 3 3 -0.38 0.7
(IgGl) 19 112 0 - 2022 3.66 2.5X10"4 k k k
18 4.35 0.7 - 18.5 3.57 3.5x10‘4 k k k
Pe 18 5 1 - 2 3 -2.07 0.038 k
(IgG2) 19 37 0 - 1549 2.60 0.0094 kk
18 11.45 1.1 - 33 3.19 0.0014 kk
Camp 18 2.65 0 - 2 3 -2.06 0.04 k
(IgG2) 19 156 0 - 2304 3.36 7. 8x1 O’4 k k k
18 4.9 1.3 - 13.8 3.48 4. 9x1 O’4 k k k
Ren 18 9.5 3 - 7 3 0.05 . 0.96
(IgG3) 19 74 5 - 1101 3.90 8 . 3xl0'5 k k k
18 8.75 0.8 - 53 3.96 7. 3xl0’5 k k k
Goe 18 9 1 - 6 7 -2.90 0.0032 kk
(IgG3) 19 51 0 - 1005 0.68 0.5
18 27.65 5.3 - 140 2.45 0.014 k
Carter 18 1.4 0 - 2 8 -2.80 0.0048 kk
(IgG4) 19 21 0 - 499 1.50 0.12
18 5.2 0.2 - 57.5 3.35 7. 9x10"4 k k k
Reeder 18 2.4 0 - 134 -1.30 0.19
(IgG4) 19 130 0 - 2624 3.90 9.4x1 O'5 k k k
18 3.55 0.8 - 16.8 3.66 2. 5x1 O’4 k k k
Table 5.2 IgMRF levels (jxg/ml): Mann-Whitney: N v SLS v PS
* p < 0.05 • ** p < 0.01; *** p < 0.001
Normal v. PS: In contrast to SLS, the PS patients had significantly
higher levels of IgMRF as tested against most of the target antigens,
the exceptions being the IgG3 example Goe and IgG4 Carter, where the
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trend was nevertheless consistent (Table 5.2, Figures 5.2 to 5.9).
SLS v. PS: Given the above contrast, it is not surprising to find 
that the PS patients had significantly higher levels than in SLS, of 
IgMRF when tested against each of the eight target antigens (Table
5.2, Figures 5.2 to 5.9). As for IgMRF assayed by Fc-Per, despite the 
statistically significant differences between SLS and PS it should be 
noted that there was considerable overlap between the groups, when 
IgMRF was assayed by these alternative antigens.
To test whether a supra-normal circulating IgMRF level (assayed by 
each of the above antigens) in early synovitis would predict 
persistence of disease, the upper limit of normal was defined as the 
90th centile of the values for the normal subjects. Using the Chi 
test, the finding of a supra-normal IgMRF level carried a 
significantly increased relative risk for PS of between 2.38 and 5.0 
depending on the test antigen (Table 5.3). These values for relative 
risk and the corresponding sensitivities and specificities are very 
similar to those for the RA Latex (page 96) which, however, remains 
marginally the stronger predictor.
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Antigen
(90cle)
Above
SLS
normal
PS
Risk Conf-Int Sens
%
Spec
%
Chi2 P
Fc-Per
(8.4)
5 16 3.43 1.7 - 7.0 80 74 11.3 0.0008
Cri
(12.8)
4 16 4.53 2.1 - 9.9 84 78 14.3 0.0004
Ware
(16.6)
4 15 3.6 1.6 - 8.1 79 78 9.7 0.0018
Pe
(32.0)
0 11 3.25 1.7 - 6.3 58 100 12.2 0.0005
Cam
(13.0)
1 15 4.9 2.3 - 10.3 79 94 17.4 3x1 O'5
Ren
(42.5)
1 11 2.86 1.4 - 5.6 58 94 9.3 0.0023
Goe
(104)
0 9 2.8 1.4 - 5.5 47 100 8.8 0.0029
Carter
(32.3)
0 6 2.38 1.1 - 5.3 31 100 4.6 0.031
Reeder
(10.2 )
3 16 5.0 2.2 - 11.7 84 83 14.3 0.0002
Table 5.3 IgMRF: Specificity for IgG subclass as predictor of PS
For Fc-Per n = 19 SLS, 20 PS; for others n = 18 SLS, 19 PS 
90cle = 90th centile of normal population (y^ g/ml)
Correlations between IgMRF of differing IgG subclass specificity: The 
above Chi analysis measures the quantitative usefulness of the 
different assays but to appreciate the qualitative pattern of IgMRF 
levels it is important to know if a given patient was producing 
similar levels of each specificity of IgMRF. Table 5.4 shows the high 
correlation coefficients between the levels of IgMRF of each 
specificity tested, taking the SLS and PS patients all together.
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Fc-Per Cri Wa Pe Cam Ren Goe Carter Reed
Cri 0.68
Wa 0.81 0.92
Pe 0.77 0.66 0.66
Cam 0.74 0.66 0.65 0.98
Ren 0.63 0.80 0.69 0.92 0.92
Goe 0.72 0.83 0.82 0.88 0.92 0.93
Carter 0.75 0.58 0.60 0.98 0.97 0.89 0.87
Reeder 0.72 0.70 0.64 0.96 0.96 0.95 0.88 0.95
Age 0.09 0.01 0.04 0.02 0.01 0.01 0.01 0.01 0.01
.59 .97 .83 .91 .96 .98 .99 .97 .95
ESR 0.24 0.09 0.16 0.13 0.21 0.10 0.19 0.13 0.13
.14 .58 .34 .43 .21 .54 .25. 44. .42
RA Latex 0.49 0.38 0.43 0.34 0.38 0.35 0.41 0.32 0.34
.002 .018 .008 .040 .021 .030 .010 .050 .036
Table 5.4 IgG subclass specificity of IgMRF:
Correlation coefficients; SLS and PS taken together
Significance level < 0.0001 unless stated (given as the lower figure 
for: age, ESR, RA Latex)
If the specificities for IgG subclasses 2, 3 and 4 are considered 
first, the correlations between them are very high indeed, with 
coefficients at least as high as 0.88 and an example plot is shown in 
Figure 5.10. Slightly lower but still significant correlations are 
seen between levels of IgMRF with specificity for IgGl, and the other 
subclasses. This is in part due to a small number of outliers, having 
particularly high levels of IgGl specific IgMRF, without a parallel 
increase in levels of IgMRF of other specificities (Figure 5.11, as 
an example). In general, however, if there was an increase in IgMRF 
in early synovitis, this was contributed to by IgMRF of each tested 
specificity in parallel.
136
It is worthy of note that the leveis of these IgMRF did not correlate 
with either age or ESR, and only weak correlations were seen with the 
RA Latex.
Fc-Per Cri Wa Pe Cam Ren Goe
Cri 0.59
Wa 0.62 0.96
Pe 0.16 0.52 0.55
Cam 0.19 0.54 0.68 0.66
Ren 0.20 0.39 0.51 0.69 0.84
Goe -0.10 0.36 0.39 0.86 0.70 0.69
Carter 0.12 0.72 0.57 0.59 0.20 0.09 0.52
Reeder 0.32 0.87 0.72 0.40 0.24 0.06 0.30
Table 5.5 IgG subclass specificity of IgMRF: Correlation coefficients 
SLS patients only
  = significance level greater than 0.05
  = coefficient appreciably less than for SLS and PS together
A study of the correlations between the IgMRF of differing subclass 
specificities within the groups SLS and then PS allows comparison of 
the pattern of IgMRF production. Table 5.5 reveals the much lower 
correlation values and often loss of significance when the SLS group 
alone is examined. The change is partly due to the low absolute 
values for each variable with, in any one patient, some specificities 
being undetected and other specificities having moderate levels. In 
contrast, for PS (Table 5.6), levels of IgMRF of the varying 
specificities tended to parallel each other in a given patient.
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Fc-Per Cri Wa Pe Cam Ren Goe
Cri 0.60
Wa 0.76 0.91
Pe 0.73 0.60 0.59
Cam 0.69 0.60 0.58 0.97
Ren 0.55 0.76 0.63 0.91 0.91
Goe 0.65 0.79 0.78 0.87 0.90 0.92
Carter 0.71 0.52 0.53 0.97 0.97 0.88 0.85
Reeder 0.67 0.65 0.57 0.96 0.95 0.95 0.86
Table 5.6 IgG subclass specificity of IgMRF: Correlation coefficients 
PS patients only
= significance level greater than 0.05
  = coefficient appreciably less than for SLS and PS together
Summary of IgG subclass specificity of IgMRF: Quantitative 
differences were seen between the SLS and PS groups but with 
considerable overlap. Qualitatively, IgMRF of each tested specificity 
was detected in both SLS and PS, with strong correlation in the 
levels of IgMRF of the different specificities in PS but a rather 
less consistent pattern in SLS. In an attempt to examine further any 
possible qualitative differences between the SLS and PS groups, the 
expression of cross-reactive idiotopes (CRI) on the IgM and IgMRF was 
studied.
5.5.3 Capture ELISA: Cross-reactive idiotope (CRI)-bearing IgM 
In this set of experiments the subjects’ sera were added to ELISA 
plates pre-coated with monoclonal antibody (McAb) with specificity 
for CRI as detailed in the Methods section, the focussing on IgM
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being achieved by the use of an anti-human IgM antibody at the 
visualisation stage. It is re-emphasised that this quantitation 
includes IgM both with and without RF activity. Previous work, in the 
laboratory where the assays were performed for this chapter of the 
thesis, showed that in a panel of 163 IgM paraproteins 35% of IgMRF 
(9 of 26) expressed the G6 CRI but only 3% (5 of 137) non-RF 
paraproteins expressed this CRI141. This tended to suggest that McAb 
raised against monoclonal IgMRF, would detect expression of CRI 
mainly on IgM with RF activity rather than without. In addition, for 
two patients from the PS group (pt 97 and 104) who had high levels of 
IgMRF (by direct binding ELISA to Fc-Per, above), RF was isolated 
from the sera by affinity chromatography on immobilized IgG. The 
expression of G6 and G8 CRI were quantified in the IgMRF and IgM non- 
RF fractions. That the CRI were expressed mainly within the IgMRF 
fraction (Table 5.7) suggested that the levels of CRI expression in 
the whole sera (IgM and IgMRF) would be due mainly to the RF 
fraction.
Patient CRI Total^g/ml X in RF X in non-RF ZCRI+Ig]
97 G6 60.16 92.3 7.7 2
G8 188.20 87.0 . 13.0 5
104 G6 8.16 72.0 28.0 2
G8 35.84 83.5 16.5 4
Table 5.7 G6 and G8 CRI-bearing IgM in RF and non-RF serum fractions
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CRI n Median Range Z-value p-value
SLS SLS SLS N v SLS
PS PS PS N v PS
N N N SLS v PS
C7 19 132 34 - 458 2.60 0.0093 **
20 147 7.5 - 627 3.20 0.0012 **
32 46.2 2.0 - 516 0.80 0.40
17_109 9 2.3 0.5 - 10 1.80 0.068
11 18.5 0 - 495 3.10 0.002 **
11 1.0 0.25 - 4.3 2.58 0.0098 **
HI 19 0.0 0 - 15.6 -0.46 0.64
20 1.8 0 - 25.6 1.57 0.12
32 0.11 0 - 1.0 1.57 0.11
G6 19 3.4 0 - 30.8 2.70 0.0068 **
20 5.2 0.8 - 33.3 4.17 2. 9x10'5 •kick
32 1.07 0 - 14.1 1.18 0.24
G8 19 6.3 0 - 114 2.46 0.014 k
20 20.1 0.8 - 116 4.50 6 . 6x1 O'6 •kick
30 1.85 0.1 - 25.5 2,60 0.0093 kk
Table 5.8 Cross-reactive idiotope (CRI) bearing IgM levels (ug/ml): 
Mann-Whitney: Normal subjects (N) v SLS v PS '
* p < 0.05; ** p < 0.01; *** p < 0.001
Normal v. SLS: In some contrast to the IgG subclass specificity of 
IgMRF, CRI-bearing IgM in SLS show a trend to higher than normal 
levels (Table 5.8), reaching statistical significance for C7, G6 and 
G8 but failing to do so for 17_109 (for which small numbers of 
patients were tested). For HI the trend is reversed but the 
apparently lower levels of this CRI-bearing IgM do not reach 
statistical significance.
Normal v. PS: For each CRI tested the levels of IgM in the PS group 
were significantly higher than in the normal subjects.
SLS v. PS: For three of the CRI-bearing IgM tested (C7, HI, G6), no 
significant difference was seen between the two groups of early
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synovitis patients. The levels were significantly higher in PS for 
17_109 and G8 .
To ascertain whether a supra-normal level of CRI-bearing IgM was 
predictive of persistence of early synovitis (ie PS rather than SLS), 
the upper limit of normal for a given CRI-bearing IgM was set at the 
90th centile of the distribution of values obtained from normal 
subjects: the number of normal subjects studied for each CRI are 
given in Table 5.8. Only for G8 did the Chi test show a 
significantly increased relative risk of PS (Table 5.9). The 
apparently higher risk for 17_109 was negated by the small numbers 
studied and hence the wide confidence interval and poor p-value.
CRI
(90cle)
Above
SLS
normal
PS
Risk Conf'-Int Sens
%
Spec
X
Chi2 P
C7
(292)
5 9 1.46 0.8 - 2.7 45 74 1.48 0.22
17 109 
(3.17)
4 9 2.42 0.6 - 9.5 82 55 1.60 0.2
HI
(0.92)
6 11 1.58 0.9 - 2.9 55 68 2.17 0.14
G6
(5.6)
5 9 1.46 0.8 - 2.7 45 74 1.48 0.22
G8
(14.4)
4 12 2.16 1.2 - 4.0 60 79 6.1 0.013
Table 5.9 CRI-bearing IgM:
do supra-normal levels predict persistence?
90cle = 90th centile of the normal population (ng/ml); 
for n see table 5.3 '
CRI-bearing IgM as a proportion of total IgM: Some understanding of 
the pathogenesis of persistent synovitis might be obtained from an
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appreciation of what proportion of the total circulating IgM is CRI- 
bearing, comparing SLS with PS. For C7 the median value for CRI- 
bearing IgM is just over 5% of the total IgM for both groups (Table 
5.10), in a small number of cases ranging as high as 20 to 452, but 
with no significant difference between the groups. For the remaining 
CRI tested the proportions of IgM that bore CRI were much smaller, 
with median values of around IX or less. For the CRI 17_109 and G8 
the PS group had significantly higher proportions of IgM expressing 
CRI, but for HI and G6 the groups were not significantly different.
CRI n Median Range 2-value p-value
SLS SLS SLS
PS PS PS
C7 19 6.4 2.1 - 45.3
20 5.5 1 - 22.4 -0,69 0.49
17_109 9 0.21 0.03 - 0.59
11 1.1 0 - 7.9 2.28 0.023 *
HI 19 0 0 - 0.24
20 0.04 0 - 1.27 1.39 0.16
G6 19 0.18 0 - 0.78
20 0.22 0.03 - 1.72 0.72 0.47
G8 19 0.39 0 - 1.76
20 0.87 0.03 - 4.17 2.65 0.0079 **
Table 5.10 
* p < 0.05;
CRI-bearing IgM as percentage
** p < 0 .01; *** p < 0.001
of total IgM: Mann-Whitney
The significance of the above data is difficult to evaluate but is 
presented as it will be referred to in broader discussion below.
CRI-bearing IgM as a proportion of IgMRF: Since it was thought that 
the majority of the CRI expression would be within the RF rather than
ug/ml
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Figure 6.12 CRI+ IgMRF v total IgMRF
* = patient B19 IgM positive
Note different scales
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non-RF fraction of the IgM (and hence possibly be of relevance to the 
pathogenesis of persistent synovitis) the levels of CRI-bearing IgM 
were compared to the levels of IgMRF (defined by binding to Fc-Per as 
above). In both the SLS and PS groups there were individuals who had 
unrecordable values for given CRI. In addition in the SLS group some 
individuals had undetectable levels of IgMRF (5 of 19) but detectable 
levels of CRI-bearing IgM. Accordingly the results are presented 
graphically for each individual and each CRI tested.
CRI C7: As noted above (Table 5.8) there was no difference in the
values (^g/ml) for the SLS and PS groups but the PS group had higher
levels of IgMRF (Table 5.2). In SLS patients the level of C7-bearing
IgM was always higher than the IgMRF level (Figure 5.12 top) so 
clearly the McAb was detecting IgM other than in the measured RF 
compartment. In PS this is reflected in the C7-bearing IgM having no 
relationship to the IgMRB^ being higher in exactly half of the 20 PS 
patients and lower in the other half (Figure 5.12 bottom). This is in 
keeping with the epitope recognised by McAb C7 being preferentially 
associated with but not restricted to IgM with RF activity127.
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Figure 5.13 CRI+ IgMRF v total IgMRF
* = patient B19 IgM positive
Note different scales
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CRI 17-109: While there was a measurably higher level of IgM bearing 
this CRI in the PS group (Table 5.8), this accounted for very little 
of the one or two orders of magnitude difference between SLS and PS 
in the total IgMRF levels (Table 5.2) and in general the proportion 
of the IgMRF bearing this CRI was smaller in PS than in SLS (Figure 
5.13). Only in three patients (2 SLS, 1 PS) was the CRI-bearing value 
higher than that for IgMRF and those were when both variables had 
very low values. This in keeping with the 17-109 epitope being more 
restricted to IgM with RF activity, although it is known that such
1 Pfirestriction is not complete .
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Figure 6.14 CRI+ IgMRF v total IgMRF
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CRI HI: Where detected (Figure 5.14), this CRI was present in only 
very low levels, with it being undetectable in half of the patients 
in each group (11/19 SLS, 9/20 PS). With no significant difference 
between the groups in the CRI level, it made up proportionately less 
of the IgMRF. The finding of only 4 patients with this CRI level 
higher than their IgMRF level, and those at very low values for both 
the IgMRF and the CRI-bearing IgM, is in keeping with the HI epitope 
being detected by the HI McAb being mainly in the IgM compartment 
with RF activity125.
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CRI 66 and CRI G8 : Again the CRI-bearing IgM accounted for a very 
small percentage of the higher value of IgMRF in the PS patients 
(Figure 5.15). As indicated above the epitopes recognised by McAbs G6 
and G8 are mainly within the RF compartment of IgM. In keeping with 
this the CRI value was higher than that for IgMRF in only those 
patients with very low values for IgMRF. The finding of low or absent 
IgMRF being accompanied by low but measurable levels of the G6 and G8 
CRI is of interest when it is noted that three such patients (Pt 68, 
93, 105 but not 43) had evidence of recent parvovirus infection, both 
clinically and by specific IgM in the same first visit serum sample. 
The only other patient with recent parvovirus infection (Pt 101) also 
had detectable levels of CRI G8 .
Summary: CRI-bearing IgM as proportion of IgMRF: Within the 
constraint that the expression of CRI is mainly but not entirely 
within the IgM with RF activity, the expression of CRI in PS is 
similar to or slightly higher than in SLS but only a very small 
proportion of the IgMRF in PS bears the CRI tested.
5.5.4 Direct binding ELISA: estimation of CRI-bearing IgMRF 
An alternative approach to the study of CRI expression on IgMRF was 
to use the McAb to inhibit its binding to Fc-Per. For these complex 
assays a limited number of patients were selected (n: SLS = 8 ; PS = 
10) and values for the normal population are not available. Each 
patient’s serum was incubated with one Me anti-CRI antibody before 
being added to the Fc-Per sensitized ELISA plates. Reduction of the 
subject’s control level of binding of IgMRF to Fc-Per was ascribed to 
inhibition, by the Me anti-CRI antibody, of CRI-bearing IgMRF. The 
CRI-bearing IgMRF could be expressed in^g/ml. Three questions were
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then asked: (i) did the assay discriminate between SLS and PS? (ii) 
what proportion of the IgMRF bore the CRI tested? (iii) how much of 
the total CRI-bearing IgM had RF activity?
CRI n Median Range Z-value p-value
SLS SLS SLS
PS PS PS
C7 8 0.65 0.27 - 4.2
10 0 0 - 2.8 -1.8 0.08
17_109 8 0 0 - 3.6
10 0 0 - 1.43 -0.4 .0.67
HI 8 0 0 - 5.1
10 0 0 - 14.3 -0.7 0.46
G6 8 0 0 - 1.4
io- 0 0 - 5.9 0.2 0.87
RABKO 8 1.31 0 - 3.4
10 0.20 0 - 7.37 -0.7 0.44
RABAN 8 1.34 0 - 4.5
10 0 0 - 5.7 -1.4 0.17
Table 5.11 CRI-bearing IgMRF (^g/ml): SLS v. PS: Mann-Whitney 
(inhibition assay)
RABKO and RABAN are rabbit polyclonal antibody preparations.
SLS v. PS: Although there was a trend for the PS patients to have 
lower levels of CRI-bearing IgMRF (Table 5.11), this did not reach 
statistical significance for any CRI tested.
Percentage of the total IgMRF bearing CRI: Using the inhibition assay 
there was, as for the capture assay, a consistent trend for the PS 
patients to have low proportions of their IgMRF expressing CRI. 
However, the only statistically significant difference between the 
groups was seen for IgMRF bearing the C7 CRI, with the SLS group
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Figure 5.16 C7 as V. IgMRF: highly skewed distribution
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having higher levels (Table 5.12). The caution needed in interpreting 
the statistical analysis of such small numbers of subjects is 
emphasised by the plot of C7 CRI-bearing IgMRF (Figure 5.16) which 
shows a highly skewed distribution.
CRI n Median Range Z-value p-value
SLS SLS SLS
PS PS PS
C7 8 6.8 0.7 - 100
10 0 0 - 14.4 -2.1 0.033
17_109 8 0 0 - 36.5
10 0 0 - 6 -0.4 0.669
HI 8 0 0 - 92.1
10 0 0 - 21.8 -0.8 0.399
G6 8 0 0 - 33.3
10 0 0 - 25.9 0.1 0.95
RABKO 8 8.9 0 - 81.0
10 4.9 0 - 51.9 -0.6 0.55
RABAN 8 9.6 0 - 1 0 0
10 0 0 - 61.7 -1.7 0.096
Table 5.12 CRI-bearing IgMRF (I total IgM): SLS v. PS: Mann-Whitney
RABKO and RABAN are rabbit polyclonal antibody preparations.
* p < 0.05; ** p < 0.01; *** p < 0.001
5.5.5 Comparing IgMRF values by the inhibition and capture assays: It 
would help to confirm the accuracy of the assumption that the capture 
ELISA assay (section 5.5.3) was measuring CRI expression on IgMRF as 
opposed to non-RF, if the values from the inhibition studies could be 
compared. However the values were not comparable, with for a given 
CRI the value obtained for some patients in the one assay being 
measurable but absent by the other assay: in other patients the 
reverse applied. The discrepancies applied.to both SLS and PS groups.
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Clearly the bonding forces in the inhibition assay are more complex 
than in the capture assay with, in different patients, differing 
relative affinities between the McAb, the IgMRF and the Fc-Per.
5.6 Discussion of B-lymphocyte studies: The value of the results in 
this chapter of the thesis can be summarised by returning to the 
three questions laid out in the aims at the beginning of the chapter.
5.6.1 The fluorescent IgG : total IgG ratio
This ratio was not significantly different between the two groups of 
early synovitis patients and the levels were not different from the 
normal population. Furthermore the value of the ratio did not 
correlate (Coefficient -0.23, sig = 0.16) with the level of RF (by 
ELISA, using Fc-Per as antigen). It seems unlikely that damaged IgG 
circulating in the peripheral blood is a principle drive for RF 
production. Study of the same phenomenon in synovial fluid would be 
interesting but impractical in early synovitis patients since even in 
the PS patients at first visit there were very few joint effusions to 
aspirate.
5.6.2 Quantitation of IgMRF
There were indeed quantitative differences in IgMRF levels between 
SLS and PS. If the ESR can be considered a reasonable reflection of 
the acute phase response and hence of disease severity, then the poor 
correlation between ESR and IgMRF levels is worthy of note (Table 
5.4). This suggests that IgMRF levels represent a dimension of the 
disease process other than severity. There were, however considerable 
overlaps between the groups in the quantitative levels of IgMRF, 
suggesting that the production of IgMRF was part of the inflammatory 
process in synovitis, rather than the cause of its persistence.
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5.6.3 Qualitative study of IgMRF
Using the specificity of the IgMRF for differing IgG subclasses to 
seek qualitative differences between SLS and PS, no particular 
specificity was exclusive to either group. Rather than categoric the 
differences between the groups were arithmetic, the main difference 
being that the quantities of IgMRF of the different specificities 
were more closely correlated in PS. It is open to speculation that 
this more uniform pattern in PS may suggest that they are a group of 
patients with a more homogeneous disease, perhaps in terms of the 
trigger factor, or in the genetic determinants of the host response. 
In contrast the slightly less uniform pattern in SLS may reflect 
differing triggering infections, or alternatively phenotypic 
differences in the host response.
Extending the qualitative evaluation to the IgMRF idiotypy, the 
differences between SLS and PS were again arithmetically continuous 
rather than categoric, with each specificity being expressed by at 
least some patients in both groups. The most important observation 
was that when high levels of IgMRF are produced (and this is mainly 
in PS) the majority of it is not accounted for by CRI-bearing IgM. 
There is evidence to suggest that the finding of CRI-bearing IgMRF 
arises from the expression of germ line genes, with minimal somatic 
mutation142'5. Accordingly the finding of a predominance of non-CRI- 
bearing IgMRF, particularly in PS, suggests a departure from use of 
those germ line genes. This lowered proportion of CRI-bearing IgMRF 
in PS may represent polyclonal activation of IgM secreting B- 
lymphocytes in a non-specific manner. Alternatively or in addition it 
may represent maturation of the immune response, with somatic 
mutation of the germ line genes, perhaps resulting from specific but 
unidentified antigenic drive.
CHAPTER 6
RESULTS
VIRAL STUDIES
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CHAPTER 6
RESULTS - VIRAL STUDIES
6.1 Aims
The aim of this section of the thesis was to determine whether any of 
the patients suffered specific viral infections coincident with the 
onset of their synovitis. Since the potential infecting viruses are 
numerous a decision was made to limit the investigation to only those 
viruses of specific interest in polyarthritis, as reviewed in the 
introductory chapter. In particular, evidence of recent infection 
with either Rubella virus or Human Parvovirus B19 was sought.
6.2 Patients selected
Serum was collected from all patients at first visit and stored in 
aliquots at -70°C. The samples were analysed in one batch by the 
routine service laboratory (blind to the diagnostic coding) at the 
end of the clinical period of the study. The allocation of patients 
to diagnostic groups (SLS or PS) was made independently of the viral 
serology results, although the results were known (the test having 
been performed by the referring clinician) for two of the B19 
positive patients (1 SLS, 1 PS) at the time of allocation. Serum was 
available for analysis from 30 SLS and 24 PS patients.
6.3 Viral serology
Using the single, first visit sample, there was considered to be 
evidence of recent infection if specific anti-viral IgM antibody was 
detected.
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6.3.1 Rubella
No patient, in either the SLS or PS groups, had evidence of recent 
Rubella infection. Seventeen patients (9 SLS, 8 PS) had no evidence 
of distant past infection, the other two-thirds of each group having 
circulating anti-Rubella IgG antibody.
6.3.2 Human Parvovirus B19 (B19)
Six patients (5 SLS, 1 PS) had specific anti-B19 IgM evidence of 
recent B19 infection and their case histories are outlined below. 
Nineteen patients had no evidence of distant past infection, as 
determined by the absence of circulating anti-B19 IgG antibody: this 
is in keeping with the finding of anti-B19 IgG in around two-thirds 
of the normal adult population as discussed previously.
6.4 Patients with recent B19 infection - case histories
6.4.1 Patient number 68: This 27yr old housewife was first seen in 
the Early Arthritis Clinic on 2nd September 1985. From the age of 
7yrs to the age of 14yrs she had attended a District General Hospital 
complaining of neck, shoulder and hand pain, with pins and needles in 
the hands. No specific diagnosis had been reached and she was managed 
conservatively with reassurance and a soft cervical collar.
During the subsequent 13 years she had been entirely well, until the 
middle of May 1985 when she developed a sore throat and hoarse voice 
and was treated with penicillin. Within one week of the onset of sore 
throat she developed pain, swelling and 3hrs morning stiffness in an 
apparently symmetrical distribution affecting hands, wrists, elbows, 
shoulders, knees and ankles but not feet. At worst she could barely 
get out of bed but after a further two weeks, using only aspirin 
600mg tid, her symptoms had almost resolved. There was no history of
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rash or contact with rash and neither of her children (aged 5yrs and 
8yrs) nor her husband had suffered a similar illness.
By the time of her first clinic visit (symptom duration 15 weeks) 
there was only slight residual pain in the knees and ankles and 
clinical examination revealed no abnormality. Confirming the clinical 
impression of remission, the ESR was 3mm/hr and CRP normal. The 
haemoglobin was 14.3G/dL, RA Latex negative. Viral serology showed 
Rubella HAI negative, B19 IgM 16U, IgG >100U indicating recent B19 
infection, with the values obtained being consistent with the 
clinical suspicion of an infection just before the onset of joint 
symptoms.
She was reviewed on three occasions over the subsequent seven months 
and the remaining symptoms had resolved within the first month. There 
were some pins and needles in the fingers, reminiscent of her teenage 
symptoms but clinical examination and nerve conduction studies were 
normal. It was considered that this symptom was unrelated to her 
acute polyarthritis and she was reassured and discharged from clinic 
with instructions to report any recurrence of the arthritis. She was 
assigned to the SLS group.
6.4.2 Patient number 92: This 27yr old housewife was first seen in 
the Clinic on 10th March 1986. Six weeks previously, having been 
completely well, she developed pain, swelling and 90mins morning 
stiffness in many joints. This began as an ache in one knee but 
"suddenly" spread to involve hands, wrists, shoulders, hips, knees 
and ankles (but not feet) in an apparently symmetrical distribution. 
At worst, during the first week, she could not fully open or close 
her hands and was given diclofenac by her General Practitioner.
Within two weeks of the onset, the.worst had eased and by the time of 
first clinic visit (duration 6 wks) there was only mild joint pain
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and morning stiffness persisting in the above listed joints. She had 
no history of rash but both of her children (aged 6yrs and 7yrs) were 
said to have had chickenpox in early January 1986, about the time of 
onset of her symptoms.
Examination at first clinic visit revealed pain at the extremes of 
neck movement, tender muscles in the lumbar region where there was 
slight global restriction in range of movement, and there was slight 
ankle swelling although those joints were cool and had full range of 
movement. The ESR was 2mm/hr, CRP normal, RA Latex negative and 
haemoglobin 14.46/dL. Viral serology revealed Rubella HAI 1:64,. 
Rubella IgM negative, B19 IgM 27U and B19 IgG 38U indicating recent 
B19 infection, the values being consistent with the six week history. 
At the first follow-up visit six weeks later the symptoms had almost 
completely resolved apart from mild pain in her back and knees and no 
abnormality was found on examination. She was allocated to the SLS 
group. Over two further visits, covering a total of six months from 
disease onset, all remaining symptoms resolved.
6.4.3 Patient number 93: This 35yr old quality assurance manager was 
first seen in clinic on 3rd February 1986. As a child he "had a 
problem" with one knee and a doctor had "put in a needle and drawn 
some fluid" but this was a transient problem and he considered 
himself entirely well so that he regularly played badminton until the 
presenting events. About the beginning of January 1986 he noticed a 
macular non-pruritic rash on only one arm, lasting only for a day or 
two. About the same time his daughter (aged 5yrs) had a runny nose 
and similar rash on her arms and chest. Just over two weeks after his 
rash he developed pain, swelling and 60mins morning stiffness in PIP, 
MCP, knees, ankles and MTP joints in an apparently symmetrical 
distribution, plus in one wrist. At worst he was unable to manipulate
buttons, walking was painful and his General Practitioner had 
commenced ibuprofen.
At the first clinic visit, two weeks from the onset of the arthritis, 
the symptoms had abated only slightly. The only positive findings on 
clinical examination were small, cool but definite effusions in both 
knees, although those joints were not tender and had full range of 
movement. In addition this previously fit man had grip strength of 
only 78mmHg (normal >300). The ESR was llmm/hr, CRP normal and 
haemoglobin 14.5G/dL. The RA Latex was not measured. From one knee 
4ml of transparent, straw coloured synovial fluid was aspirated and 
found to have a leucocyte count of 1.6xl09/L, mostly lymphocytes. 
Viral serology revealed Rubella HAI 1:32, Rubella IgM negative, B19 
IgM 50U, B19 IgG 18U, indicating distant past Rubella infection and 
recent B19 infection.
The symptoms resolved within two weeks of the first clinic visit, 
confirmed upon clinical examination at the six week follow-up visit 
which revealed no abnormality and the grip strength had returned to 
normal ( >300mmHg). He was discharged from the clinic with a request 
to report any recurrence and assigned to the SLS group.
6.4.4 Patient number 105: This 31yr old housewife, having been 
completely well with no significant past medical history, was 
admitted as an emergency to Selly Oak hospital under the care of the 
general medical team on 22nd March 1986 and reviewed for this study 
two days later. Two days prior to admission she had developed a non­
pruritic rash "like measles" on her forearms, thighs and abdomen, 
associated with a feeling of tiredness. The rash faded within two 
days. None of her three children nor her husband had a similar 
illness, although her youngest had been vaccinated against measles 
one month earlier. On the same day as the rash started she developed
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pain, swelling and 30mins morning stiffness affecting hands 
("sausage-like swelling"), wrists, shoulders, knees, ankles and MTP 
joints. At worst she was unable to fully open or close her fingers 
and was commenced on aspirin.
When first reviewed for this study (duration 4 days) the symptoms 
were past their peak. There was slight swelling of wrists, MCP, PIP, 
and ankle joints in a symmetrical pattern but all joints had full 
range of movement. The grip strength on the left was normal ( 
>300mmHg) but reduced in her (dominant) right hand (151mmHg). The ESR 
was only 8mm/hr, haemoglobin 12.6 and RA Latex negative.
Interestingly the complement components were low: C3 0.68G/L (normal 
0.75 - 1.75), C4 0.08G/L (0.14 - 0.54), suggesting possible 
complement consumption by an immune complex disease. Viral serology 
revealed Rubella HAI 1:16, Rubella IgM negative, B19 IgM >100U, B19 
IgG 38U, suggesting distant past infection with Rubella and recent 
infection with B19.
Within one week of onset her symptoms resolved sufficiently for her 
to be discharged to home. After a total of two weeks from onset, the 
symptoms had resolved to only slight pre-menstrual aching in the 
joints and she was assigned to the SLS group. She was followed in 
clinic for a total of six months by which time even the slight 
residuum had resolved and she was discharged from clinic with a 
request to report any recurrence.
6.4.5 Patient number 113: This 44yr old nun was first seen in the 
Early Arthritis Clinic on 19th May 1986. She was completely well 
until mid-March 1986 when she had diarrhoea and aching limbs for one 
day. Four days later, while bathing, she noticed a non-pruritic rash 
on arms, chest and thighs "like measles". During that same day she 
developed pain, swelling and (on subsequent days) 60mins morning
stiffness. The peak of symptoms was reached over three days and at 
worst she had difficulty dressing and walking. After one week from 
onset the symptoms began to resolve. She did not live in an enclosed 
order and one week prior to the onset she had visited her young 
nieces and nephews but there was no history of similar illness in any 
of her contacts.
At first clinic visit (symptom duration eight weeks) she volunteered 
the continuing improvement in symptoms although examination revealed 
tenderness in wrists, MCP and PIP joints with slight swelling of the 
MCP joints. The ESR was 18mm/hr, CRP normal, haemoglobin 13.7G/dL and 
RA Latex negative. The viral serology revealed Rubella HAI negative, 
B19 IgM 8U, B19 IgG 100U suggesting no previous infection with 
Rubella but recent infection with B19.
At the first follow-up visit six weeks later all symptoms had 
resolved except mild morning stiffness in the hands and shoulders, 
and clinical examination was normal. She was assigned to the SLS 
group and discharged from clinic with an invitation to report any 
recurrence.
6.4.6 Patient number 101: This 33yr old dental receptionist was first 
seen in the early arthritis clinic on 18th March 1986. She had no 
significant past medical history and had been completely well, with 
in particular no previous joint symptoms until three months prior to 
being seen. On 26th December 1985 she developed a mild non-specific 
illness with headache in the evenings for two weeks. On 7th January 
1986 she developed a slightly pruritic, macular, erythematous rash 
"all over" but mainly on legs feet and arms "like Rubella" which 
lasted three days. The day after the rash cleared she developed pain 
in her wrists, evolving within days to joint pain, swelling and 5hrs 
morning stiffness affecting: PIP, MCP, wrists, elbows, shoulders,
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hips, knees, ankles and MTP joints in an apparently symmetrical 
pattern. At worst she had great difficulty with bathing, dressing, 
walking and stairs and experienced only partial relief on starting 
ibuprofen in mid-February. During the two weeks after Christmas 1985 
her husband and two daughters (aged lOyrs and 16yrs) but not her 
third daughter (aged 14yrs) had the same rash and headache for one 
day each, without joint symptoms.
At the first clinic visit (duration of symptoms three months) there 
was: tenderness in the shoulders with slight restriction of movement; 
swelling of wrists; swelling of most of the MCP and PIP joints 
(symmetrically) with inability to completely open or close the hands; 
tenderness, swelling and slightly reduced flexion of knees; and 
tenderness on forefoot (MTP) squeeze. The grip strength was 
bilaterally reduced to 50mmHg. The ESR was 67mm/hr at this visit and 
interestingly her General Practitioner had noted it to be rising: 7th 
January 1986 - 19mm/hr; 20th January - 28mm/hr; 6th February - 
40mm/hr. The CRP in clinic was 17 and the RA Latex was positive but 
the Rose-Waaler test was negative. Viral serology arranged by the 
referring physician had shown B19 IgM positive on 24th January and at 
her first visit to the Early Arthritis Clinic in March 1986 the 
showed Rubella HAI only 1:8, B19 IgM 9.2U, B19 IgG 60U. The serology 
thus confirmed the clinical suspicion of a B19 infection around the 
time of onset of her symptoms.
She was admitted to hospital in early May 1986 (duration of symptoms 
four months) when her symptoms were so poorly controlled by piroxicam 
that she was incapacitated, with severely restricted walking, 
diminished grip, and painful restriction of movement in hands and 
shoulders. The persistent swelling of PIP, MCP and knees joints was 
confirmed on examination. The ESR remained high at 105mm/hr and the 
haemoglobin had gradually fallen to 8.3G/dL, from 11.6G/dL in the
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Figure 6.1 Response to alpha interferon therapy .
RW = Rose Waaler positive (filled) or negative (open) in serum 
(circles) or synovial fluid (triangles); Fn = functional class;
Hb = haemoglobin; T - transfusion; CIC - circulating immune complexes; 
shown over a year, from December to the following January.
January. She was assigned to the PS group and invited to take part in 
trials of experimental therapy.
Alpha Interferon - rationale and protocol (Patient 101 continued): 
Persistence in the host of virus after primary infection is well 
described for hepatitis B virus and because this is associated with 
chronic inflammation, a number of anti-viral treatments have been 
used with some success including alpha interferon146. The question of 
Parvovirus persistence is currently being studied for the animal and 
human hosts (page 46). Because of the possibility of viral 
persistence we elected to treat our patient (Number 101) with alpha 
interferon (Wellferon, kindly supplied by the Wellcome Foundation 
Ltd, Crewe) with the same regimen as used for hepatitis B. During the 
first week of treatment with alpha interferon the daily dose was 
gradually increased to the target dose of 10 Megaunits per square 
metre body surface area, given as a single subcutaneous injection.
For the subsequent twelve weeks she received lOMU/sq.m on three days 
per week. She continued taking piroxicam throughout this period.
Alpha Interferon - problems during treatment (Patient 101 continued); 
Our patient experienced mild influenza-like symptoms, well controlled 
with paracetamol. The main problem during treatment was a continued 
fall in haemoglobin: whether this was due to disease activity, marrow 
suppression by the alpha-interferon or by the B19 virus itself is not 
known, but she had been having heavy menstrual flow which resolved 
when an intra-uterine contraceptive device was removed shortly after 
the interferon trial was completed. The pattern of the changes in the 
haemoglobin are summarised in Figure 6.1. The Mean Corpuscular Volume 
showed a steady fall before and during interferon therapy until 
intervention with blood transfusion and iron, in keeping with the 
iron deficiency seen on subsequent bone marrow examination (see 
below). A fall in the platelet count (from 388 before, to a nadir on
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interferon of 121 (xl09/L)) closely followed that of the CRP and rose 
with the CRP after the end of interferon treatment, suggesting the 
recognised phenomenon of platelet count reflecting the acute phase 
response rather than necessarily a direct suppression of 
megakaryocytes by interferon. The lymphocyte count was lower than 
normal before (0.82xl09/L), during (nadir 0.45xl09/L) and after 
(regularly < 1.3xl09/L) interferon. The neutrophil count fell with 
interferon (from 5.98 to a nadir of 1.37 (xl09/L)) and recovered 
after cessation of treatment. When the haemoglobin reached 6.7G/dL 
the dose of interferon was halved for two weeks (treatment weeks 6 
and 7) and she was transfused three units of blood, after which the 
interferon was returned to full dose.
Alpha Interferon - response to treatment (Patient 101 continued): 
There was an apparent improvement during treatment in symptoms, 
clinical signs and in the acute phase response, summarised in Figure 
6.1. The functional capacity improved from great difficulty arising 
from a chair or walking across the consulting room pre-treatment, to 
keeping up with her family on a country walk in the last week of 
treatment and then relapse two weeks later, sufficiently severe to 
require admission to hospital for bed rest. The CRP closely supported 
the subjective assessments. The fall in circulating immune complexes 
may be of pathogenetic significance. The RA Latex has been 
consistently positive in this lady but interestingly the Rose-Waaler 
has only been positive in blood twice (titre 1:64) and both occasions 
were during the interferon treatment. One month prior to interferon 
the Rose-Waaler had been positive (1:64) in the synovial fluid from 
her knee.
D-Penicillamine/Placebo (Patient 101 continued): Our patient was 
managed conservatively (one week of bed rest then out-patient 
physiotherapy, co-proxamol and piroxicam) for five months after the
interferon trial had finished. She experienced fluctuating mood and 
disease activity but was able to resume her occupation, shopping and 
housework although all with some difficulty. However, in January 
1987, one year from onset of her symptoms, the symmetrical, 
peripheral poly arthritis was still active clinically and supported 
by: haemoglobin 9.6G/dL, ESR 50mm/hr, CRP 40 (normal <10). Her 
existing treatment was continued and she gave informed consent to be 
admitted to a double-blind, placebo controlled trial of D- 
penicillamine (designed to study the effect of the drug over one 
year, in recent onset arthritis of the rheumatoid type). She remained 
on the "study tablets" for four months without clinical or 
serological improvement. When she developed mildly painful 5mm 
diameter mouth ulcers (the only time she had ever these) the trial 
tablets were stopped (May 1987), the code broken and she was found to 
have been taking placebo.
Gold (Patient 101 continued): She experienced relief after intra- 
articular injection of triamcinolone to both knees but this was short 
lived. In August 1987, twenty months from onset of symptoms, she 
still had clinically apparent symmetrical, peripheral polyarthritis 
of the rheumatoid type, with ESR 95mm/hr and CRP 75. She was 
commenced on treatment with gold as Myocrisin 50mg intramuscularly 
each week and the coproxamol and piroxicam were continued. She began 
to experience improvement after two months and in January 1988, five 
months after starting gold and two years from onset of the first 
symptoms she was in symptomatic, clinical and serological remission. 
She was able to run, ride an exercise bicycle, work part-time and 
conduct activities of daily living with nil difficulty. She 
complained of slight pain in the first MTP joint of each foot, but of 
no other joint symptoms. The only abnormality on clinical examination 
was slight ulnar deviation of the fingers but there was neither
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active synovitis nor accumulated damage in any joint. The ESR was 13 
and CRP only 21, confirming the clinical impression of disease 
remission. The gold was continued in the reduced dose of 50mg per 
fortnight. When reviewed in January 1989, three years from onset of 
symptoms, the remission was sustained apart from cool but definite 
synovial swelling of one thumb inter-phalangeal joint. She has never 
had rheumatoid nodules and no definite joint.erosions have yet been 
seen on X-ray of hands and feet. 1
Probing for persistence of Human Parvovirus B19: In patient 101 there 
was the possibility of persistent infection with the virus as an 
explanation for the continued immune response. Dot-blot 
hybridisation33 was kindly carried out by Dr BJ Cohen, Virus 
Reference Laboratory, London but no B19 DNA was found in a synovial 
biopsy taken from the patient’s knee in May 1986, four months from 
onset of symptoms and just before starting the interferon treatment.
A sternal marrow aspirate performed three weeks after completing the 
interferon treatment revealed a normocellular pattern but reduced 
iron stores. It was hoped that with removal of any suppressant effect 
of the alpha-interferon therapy on erythropoiesis there might be a 
resurgence of erythropoietic activity. Since the main host cell 
infected by B19 is the erythroid precursor, it was hoped that if 
there was any B19 present in this patient, then it might replicate 
with the increased erythropoiesis. A faint positive signal was 
obtained but its significance is uncertain. The polymerase chain 
reaction method of DNA detection147 is being developed for this virus
and will be applied to this marrow sample.
6.5 Review of measured variables in B19 arthritis patients
With only 5 SLS and 1 PS patient having had recent B19 infection, it
would be inappropriate to compare them with each other or with their
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respective outcome groups (SLS or PS) in a formal statistical 
analysis. Review of the median and range values for the clinical 
variables (chapter 3) would suggest, however, that the B19 patients 
are representative of their groups for example in terms of age, sex, 
duration of disease at presentation and grip strength. It is 
particularly interesting that the strongest selected variable, the RA 
Latex, was able to discriminate between the B19 IgM positive SLS 
patients (all RA Latex negative) and the B19 IgM positive PS patient 
(RA Latex positive). Unfortunately none of the B19 IgM positive 
patients were among the 18 SLS and 10 PS patients (chapter 4) who had 
T-lymphocyte subsets assayed at first clinic visit.
Antigen Fc-Per Cri Ware Pe Camp Ren Goe Cart Reed
median SLS 3.4 2.9 3.6 5.0 2.65 9.5 9.0 1.4 2.4
range SLS 0 - 
46
0 - 
70
0 -
33
1 -
23
0 -
23
3 - 
73
1 -
67
0 -
28
0 -
134
Pt 68 0 3.0 6.3 7.4 6.7 3.6 9.8 1.1 2.3
Pt 93 3.4 2.9 1.5 4.3 1.3 11.7 1.7 0 1.6
Pt 105 6.6 28.8 22.3 23.1 23.4 73.5 66.8 3.7 11.0
median PS 90 149 112 37 156 74 51 21 130
range PS 2 -
1114
1 - 
2598
0 -
2022
0 -
1549
0 -
2304
5 - 
1101
0 - 
1005
0 -
499
0 - 
2624
Pt 101 195 336 . 304 48 179 91 237 31 236
Table 6.1 IgMRF levels (jj^ g/ml) in B19 positive patients
Four B19 IgM positive patients (3 SLS, 1 PS) were assayed for IgMRF:
their values were representative of their outcome groups (Table 6.1) 
but interestingly (as was the case for the clinical variables) 
patient 101 (in the PS group) had markedly different values from the 
other B19 IgM positive patients (who were in.the SLS group). The
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results of the capture ELISA assay quantifying CRI-bearing IgM levels 
were presented graphically and discussed for the B19 IgM positive 
patients (chapter 5). The values obtained (Table 6.2) seem to be 
representative of the respective outcome groups in the case of C7,
HI, G6 , G8 and the one value for 17_109. The possible exception was 
patient 105 (SLS) who had the highest values in the SLS group for HI,
G8 and almost for G6 . However one B19 IgM negative patient (Patient 
43) had similar levels, so the phenomenon is not confined to B19 
positive SLS.
CRI C7 17_109 HI G6 G8
median SLS 132 2.3 0.0 3.4 6.3
range SLS 34 - 0.5 - 0 - 0 - 0 -
458 10 15.6 30.8 114
Pt 68 132 - 0.4 3.7 8.8
Pt 93 101 0.5 1.4 3.8 6.3
Pt 105 458 - 15.6 25.6 114
median PS 147 18.5 1.8 5.2 20.1
range PS 7.5 - 0 - 0 - 0.8 - 0.8 -
627 495 25.6 33.3 116
Pt 101 93.8 - 11.8 11.5 76.4
Table 6.2 Cross-reactive idiotope (CRI) 
in B19 positive patients
bearing IgM levels (j^ g/ml)
Only one B19 IgM positive patient (Patient.93) was included in the 
inhibition of direct binding ELISA assay of CRI-bearing IgMRF 
(chapter 5) and his results were very close to the median for his 
outcome group.
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6,6 Discussion of viral studies
6,6,1 Discussion - viral serology results:
Rubella: The finding of no patients with post-Rubella arthritis 
presumably reflects the increasing level of community immunity as a 
result of screening women near puberty and vaccinating those found to 
be non-immune, with further monitoring of the immunity in the 
obstetric service. The role of Rubella in arthritis will possibly 
reduce further with the introduction of the combined vaccination 
against mumps, measles and rubella for all children prior to entering 
school.
Human Parvovirus B19: In view of the wide range of disease duration 
at presentation, we chose to use the single serum sample obtained at 
first visit, to determine recent infection on the basis of. specific 
anti-B19 IgM. Previous studies have also included patients with 
rising titres of anti-B19 IgG : however since we were able to detect 
IgM as late as three months after the clinically apparent infection, 
when the IgG titres would have reached a plateau, it is unlikely that 
paired IgG titres would have included any more patients. The 
recruitment period for this study was from May 1984 to May 1986. All 
six of our positive patients experienced infection in the winter of 
1985/86. The availability of serological testing for B19 was not 
widely known at that time so there are no accurate figures for the
incidence of B19 infection in the community over the same period.
1 1However one community based study of a B19 epidemic in a school 
revealed that of the 54 anti-B19 IgM positive adult contacts, fully 
26 had acute symmetrical polyarthropathy, but lasting a median of 
only 10 days. Our figures confirm the benign nature of B19 arthritis 
with the majority of cases being sub-clinical and of those who do 
come to the attention of their General Practitioner, spontaneous 
remission usually ensues before any hospital referral, even when the
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hospital is actively recruiting such cases.
Perhaps more intriguing than the anti-B19 IgM positive patients are 
the 24 SLS patients with unexplained polyarthritis, where the nature 
of the trigger remains elusive, as it does in all but one of the PS 
patients.
6.6.2 Discussion - case histories:
The analysis of the clinical data (chapter 3) suggested that the SLS 
patients had a very similar disease pattern to PS in all but 
persistence. The concept of SLS as a model for PS (and hence for RA) 
is further refined in this chapter with the identification of a 
specific trigger for SLS in five patients who would appear to be 
representative of the SLS group, in terms of the variables measured 
for this study.
Even though B19 arthritis is usually benign the cases described here 
indicate that for some patients the arthritis is sufficiently severe 
to seek medical help and even to require hospital admission. Their 
subjective complaints are supported by clinical observation with, for 
example, very real reduction in grip strength in the earliest weeks 
with subsequent recovery. The ability of a virally induced arthritis 
to mimic rheumatoid arthritis in all but persistence (and arguably in 
severity) suggests that many components of the inflammatory process 
we recognise as polyarthritis, are common to both SLS and PS and 
hence independent of the characteristic of persistence.
The case of patient 101 has been described in detail precisely 
because she would appear to be the exception to the rule of a benign 
prognosis for post-B19 arthritis. There is little doubt that she and 
her family suffered infection with B19 and that within days she 
experienced her first ever joint symptoms. We were unable to 
demonstrate conclusively any persistence of the B19 virus but
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although the methods used and the tissues chosen were the only ones 
available at the time, it is clear that the search could not be 
exhaustive. Whether, in susceptible hosts, persistence of B19 virus 
drives a chronic immune reaction, or alternatively transient 
infection triggers an appropriate immune reaction which escapes the 
normal controlling mechanisms, remains open to further investigation. 
Although not germane to the prediction of persistence in recent onset 
synovitis, the details of treatments for patient 101 are given lest 
they influenced the outcome. There was little effect on symptoms or 
signs from the placebo D-penicillamine phase of treatment. The timing 
of onset of remission once gold was started is in keeping with this 
having been due to the gold. It remains possible that the remission 
was coincidental and spontaneous but she continues to have very 
limited but definite synovitis in one joint, which is not the 
experience to date of spontaneously remitting B19 arthritis where 
there may be continuing non-specific symptoms but not definite 
synovitis. The temporary benefit from alpha interferon may have been 
due to incomplete elimination of putative viral persistence or to 
temporary immunomodulation and the further investigation of these 
possibilities, using serial data from our patient may help to 
elucidate the mechanism of her persistent synovitis.
It is clear that in patient 101 the B19 arthritis was severe and 
remained so for longer than any previously reported B19 arthritis. On 
many occasions her arthritis fulfilled the ARA criteria for the 
diagnosis of RA. The B-lymphocyte data obtained from this patient 
would support the clinical decision to assign her to the PS group. If 
she were to develop characteristic joint erosions or rheumatoid 
nodules it would be hard to refute the diagnosis of RA. In the 
meantime it is a matter of philosophy whether her diagnostic label 
should be "a persistent post-viral polyarthritis of the rheumatoid
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type" or simply RA with an identified trigger. In the context of 
possible mechanisms of persistence it was particularly interesting to 
find she is homozygous for HLA DR4, but that will not resolve the 
question of the diagnostic label until more information is available 
from epidemiological studies which include the relationship of HLA 
phenotype to speed of recovery from B19 arthritis. Any study of B19 
arthritis as a model for RA will have to consider the two identified 
outcomes, the commoner being SLS but now with PS as a possibility.
CHAPTER 7
DISCUSSION
AND
CONCLUDING COMMENTS
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CHAPTER 7 
DISCUSSION
7.1 The patients
A total of 112 patients with musculo-skeletal symptoms of recent 
onset has been screened, with 65 of these having the symptoms of a 
symmetrical, peripheral polyarthritis similar to that of Rheumatoid 
Arthritis (RA). As a result of specifically soliciting from general 
practitioners their patients with recent onset of disease, these 65 
patients were seen earlier than would have been possible through more 
routine methods of referral. Since the study excluded anyone with 
more than six months of symptoms, the 65 patients reported here were 
seen earlier than in most published studies of early RA. Accordingly 
they are a particularly rare and valuable group in the study of RA. 
Conceived on similar lines to the present work, a previous study140 
also included patients with recent onset arthritis but had one entry 
requirement that patients should have at least probable RA (by ARA 
criteria) during the study and hence patient selection was possibly 
more specific and less sensitive than for the present study.
7.2 Constraints on data interpretation
The following considerations are important because they underlie the 
formal data analysis for each results chapter.
7.2.1 Selection
The response from general practitioners was varied, with some 
referring several patients and others (the majority) referring none. 
This study therefore is not (and was not designed to be) 
epidemiologically sound in the sense of representing the experience 
of the entire at-risk population. However the study was designed to
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address two main areas of ignorance: (i) if a treatment is to be 
applied to early RA, how easy will it be to select appropriate 
patients? and (ii) what can be learned of the pathology of chronic RA 
from study of its earliest stages?. If either of these questions are 
applied in routine clinical practice, the recruitment method used 
here will be common, and is therefore relevant.
7.2.2 Definition of outcome
I allocated a patient to one of the disease groups (SLS or PS) based 
on the patient and myself agreeing to disease being present or 
absent. Unlike the broader clinical experience where patients may 
complain of vague symptoms even after the clinician judges there to 
be no disease present, the patients in this study had, in general, 
dramatic symptoms at the outset and were keen to welcome remission if 
it came. I would suggest that although this study was not designed to 
measure it, the definition of outcome was so categoric that the 
inter-observer variation would be low.
The time at which an outcome was defined for a patient was generally 
within six to twelve weeks of their first visit to clinic. This 
allocation was much earlier than in a previous study140 where the 
analysis was made on the basis of patients being followed for a 
minimum of three years. That study included three outcome groups: 
category 1 - no swelling or joint erosions; category 2 - soft tissue 
swelling but no erosions; category 3 - erosions. The SLS group in the 
present study corresponds to the category 1 of the previous study.
The PS group is likely to include categories 2 and 3, assuming that 
in the present study the development in time of joint erosions will 
be confined to the PS group. No patient in the present study is known 
to have crossed over after allocation to an outcome group but long
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term follow-up studies are in progress and will include comparison of 
the radiographic examination of the hands and feet performed on all 
patients at entry to the study and at follow-up: clearly a disease 
duration of three to six months is too early to comment on 
development of erosions52.
7.2.3 Single observations at point time
All of the analysis is based on each variable being measured only 
once at a single point in time, namely the patient’s first visit to 
the early arthritis clinic. By design this thesis examined only those 
first visit data. It is likely that in clinical practice the 
selection of a patient for entry to a therapeutic study would depend 
on the gradient of disease activity based on measuring selected 
variables at a minimum of two time points. Serial data available on 
most of the patients presented here will be the subject of further 
study to examine whether they confirm or change the current 
conclusions.
7.2.4 Statistical techniques and validity
In the univariate analysis of many variables, the need for the 
correction in the level of statistical significance for the number of 
variables recorded has been discussed in chapter 3. In chapters 4 and 
5 the T-lymphocyte and B-lymphocyte studies can be considered as 
independent studies with small numbers of variables. The significance 
values in those (most of which would remain significant and would not 
alter interpretation if corrected for the number of variables 
recorded) have been used as a guide to interpreting the pattern of 
changes, in the hope of understanding underlying pathogenesis. 
Notwithstanding significant differences, in univariate analysis the 
striking finding was of overlap between the groups (SLS and PS). This
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overlap was further confirmed by the multivariate analysis (stepwise 
variable selection) which, although identifying the most predictive 
of the recorded variables, was stiil only able to account for about 
half of the variability in outcome.
7.3 Clinical variables
7.3.1 Natural history
The critical observation first noted by others and studied in detail 
here, is that people experiencing acute, severe, disabling peripheral 
polyarthritis can expect one of two outcomes: spontaneous remission 
within about six months, or chronic disease that is similar or 
identical to RA. It is worth emphasising the point which does not 
emerge clearly from previous studies: even those patients whose 
recent onset synovitis is destined to remit, experience a severe 
arthritis. A typical story of a patient with SLS, which cannot be 
reflected in bare statistical analysis would be as follows:
"I awoke early one morning - I was well the night before - and I 
could not move. I was in terrible pain, all stiff. My husband had to 
help me out of bed and to the toilet. I cried because I was terrified 
it would never leave me".
For the fortunate patient with SLS the emotional impact of the 
disease will soon resolve with the clinical remission, unlike in the 
PS patient. For the statistician the possibility of predicting 
outcome on the basis of presenting features has been explored in 
detail in the clinical data analysis (chapter 3) and by previous 
authors with, for example the rapid rate of onset of symptoms being 
considered a benign prognostic feature by some59 but not by others58. 
However, if the long term review of the present study’s patients 
confirms the allocation to outcome groups, then prediction of outcome 
on very early data will be unnecessary since spontaneous remission
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was found to declare itself within one or two follow-up visits 
(interval six weeks) and generally by disease duration six months. 
That duration would be suitable for all but the most aggressive early 
treatment protocols.
7.3.2 Clinical variables - SLS as a model for PS
The outstanding clinical observation is that in the earliest stages 
the patients with SLS have disease that is.apparently very similar to 
PS and although symmetry was not formally analysed, the pattern of 
joint involvement was pre-selected for being symmetrical. This 
similarity between SLS and PS is supported by the detailed 
statistical analyses of the clinical variables which are more 
remarkable for the overlap between the groups than for the 
discrimination between them. The main outcome of the clinical 
analysis then is not the prediction of persistence but rather the 
realisation that in the brief but severe arthritis of SLS lies a 
human model for the study of PS and hence for the study of rheumatoid 
arthritis. The absence of chronicity of inflammation and accumulated 
joint damage enhance the value of the model by allowing a 
reductionist approach to the understanding of their aetiology: it 
should help to differentiate between those phenomena of inflammation 
common to any polyarthritis from those mechanisms intrinsic only to 
chronic disease.
In considering the pattern of joint involvement, the similarities 
between the two groups (SLS and PS) were emphasised particularly by 
the poor combined sensitivity and specificity of most of the joint 
variables (Appendix 1, Table Al.l). Considering the combined 
sensitivity and specificity (referred to as "accuracy" in the 
description of the 1987 ARA criteria55) it is interesting to note
that the most predictive (for PS) of the joint variables in the 
present study are those defined as being present by the clinician, 
namely swelling at wrist, MCP and PIP joints (sensitivity/specificity 
(%) 65/83, 79/61, 69/69 respectively). The values for sensitivities 
and specificities in the present study of recent onset disease are 
only slightly lower than in the description of the ARA criteria for 
the diagnosis of RA55, which were developed in patients with longer 
established disease. It emerges that by the time of presentation two- 
thirds. or more of the SLS patients did not have (objective) swelling 
at those joints: this is partly because many were already undergoing 
remission (compare with the much lower specificities of the 
(subjective) swelling reported by patients in those same joints) and 
hence as a group the SLS patients had less severe disease at first 
clinic visit, than the PS patients. This difference in severity 
between the groups is seen also in the routine laboratory variables, 
with for example the ESR being higher in the PS group. Clearly, 
however, it is possible for a patient to have a high ESR and still 
undergo remission: the acute phase response is therefore likely to be 
part of any polyarthritis rather than be a determinant of chronicity. 
This is consistent with the production of acute phase proteins by the 
liver being induced by interleukin-1 (IL-1), produced in turn by the 
non-antigen specific monocyte/macrophage lineage148,149 (although 
now thought to be in conjunction with IL-6 ) and so likely to 
occur if there is inflammation of sufficient-synovial tissue, 
irrespective of cause or chronicity.
7.4 B-lymphocyte studies - a dichotomous discrimination?
7.4.2 RA Latex and IgMRF quantitation
The simple slide latex test for RF, returning merely a positive or 
negative result, has been regarded as a useful screening test which
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lacks specificity and, for diagnostic purposes, has to be supported 
by a more specific test (eg Rose-Waaler test or quantitation of the 
latex result). It was therefore surprising to find a near-dichotomy 
in the results for the RA Latex in the present study with very little 
overlap between SLS and PS (sensitivity/specificity for PS being 
79/89 Z). It was even more remarkable to find the RA Latex positive 
in only one of the six post-Human Parvovirus B19 patients, and that 
was in the patient with Persistent Synovitis. This strongly suggests 
that the production of RF (so defined) is not common to all 
inflammatory polyarthritis but is almost restricted to persistent 
synovitis. That its presence in the peripheral blood is not, however, 
necessary for persistence is evidenced by the six PS patients in whom 
the test was negative: in turn this is in keeping with the finding of 
a positive RF in only some 70% of patients with otherwise typical
pg
R A ' . It could be argued that a positive RA Latex reflected disease 
severity, since the correlation between RA Latex and ESR was moderate 
(coefficient 0.65, p > 0.0001) but the weakness of the apparent 
correlation (between a categoric variable and a continuous variable) 
was revealed on regression analysis, with the ESR accounting for only 
42% of the variability in RA Latex. That the RA Latex is not simply a 
marker of disease severity is further supported by the finding that 
the quantity of IgMRF did not correlate with the ESR either (chapter 
5, Table 5.4). The increased levels of IgM (with and without RF 
activity) in PS compared with SLS would be consistent with the 
provision of increased T-cell help for B-cells, suggested by the 
finding in PS of higher numbers of activated TFR+CD4 lymphocytes in 
the peripheral blood.
This then suggests a specific role for RF in PS. That such a role 
might be physiological, aimed at binding circulating immune complexes
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and enhancing their removal from the circulation151, would be 
supported by the finding of a close correlation between IgMRF levels 
irrespective of the IgG subclass used as target in the assay (chapter 
5, Table 5.4). Thus the main antigen for IgMRF would be self IgG-Fc 
of a range of subclasses. Superficially there is a suggestion that 
the RA Latex (using rabbit IgG as antigen) is more discriminating 
between SLS and PS (relative risk for PS 5.31, Chi2 30.0, table 3.4) 
than is a supra-normal IgMRF level using human IgG as antigen 
(relative risk for PS 3.43, Chi2 11.3 (RF-Per) table 5.3). However, 
the respective sensitivities and specificities are remarkably 
similar, especially considering that the RA Latex is a naturally 
categoric variable and the supra-normal IgMRF level depends on the 
validity of the normal population sample, and considering that the 
IgMRF levels were performed on a smaller number of subjects than for 
RA Latex.
7.4.3 Qualitative differences in IgM(RF) between SLS and PS 
If the above model of IgMRF as having a physiological, clearance role 
with wide specificity for IgG is true, it begs the question of why 
the idiotypy of the IgMRF is different in SLS versus PS. It appears 
that in both SLS and in PS there is IgMRF with specificity for IgG 
but the levels are higher in the PS patients (albeit with 
considerable overlap with SLS and indeed with normal subjects). In 
both SLS and PS expression of cross-reactive idiotopes (CRI) on IgMRF 
can be detected. (The argument that the assays measure CRI expression 
mainly IgM with RF activity has been addressed in detail in Chapter 
5). The levels of some but not all of the measured CRI are slightly 
higher in PS than in SLS. However the striking feature in PS is that 
the much higher total levels of IgMRF in the PS patients are largely 
accounted for not by CRI-bearing IgMRF but by greatly increased
levels of non-CRI-bearing IgMRF. Indeed there is a disproportionate 
elevation in the non-CRI-bearing IgMRF in the PS group of patients. 
This additional production in PS of IgMRF which does not express the 
tested CRI suggests alteration in fine structure of the variable 
region of such IgMRF, arising from a departure from the use of germ- 
line sequences in PS, through somatic mutation. This would mean that 
in addition to so-called "natural antibodies" (being generally low 
affinity, cross-reactive and of IgM class) the PS patients were also 
producing more specific, higher affinity, "pathogenic antibodies".
The CD5 antigen is expressed on the surface of a subset of B-cells in 
normal mice152 (previously referred to as Ly-1 positive cells) and in 
humans153,154 (previously known as Leu-1 positive cells). This 
subset produces IgM antibodies with activities including anti-RBC, 
anti-IgG and anti-ssDNA. CD5+ B cells are present in patients with RA 
and indeed have been found in increased numbers compared with normal 
subjects ’ but their numbers do not correlate with the levels 
of total IgMRF in the patients. The autoantibodies they produce are 
thought to be of low affinity and to have been translated and 
transcribed from germ-line genes without somatic mutation. Since the 
CD5+ cells occur in health as well as disease (albeit in different 
amounts) the antibodies they produce are thought to have a 
physiological role . It seems likely that in both SLS and PS 
patients these CD5+ B-cells will be found to be present, to be 
secreting CRI+ IgMRF, and perhaps with increased numbers in the PS 
patients. However the increase in non-CRI-bearing IgMRF in the PS 
patients would suggest that in addition they have CD5- (negative) B- 
cells present, producing IgMRF of a "pathogenic" nature, with altered 
specificity as a result of somatic mutation.
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Support for the concept of somatic mutation in IgMRF production in PS 
comes from the murine models of lupus where the pathogenic (IgG) 
antibodies appear to result from somatic mutation. Variability in the 
specificity of auto-antibodies from genetically identical (within 
(NZBxNZW)Fl and also within MRL-lpr/lpr) groups of mice cannot arise
1 57 15ftfrom the germ-line ’ . Furthermore DNA sequence analysis 
supports the use of somatic mutation in auto-antibody production in 
MRL mice159. The somatic mutations are believed to occur randomly and 
those B-cell clones producing higher affinity antibodies are selected 
by their preferential binding to antigen160'2.
It appears then that somatic mutation may be occurring in PS and the 
question can then be asked about the nature of the driving antigen.
One possibility is that the change in fine structure results in 
increased affinity for the putative main target antigen, the Fc 
portion of IgG. Arguably this might enhance clearance of IgG 
complexed to foreign antigen or, through cross-linking of the Fc 
component of IgG molecules specifically bound to a microbial cell 
surface, enhance opsonisation . For the future that hypothesis 
could be tested by comparing the affinity,.for IgG bound to antigen, 
of CRI-bearing and non-bearing IgMRF. Work to date suggests that 
IgMRF in RA are generally of low affinity for autologous circulating 
IgG54.
An alternative hypothesis would suggest that normal IgG is not the 
main target antigen for IgMRF and that its affinity for IgG arises 
from cross reactivity with an alternative (exogenous or self) primary 
antigen. Recruitment of clones of B-lymphocytes producing non-CRI- 
bearing IgMRF could be antigen driven, and might persist through 
either persistence of the primary antigen, or through cross­
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reactivity with self IgG.
As discussed in chapter 1, one such antigen could be IgG that had 
been damaged at a site of inflammation. However, the levels of free- 
radical damaged IgG were not abnormal in the peripheral blood of the 
SLS and PS groups of patients. This could be because the hypothesis 
is wrong and free-radical damaged IgG is not a persistent stimulus 
for RF production. The hypothesis could alternatively be correct if 
the avid binding of RF to damaged IgG resulted in the clearance of 
the latter from the circulation and the findings in the PS patients 
reflect antibody (RF) excess. Work is in progress to attempt to 
quantify free-radical altered IgG extracted from circulating immune 
complexes.
Any departure from considering IgG.as the main antigen for IgMRF 
would have to account for the continued ability to bind to IgG 
despite affinity maturation in favour of binding to a putative 
alternative antigen. Candidates for consideration as target antigens 
for IgMRF would include those of infectious agents. Such a model 
would have, at its simplest, the IgMRF binding the microbial antigen 
directly, without the need for an antigen-specific IgG molecule as 
intermediary. A formal study of any affinity of non-CRI-bearing IgMRF 
for the antigens of arthritogenic organisms would be worthwhile, 
including for example the structural proteins of the Human Parvovirus 
B19 in patients who have recently been infected. However, although 
some RF have been identified as having specificity for antigens other 
than IgG, these have been the exception, with most RF not having an 
identified alternative specificity54.
The complexity of the exogenous antigen model can be increased by
considering the IgMRF as an anti-idiotypic antibody. The expression
of receptors for Fc on the surface of some micro-organisms (allowing
them to sequester host anti-microbial antibodies) might lead to a
host response with antibody (Abl) specific for any unoccupied
microbial Fc receptor and would have Fc as its internal image. An
anti-idiotypic (controlling) antibody (Ab2) would then have anti-Abl
specificity and as a consequence also anti-Fc specificity, ie RF- 
1 finactivity . The relative affinities of CRI-bearing (germ-line) 
versus non-CRI-bearing (possibly non-germ line) IgMRF for IgG-Fc 
might test the alternatives. If simple cross-reactivity between an 
exogenous antigen and IgG were true, then with affinity maturation 
towards the exogenous antigen, the (cross-reactive) affinity for IgG- 
Fc might be expected to decrease. If the anti-idiotype model were 
more accurate, the same affinity maturation might be parallelled by 
increased affinity (of Ab2) for IgG-Fc.
7.4.4 B-lymphocyte studies: summary
The studies of both the quantity and quality of IgMRF production 
suggest differences in the nature of the inflammation in PS compared 
with SLS. These differences do not simply reflect disease severity 
and their near-dichotomous nature may indicate a role for specific 
forms of IgMRF in the chronicity of disease in PS. Whether the role 
is causative of chronicity or in response to it, remains an open 
question which might be addressed by the study of antigen-specific 
arthritis models.
7.5 T-lymphocyte studies
Although only phenotypic studies were performed it is interesting to 
combine the results with those from the B-lymphocyte studies to 
speculate on corresponding functional mechanisms.
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7.5.1 Activated T-lymphocytes
It was clear from the results presented in chapter 4 that in terms of 
circulating T-lymphocytes, the main differences between the SLS and 
PS groups lay within the activated population of T-lymphocytes, and 
in particular within the CD4+ subset of the activated cells. The 
greatly increased levels of TFR+,CD4+ cells suggests the presence of 
increased availability of T-cell help (by cytokine production) for B- 
lymphocytes. The IgM levels in PS being higher than in SLS would 
superficially support that assertion.
7.5.2 Failure of Ig class switching
- possible differential cytokine production?
The probability that affinity maturation is taking place in PS was 
discussed above, and in a normal immune response one would expect 
this to be accompanied (within about 10 days from first antigen 
challenge) by a rising specific IgG and then (after some weeks) by a 
fall in the specific IgM level. The existence in a primary immune 
response of that IgM antibody with specificity for an antigen, 
indicates that at least a degree of affinity maturation may take 
place in advance of isotype switching. This suggestion is supported 
by evidence from experimental systems that somatic mutation takes 
place before, during and after isotype switching162,164'5.
In order to develop this discussion further a degree of extrapolation 
is now required, since the observations for this thesis were made at 
a single point in time for each patient and sequential data has not 
been presented. In addition no studies of IgGRF were performed on 
these patients. Equating the PS patients to RA would suggest that the 
elevated IgMRF levels observed in this study can be expected to
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persist: supra-normal levels of IgMRF are found in RA patients 
decades after the onset of their disease and indeed this phenomenon 
forms one of the ARA criteria for the diagnosis of RA. In contrast, 
although IgGRF is identified in RA, it is not usually the predominant 
Ig class and indeed when it becomes so, it is associated with a 
change in the disease manifestations towards systemic vasculitis54. I 
would suggest that in PS although affinity maturation of the immune 
response (compared to that of SLS) appears to have taken place (mean 
disease duration at first visit PS =14.2 weeks), the immunoglobulin 
class-switching is at best incomplete. It might be possible on future 
PS patients follow this possible affinity maturation serially from 
the earliest days of symptoms and to include examination of the 
cytokines produced by their CD4+ lymphocytes. It may be that in PS 
the CD4+ cells supply cytokines required for the proliferation of B- 
lymphocytes and their secretion of immunoglobulin, but fail to supply 
the cytokines required to complete class-switching. A simple scheme 
has been suggested for the cytokine control of Ig production, with 
IL-4 involved in B-cell activation (in conjunction with antigenic 
stimulation), IL-5 being involved in B-cell proliferation and IL-6
1 fifiinvolved in B-cell differentiation to plasma cells . In that simple 
scheme affinity maturation and isotype switching occur in presence of 
IL-6 but the authors pointed out that IL-6 increases the mRNA for 
both gamma and mu chains, ie that the effect is not isotype specific. 
Since that review was produced (about one year ago) it has become 
clear that the picture is far more complex: individual (recombinant) 
cytokines, tested in purified B-cell preparations, can have 
contradictory effects (enhancement or suppression) depending on the 
state of pre-activation of the B-cell, and the relative amounts of 
other cytokines present167. Furthermore, a degree of isotype 
specificity has been suggested, with IL-4 being associated with IgGl
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and IgE production (depending on how the B-cells are stimulated),
1 fi7IL-5 with production of IgA, and gamma interferon with IgG2a . In 
addition recent work has suggested that not all the cytokines have 
been fully characterised, with a possible novel B-cell 
differentiation factor being involved in the very late stages of B- 
cell differentiation168.
All this leaves room for speculation that the persistence of RF of 
the IgM isotype, despite somatic mutation, arises as a result of an 
aberration (fault or virtue) in the control of isotype switching, due 
to a differential cytokine effect (at any stage of the signalling: 
transcription, secretion, binding or transduction).
Whether the incomplete isotype-switching were advantageous (in 
avoiding systemic vasculitis, for example) or an embarrassment (in 
promoting persistence), it would of course have to be restricted to a 
very limited part of the host’s immune repertoire: patients with RA 
can mount normal class switching in response to common infecting 
organisms.
7.6 Viral studies
The search for a viral aetiology for the arthritis in these patients 
was deliberately confined to those viruses which may be amenable to 
further study in the foreseeable future. Human Parvovirus B19 (B19) 
is known to infect the susceptible population in epidemics. The 
resulting "fifth disease" in children is mild but the rash alerts the 
school and medical authorities to the epidemic. That awareness, added 
to the high incidence of arthritis in affected adult contacts 
(especially the mothers), offers the opportunity to study useful 
numbers of patients with an arthritis arising in response to an
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identified and well characterised antigen. Rubella was studied in 
addition partly because of the similarity in the clinical picture but 
also because the assay performed on the serum to detect a specific 
immune response uses a near identical method to that for B19: the 
Rubella results are therefore a control for any non-specific immune 
response.
7.6.1 Clinical picture of B19 arthritis
Of the six patients shown to have specific anti-B19 IgM near the 
onset of their arthritis, five were typical SLS patients. Even though 
there was variation in the severity of B19 arthritis, the patients 
here demonstrate a consistency in the pattern of joint involvement 
which is further supported by observations by previous authors42,43.
The general conclusion arising from the clinical studies (chapter 3), 
that SLS offered a model for the study of PS (and hence for the study
of RA), can therefore be refined to using B19 arthritis as a model
for RA. Hence with a known antigen and with the usual outcome known, 
the host responses should be amenable to specific study and 
comparison with the wealth of observations on the immune system, in 
RA.
The finding of one patient with B19 arthritis which evolved to a 
persistent synovitis was unexpected but potentially increases the 
value of the model. In response to a given antigenic challenge 
(serological and DNA sequencing studies suggest little or no 
variation in the structure of the B19 Parvovirus recovered in 
different epidemics169), the finding of diversity of outcome suggests 
that the differences lie at the level of the host response to the
antigen. At the simplest level, a limited number of serial serum
samples are available from the B19 patients and it might be possible
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to further study affinity maturation through any changes over time in 
the idiotope expression on IgMRF, and to more formally examine the 
possibility of incomplete Ig class-switching. If future patients 
could be seen sufficiently early, serial functional studies of the T- 
lymphocytes, in particular cytokine production, might help to explain 
the persistence of IgMRF in RA.
7.6.2 Persistent infection or persistent host response?
The question of the possible persistence of Human Parvovirus B19 has 
been discussed above (page 46) and so far no definite conclusion can 
be drawn. Our results so far have failed to demonstrate any 
persistence of the virus (see chapter 6, case 101) but development of 
the polymerase chain reaction method147,170'1 with its increased 
sensitivity might define how long virus persists, although the 
studies are limited by the availability of host tissue.
Animal models of persistent immune response have suggested that the 
triggering antigen may only be necessary early in the disease, with 
host T-lymphocytes responsible for persistence, and with disease 
transfer mediated by antigen specific T-lymphocytes172. The 
association of RA with particular class II major histocompatibility 
complex (MHC) antigens173, together with the recognition of the role 
played by the MHC molecules in presentation of antigen to the T- 
lymphocyte receptor63, suggests that T-lymphocyte recognition of 
antigen may be crucial in the pathogenesis of RA. In RA the 
difficulty lies in choosing which antigen to study from a large 
number of candidates. Previous viral studies in RA have been
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inconclusive26 indicating the need to use more precisely defined
i . 174viral antigens .
7.7 B19 arthritis as a model for RA - work in progress 
From the observations in this thesis I have developed the hypothesis 
that B19 provides a model for the study of RA, with differing outcome 
of infection with a given antigen being determined by differing host 
response. I will present in this section further justification for 
choosing this virus and the specifics of the work which has now begun 
to test the hypothesis. Having previously discussed the possibility 
of persistence in the host of the B19 virus and the intention to 
continue to probe for its presence, I will now concentrate on the 
study of the host response. Precedents for this kind of work are 
established in other virus systems (for example Foot and Mouth
1 7*^  1 7 f t
Disease virus and influenza virus but have not been applied to 
the rheumatic diseases.
7.7.1 Human Parvovirus B19 antigens available for study 
B19 arthritis provides the opportunity to study T-lymphocyte 
responses to defined viral antigens. B19 is a structurally simple, 
well characterised, single strain, single stranded DNA (5.5Kb) virus.
A Q
Culture of the virus requires human bone marrow and so the only 
practical but rare source of the whole virus remains viraemic plasma. 
Small quantities of viraemic plasma.are available but the planned 
studies will require larger amounts of antigen, and so the supply of 
whole virus will be reserved for very selected studies. Recent
QQ A OC
cloning , and sequencing of the viral genome has improved the 
understanding of its structure. Furthermore, expression of some 
partial B19 cDNA clones to yield antigenic polypeptides has permitted 
the description of epitopes recognised by anti-viral antibodies
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(B-cell epitopes)177. Equivalent studies on T-cell defined epitopes 
have not yet been performed. To date, there are no published studies 
of T-cell responses to whole virus. The search for T-cell epitopes 
can be narrowed further: firstly by considering the published 
transcription map178 to determine the likely proteins encoded by the 
virus and secondly, by examining the sequence of a given protein, for 
peptides containing amino-acid sequences that correspond to 
algorithms designed to predict sequences which can be recognised by 
T-cells when bound to MHC antigens179. Once selected, candidate 
peptides can be synthesised directly (the algorithms generally 
require peptides of some 8 to 10 amino-acids in length) or 
alternatively, viral constructs which contain these relevant 
sequences may be used.
I have now obtained, from several of the cited workers in the field, 
peptides synthesised from the B19 sequence on the basis of the 
algorithms, protein expressed by partial cDNA B19 clones in E. Coli, 
and expressed protein from a partial cDNA clone in a mammalian cell 
line (unpublished data). These materials are therefore ready to be 
applied to the study of the study of the immune response to specific 
antigens, in different hosts.
7.7.2 B19 arthritis - possible mechanism for differing host response 
The association of RA with particular MHC antigens , for example 
DR4, suggests that it would be worth exploring the processing and 
presentation of antigen to T-cells by antigen processing/presenting 
cells of differing MHC phenotypes. Preliminary evidence in B19 
arthritis suggests that no particular MHC phenotype is associated 
with the development of arthritis, but its persistence may be 
associated with DR4 while DR1 appears to be protective12. Given the
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structural similarity between DR1 and some of the sub-types of 
DR4180, that dichotomy is surprising and would have to be confirmed 
by further work. Nevertheless it is known that for a given antigen, 
the different epitopes which are recognised by T-cells are determined
1 fi1by MHC antigens . It is possible therefore, that different B19 
antigenic epitopes are recognised according to the MHC phenotype in 
the host. These differences may influence the persistence of B19 
arthritis either by deficient elimination of the virus or by cross­
reactivity between particular B19 epitopes and self antigens.
The work now in progress is therefore examining T-lymphocyte in vitro 
proliferative responses to defined B19 antigens in a number of 
clinical groups of subjects: these are defined according to recent, 
distant or nil evidence of B19 infection (by presence or absence of 
specific anti-B19 IgG and IgM), the presence or absence of an acute 
arthritis (self-limiting or persistent), and the presence or absence 
of rheumatoid arthritis (classically defined). The results will then 
be viewed in the context of the subjects’ MHC phenotypes.
7.8 Concluding comments
In this study of patients with recent onset arthritis two main 
conclusions emerge, one pragmatic and related to clinical practice, 
and the other an hypothesis, that there is a new model for the study 
of pathogenetic mechanisms in RA.
The clinical studies reveal that at their very first visit to clinic, 
patients with recent onset polyarthritis can be assigned to either 
SLS or PS with only limited certainty. However within a further six 
weeks the certainty is greatly enhanced. This still means that at 
less than six months of disease duration we can identify those
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patients with serious, persistent disease who may benefit from early 
treatment. It may be that this opens an early therapeutic window, 
after disease onset but before "chronicity" is established, when it 
would be possible to alter the course of the disease.
The second important conclusion lies in the realisation that the 
phenomenon of SLS might serve as a human disease model for the study 
of rheumatoid arthritis. It may be hypothesised that in PS and SLS 
the triggers are the same but the difference in outcome is determined 
by the variation in host response. This hypothesis can be tested by 
further refining the model to suggest that infection with Human 
Parvovirus B19 offers the specific opportunity to investigate the 
molecular mechanisms of the MHC restriction of host immunity and 
possible autoimmunity. This may sharpen the advancing edge of our 
knowledge of man’s interaction with his environment through an immune 
system so sadly perturbed in people with rheumatoid arthritis.
APPENDIX
APPENDIX 1
EARLY ARTHRITIS CLINIC
PRELIMINARY SCREENING FORM 
(First Visit)
Survey No.
Date_____
Unit No__
NHS No
Telephone_____________
Sex
DOB
Occupation Now:
Past:
Presenting complaint
History
Name___
Address
Onset Date
Duration of disease at presentation 
Age
Type Hours =1 
Days -2 
Weeks =3
Pain Severity 0= nil 
1= slight 
2= moderate 
3= severe 
4= very severe
Stiffness 0= No 
1= Yes
EMS duration in minutes
Severity 0= nil 
1= slight 
2= moderate 
3= severe 
4= very severe
NAME 
DATE_____ B = stiff
^  = pain  
= swelling
□ □□
I
For the following 0= No
1= Yes
3= Don’t know
Swelling
Prodromos
Recent systemic illness 
Recent immunisation
Recent life event
Associated symptoms:
Red eyes 
Dry eyes 
Dry mouth 
Rash 
Backache 
GI upset 
Weight loss 
Other
Non-RA symptoms:
Mouth ulcers 
Genital ulcers 
Dysuria
Photosensitivity 
Psoriasis 
Muscle pain 
Muscle weakness 
Dysphagia 
Raynauds 
Other arthritis
Family history
Sexual history 
Past medical history
Drug history
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GENERAL EXAMINATION
General: Nodes [ ]
Nodules [ ]
Rash [ ]
Cardiovascular
Respiratory
Abdominal
Central Nervous
NAME
DATE
□  □□□□
□ □□ □
0/E
o = \y rom 
^  = pain
= swelling
aODDD
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METROLOGY
Ritchie: 0= No tenderness
1= Pain
2- Pain and winces
3= Pain, winces and withdraws
RIGHT LEFT
TMJ ____ ____
Neck ____
Thoraco/lumbar_______________________
Acromio-clavicular ____ ____
Sterno-clavicular__________ ____
Shoulder_______________ _______________________
Elbow ____ ___
Wrist ____ ____
MCP
PIP
DIP
Hip
Knee
Ankle
Subtalar
MTP
Total
No of inflammed joints
Grip strength: Right i) 
Left i)
ii)
ii)
iii)
iii)
IMPRESSION
Main diagnosis:
Concurrent conditions
PLAN
1) Investigation screen (see below)
2) Advice and simple analgesia
3) Review in 6 (?) weeks
4) Other
First visit screening investigations:
Haemoglobin
WBC
Platelets
ESR
RA Latex 
Rose Waaler 
ANA 
CRP
Store 10ml serum at -70°C
X-Ray if indicated: Hands
Wrists
CXR
Feet
Urinalysis:
197
Table Al.l Pattern of joint involvement
Jnt Varble No
SLS
Pos
PS
R Risk Conf-int Sens Spec Chi2 P
TMJ Pain 0 3 2.30 0.70-7.50 10 100 1.9 0.176
NECK Stiff 6 8 1.39 0.76-2.55 28 83 1.13 0.29
Pain 11 7 0.84 1.52-0.46 24 69 0.33 0.56
ROM 2 7 2.00 0.93-4.26 24 94 3.22 0.073
TND 3 5 1.48 0.50-4.38 17 92 0.50 0.48
SHDR Stiff 13 17 1.68 0.96-2.94 53 63 3.27 0.07
Pain 15 21 2.07 1.16-3.67 72 58 6.14 0.0132
ROM 2 11 2.43 1.42-4.15 38 94 10.52 0.0011
TND 5 13 2.12 1.24-3.61 45 86 7.67 0.0056
ELB Stiff 9 8 1.09 0.87-1.36 28 75 0.56 0.81
Pain 13 12 1.14 0.88-3.38 41 64 0.19 0.66
ROM 1 3 1.74 0.40-7.50 10 97 0.55 0.46
TND 2 2 1.14 0.88-4.90 7 94 0.09 0.76
WRST Stiff 18 13 0.89 1.55-0.51 45 50 0.17 0.67
Pain 23 20 1.12 0.66-1.89 69 36 0.18 0.67
Big 13 16 1.53 0.89-2.63 55 64 2.36 0.12
ROM 3 8 1.87 0.92-3.81 28 92 2.98 0.08
TND 7 13 1.80 1.06-3.04 45 81 4.86 0.0275
SWL 6 19 3.04 1.77-5.22 65 83 16.19 0.0001
MCP Stiff 22 20 1.23 0.66-2.27 69 39 0.43 0.51
Pain 26 17 0.72 1.26-0.41 59 28 1.33 0.25
Big 22 18 1.02 0.62-1.68 62 39 0.01 0.93
ROM 5 13 2.12 1.25-3.61 45 86 7.68 0.0056
TND 8 12 1.58 0.92-2.71 41 78 2.77 0.096
SWL 14 23 2.95 1.54-5.64 79 61 10.70 0.0011
PIP Stiff 22 17 0.96 1.42-0.64 59 39 0.04 0.84
Pain 21 13 0.73 1.29-0.41 45 42 1.17 0.28
Big 19 17 1.15 0.64-2.06 59 47 0.22 0.64
ROM 5 11 1.86 1.08-3.20 38 86 5.00 0.025
TND 6 9 1.50 0.84-2.68 31 83 1.87 0.17
SWL 11 20 2.46 1.39-4.36 69 69 9.50 0.002
DIP ANY 6 0 0.00 0.00-0.00 0 83 3.52 0.06
Back Pain 4 5 1.30 0.30-5.63 17 89 0.12 0.73
HIP Pain 6 3 0.67 0.15-2.95 9 83 0.28 0.60
Knee Stiff 18 19 1.42 0.82-2.45 65 50 1.58 0.21
Pain 22 24 2.00 0.51-4.08 83 39 3.64 0.056
Big 13 17 1.68 0.96-2.95 59 64 3.27 0.07
ROM 2 11 2.43 1.42-4.15 38 93 10.52 0.0012
TND 2 6 1.87 0.55-4.35 21 94 2.15 0.14
SWL 5 13 2.12 1.25-3.61 45 86 7.68 0.0056
Ankl Stiff 9 7 0.94 0.53-1.66 24 73 0.04 0.83
Pain 11 9 1.02 0.43-2.43 31 69 0.01 0.97
Big 10 14 1.57 0.93-2.64 48 72 2.90 0.09
SWL 3 8 1.87 0.92-3.81 28 92 2.98 0.084
MTP Stiff 5 8 1.52 0.83-2.76 28 86 1.88 0.17
Pain 9 15 1.82 1.07-3.09 52 75 4.92 0.0265
TND 4 10 1.92 1.09-3.36 34 55 5.19 0.0227
Univariate comparison of joint involvement patterns in SLS and PS
with those variables with p<0.05 being underlined. The abbreviations 
indicate the joint, variable, number of patients positive in each 
group, the relative risk (and its 95X confidence limits) for PS of a 
positive variable and the sensitivity and specificity for PS.
REFERENCES
199
1 Ropes MW, Bennet GA, Cobb S, Jacox R, Jessar RA. Revision of
diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 
1958; 9: 175-176.
2 Bennett PH, Burch TA. New York symposium on population studies in
the rheumatic diseases: new diagnostic criteria. Bull Rheum Dis 
1967; 17 (8 ): 453-455.
3 Short CL. The antiquity of rheumatoid arthritis. Arthritis Rheum
1974; 17 (3): 193-205.
3a Sydenham T. Medical observations concerning the history and cure
of acute diseases 1676, translated by RG Latham. London: The New 
Sydenham Society 1881: 185. Cited in Short CL 3.
3b Landre-Beauvais AJ. Should we recognise a new type of gout, to be 
called primary asthenic gout? Thesis 1800, cited and translated 
in part in Short CL 3.
4 Garrod AB. The nature and treatment of gout and rheumatic gout.
London: Walton and Maberly, 1859.
5 Short CL, Bauer W, Reynolds WE. Rheumatoid arthritis. Cambridge,
Mass: Harvard University Press, 1957.
6 Brewerton DA, Caffrey M, Hart FD, James DCO, Nicholls A, Sturrock
RD. Ankylosing spondylitis and HL-A B27. Lancet 1973; 904-907.
7 Stastny P. Rheumatoid arthritis: joint report. In
Histocompatibility testing 1980. Terasaki PI, ed. Los Angeles,
Ca: UCLA tissue typing laboratories, 1980; 681-686.
8 O ’Sullivan JB, Cathcart ES. The prevalence of rheumatoid
arthritis: follow-up evaluation of the effect of criteria on 
rates in Sudbury, Massachusetts. Ann Int Med 1972; 76: 573-577.
9 Fourie ED, Morrison JGL. Rheumatoid arthritic syndrome after
chikungunya fever. SA Med J 1979; 56: 130-132.
10 Walker DR. A clinical and laboratory study of patients with
chronic arthritis following infection with chikungunya and other 
arboviruses. B Med Sci Thesis, University of Newcastle-upon-Tyne, 
1986.
11 Woolf AD, Campion G, Chishick A, Wise S, Cohen BJ, Dieppe PA. An
epidemiological study of human parvovirus infection on adults. 
Brit J Rheumatol 1986; 25 (Abs 1): 2.
12 Woolf AD, Campion GV, Klouda P, Chishick A, Cohen B, Dieppe PA.
HLA and the clinical manifestations of human parvovirus 
infection. Brit J Rheumatol 1986; 25 (Abs 2): 35.
200
13 Grahame R, Armstrong M, Simmons N, Wilton JMA, Dyson M, Laurent R,
Millis R, Mims CA. Chronic arthritis associated with the presence 
of intrasynovial Rubella virus. Ann Rheum Dis 1983; 42: 2-13.
14 Tingle AJ, Allen M, Petty RE, Kettyls GD, Chantler JK. Rubella
associated arthritis. 1 Comparative study of joint manifestations 
associated with natural Rubella infection and RA 27/3 Rubella 
immunisation. Ann Rheum Dis 1986; 45: 110-114.
15 Chantler JK, Ford DK, Tingle AJ. Persistent Rubella infection and
Rubella associated arthritis. Lancet 1982; 1: 1323-1325.
16 Martensis TW, Bland JH, Phillips CA. Rheumatoid arthritis after
Rubella. Arthritis Rheum 1968; 11 (5): 683-687.
17 McCormick JN, Duthie JJR, Gerber H, Hart H, Baker S, Marmion BP.
Rheumatoid polyarthritis after Rubella. Ann Rheum Dis 1978; 37:
266-72.
18 Tingle AJ, Yang T, Allen M, Kettyls GD, Larke RPB, Schulzer M.
Prospective immunological assessment of arthritis induced by 
Rubella vaccine. Infect Immun 1983; 40, (1): 22-28.
19 Rawls W. Congenital Rubella: the significance of virus
persistence. Prog Med Virol 1968; 10: 238-85.
20 Hart H, Marmion BP. Rubella virus and rheumatoid arthritis. Ann
Rheum Dis 1977; 36: 3-12.
21 McGuire TC, Adams DS, Johnson GC, Kievjer-Anderson P, Barbee DD,
Gorham JR. Acute arthritis in Caprine Arthritis Encephalitis 
Virus challenge exposure of vaccinated or persistently infected 
goats. Am J Vet Res 1986; 47, (3): 537-540.
22 Singh VK, Tingle AJ, Schulzer M. Rubella associated arthritis. 2
Relationship between circulating immune complex levels and joint 
manifestations. Ann Rhuem Dis 1986; 45: 115-119.
23 Chantler JK, Da Roza DM, Bonnie ME, Reid GD, Ford DK. Sequential
studues on synovial lymphocyte stimulation by Rubella antigen and 
Rubella virus isolation in an adult with persistent arthritis.
Ann Rheum Dis 1985; 564-568.
24 Ford DK, Da Roza DM. Observations on the responses of synovial
lymphocytes to viral antigens in rheumatoid arthritis and 
Reiter’s syndrome. J Rheumatol 1983; 10: 643-646.
25 Ford DK, Da Roza DM. Further observations on the respones of
synovial lymphocytes to viral antigens in rheumatoid arthritis. J 
Rheumatol 1986; 13: 113-117.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
201
Phillips PE. Editorial: Lymphocyte responses to viral antigens in 
rheumatoid arthritis. J Rheumatol 1986; 13 (1): 6-8 .
Hildebrant HM, Maasab HF. Rubella synovitis in a one year old 
patient. N Eng J Med 1966; 274: 1428-30.
Weibel RE, Stokes J, Bunyak EB, Hilleman MR. Rubella vaccination 
in adult females. N Eng J Med 1969; 280: 682-685.
Fraser JRE, Cunningham AL, Hayes K, Leach R, Lunt R. Rubella 
arthritis in adults. Isolation of virus,. cytology and other 
aspects of the synovial reaction. Clin Exp Rheumatol 1983; 1: 
287-293.
Robinson M. An epidemic of virus disease in South Province 
Tanganyika territory in 1952-53. General description and 
epidemiology. Trans Royal Soc Trop Med Hyg 1955; 49: 33-57.
Brighton SW, Prozesky OW, De La Harpe AL. Chikungunya virus 
infection: retrospective study of 107 cases. S Afr Med J 1983;
63: 313-315.
Kennedy AC, Fleming J, Solomon L. Chikungunya viral arthropathy: a 
clinical description. J Rheumatol 1980; 7 (2): 231-236.
Anderson MJ, Jones SE, Minson AC. Diagnosis of human parvovirus 
infection by dot-blot hybridisation using cloned viral DNA. J Med 
Virol 1985; 15: 163-172.
Clewley JP. Detection of Human Parvovirus using a molecularly 
cloned probe. J Med Virol 1985; 15: 173-181.
Shade RO, Blundell MC, Cotmore SF, Tattersail P, Astell CR. 
Nucleotide sequence and genome organisation of human parvovirus 
B19 isolated from the serum of a child during aplastic crisis. J 
Virol 1986; 58 (3): 921-936.
Anderson MJ, Pattison JR. The human parvovirus: brief review. Arch 
Virol 1984; 82: 137-148.
Kurtzman G, Ozawa K, Cohen B, Hanson G, Oseas R, Young N. Chronic 
bone marrow failure due to persistent B19 Parvovirus infection. N 
Eng J Med 1987; 317: 287-294.
Dijkmans BAC, van Elsacker-Niele AMW, Salimans MMM, van Albada- 
Kuipers GA, de Vries E, Welland HT. Human Parvovirus B19 DNA in 
synovial fluid. Arth Rheum 1988; 31: 297-281.
Ozawa K, Kurtzman G, Young N. Replication of the B19 Parvovirus in 
human bone marrow cell cultures. Science 1986; 233:883-6.
202
40 Seigl G. Biology and pathogenicity of autonomous Parvoviruses. In:
Berns KI, ed. The Parvoviruses.New York: Plenum Press, 1984; 297- 
362.
41 Ager EA, Chin TDY, Poland JD. Epidemic erythema infectiosum. N Eng
J Med 1966; 275; 1326-1331.
42 White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Bacon PA.
Human parvovirus arthropathy. Lancet 1985; 1: 419-421.
43 Reid DM, Reid TMS, Brown T, Rennie JAN, Eastmond CJ. Human
parvovirus associated arthritis: a clinical and laboratory 
description. Lancet 1985; 1: 422-425.
44 Cohen BJ, Buckley MM, Clewley JP, Jones VE, Puttick AH, Jacoby RK.
Human Parvovirus infection in early rheumatoid arthritis and 
inflammatory arthritis. Ann Rheum Dis 1986; 45: 832-8.
46 Unsworth J, Sturman S, Lunec J, Blake DR. Renal impairment
associated with non-steroidal anti-inflammatory drugs. Ann Rheum 
Dis 1987; 46: 233-236.
47 McConkey B, Crockson RA, Crockson AP, Wilkinson AR. The effects of
some anti-inflammatory drugs on the acute-phase proteins in 
rheumatoid arthritis. Q J Med 1973; 42: 785-791.
48 Dixon JS, Pickup ME, Lowe JR, Hallett C, Lee MR, Wright V.
Discriminatory indices of response of patients with rheumatoid 
arthritis treated with D-penicillamine. Ann Rheum Dis 1980; 39: 
301-311.
49 Grindulis KA, McConkey B. Outcome of attempts to treat rheumatoid
arthritis with gold, penicillamine, sulphasalazine, or dapsone. 
Ann Rheum Dis 1984; 43: 398-401.
50 Burton KE, Wright V. Functional assessment. Brit J Rheumatol 1983:
22(S): 44-47.
51 Scott DL. Penicillamine. In: Goddard D, Butler R. Rheumatoid
arthritis, the treatment controversy. London: Macmillan, 1984; 
37-55.
52 Brook A, Corbett M. Radiographic changes in early rheumatoid
disease. Ann Rheum Dis 1977; 36: 71-73.
53 Amos RS, Constable TJ, Crockson AP, McConkey B. Rheumatoid
arthritis: relation of serum C-reactive protein and erythrocyte 
sedimentation rates to radiographic changes. Brit Med J 1977; 1: 
195-197.
203
54 Carson DA. Rheumatoid factor. In: Kelly WN, Harris ED, Ruddy S,
Sledge CB, eds. Textbook of Rheumatology, 2nd edition. 
Philadelphia: WB Saunders, 1985; 664-679.
55 Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism
Associtation 1987 revised criteria for the classification of 
rheumatoid arthritis 1988; 31: 315-324.
56 Duthie JJR, Brown PE, Truelove LH, Baragar FD, Lawrie AJ. Course
and prognosis in rheumatoid arthritis: a further report. Ann 
Rheum Dis 1964; 23: 193-202.
57 Ragan C, Farrington E. The clinical features of rheumatoid
arthritis: prognostic indices. JAMA 1962; 181 (8): 663-667.
58 Jacoby RK, Jayson MIV, Cosh JA. Onset, early stages, and prognosis
of rheumatoid arthritis: a clinical study of 100 patients with 
11-year follow-up. Brit Med J 1973; 2: 96-100.
59 Fleming A, Crown JM, Corbett M. Prognostic value of early features
in rheumatoid disease. Brit Med J 1976; 1: 1243-1245.
60 Luukkainen R, Kaarela K, Isomaki H, Martio J, Kiviniemi P, Rasanen
J, Sarna S. The prediction of radiological destruction during the 
early stage of rheumatoid arthritis. Clin Exp Rheumatol 1983; 1: 
295-298.
61 Otten HA, Boerma FW. Significance of the Waaler-Rose test,
streptococcal agglutination, and antistreptolysin titre in the 
prognosis of rheumatoid arthritis. Ann Rheum Dis 1959; 18: 24-28.
62 Woolf AD, Hall ND, Kantharia B, Maymo J, Goulding NJ, Maddison PJ.
Predictors of 5 year outcome of early synovitis. Brit J Rheumatol 
1986; 25, Abs 2: 24.
63 Grey HM, Chestnut R. Antigen processing and presentation to T-
cells. Immunol Today 1985; 6 : 101-106.
64 Bacon PA, Sewell RL, Crowther D. Reactive lymphoid cells
("immunoblasts") in autoimmune and haematological disorders. Clin 
Exp Immunol 1975; 19: 201-208.
65 Meriard HA, Hairn T, Peltier AP. In vitro studies on peripheral
blood leucocytes in rheumatoid arthritis. Ann Rheum Dis 1974; 33: 
361-5.
66 Carter SD, Bacon PA, Hall ND. Characterisation of activated
lymphocytes in the peripheral blood of patients with rheumatoid 
arthritis. Ann Rheum Dis 1981; 40: 293-8.
204
67 Janossy G, Panayi G, Duke 0, Bofil M, Poulter L, Goldstein G.
Rheumatoid arthritis: a disease of T-lymphocyte - macrophage 
immunoregulation. Lancet 1981; 2: 839-42.
68 Paulus HE, Machleder HI, Levine S, Yu DTY, Macdonald NS.
Lymphocyte involvement in rheumatoid arthritis. Arth Rheum 1977; 
20: 1249-1262.
69 Karsh J, Klippel JH, Plotz PH, Decker JL, Wright DG, Flye MW.
Lymphophoresis in rheumatoid arthritis. Arthritis Rheum 1981; 24: 
867-873.
70 Bacon PA, Salmon M, Blann AD, Scott DGI, Farr M. Lymphocyte
subpopulations and NSAID: methodological aspects. Inflammation 
1984; 8 (S): 81.
71 Larrick JY, Cresswell P. Transferrin receptors on human B and T
lymphoblastoid cell lines. Biochim Biophys Acta 1979; 583: 483- 
490.
72 Galbraith GMP, Goust JM, Mercurio SM, Galbraith RM. Transferrin
binding by mitogen stimulated human peripheral blood lymphocytes. 
Clin Immunol Immunopathol 1980; 16: 387-395.
73 Page Faulk W, Hsi B-L, Stevens PJ. Transferrin and transferrin
receptors in carcinoma of the breast. Lancet 1980; 2: 390-2.
74 Hamilton TA. Regulation of transferrin receptor expression in
concanavalin A stimulated and gross virus transformed rat 
lymphocytes. J Cell Physiol 1982; 113: 40-6.
75 Sutherland R, Delia D, Schneider C, Newman R, Kemshead R, Greaves
M. Ubiquitous cell surface glycoprotein on tumour cells is 
proliferation associated receptor for transferrin. Proc Natn Acad 
Sci USA 1981; 78: 4515.
76 Salmon M, Bacon PA, Symmons DPM, Walton KW. Transferrin receptor
expression by stimulated cells in mixed lymphocyte culture. 
Immunology 1985; 54: 559-64.
77 Salmon M, Bacon PA, Symmons DPM, Blann AD. Transferrin receptor
bearing cells in the peripheral blood of patients with rheumatoid 
arthritis. Clin Exp Immunol 1985; 62: 346-352.
78 Salmon M. Transferrin receptor bearing cells in rheumatoid
arthritis and an in vitro model of lymphocyte activation. PhD 
Thesis. University of Birmingham 1986.
79 Reinherz EL, O ’Brien C, Rosenthal P, Schlossman SF. The cellular
basis for viral induced immunodeficiency: analysis of monoclonal 
antibodies. J Immunol 1980; 125: 1269-74.
80
81
82
83
84
85
86
87
88
89
90
91
92
205
Waaler E. A factor in human serum activating the specific 
agglutination of sheep blood corpuscles. Third International 
Congress for microbiology, New York. Abstracts of communications. 
1939; 351.
Waaler E. On the occurrence of a factor in human serum activating 
the specific agglutination of sheep blood corpuscles. Acta Path 
Microbiol Scand 1940; 17: 172-178.
Rose HM, Ragan C, Pearce E, Lipman MO. Differential agglutination 
of normal and sensitised sheep erythrocytes by sera of patients 
with RA. Proc Soc Exp Biol Med 1948; 68: 1-6.
Pike RM, Sulkin SE, Coggeshall HC. Serological reactions in RA II. 
Concerning the nature of the factor in RA serum responsible for 
increased agglutination of sensitised sheep erythrocytes. J 
Immunol 1949; 63: 447-463.
Franklin EC, Holman HR, Muller-Eberhard HJ, Kunkel HG.
Differential agglutination of normal and sensitised sheep 
erythrocytes by sera of patients with RA. J Exp Med 1957; 105: 
425-438.
Torrigiani G, Roitt IM. Antiglobulin factors in sera from patients 
with rheumatoid arthritis and normal subjects. Quantitative 
estimation in different immunoglobulin classes. Ann Rheum Dis 
1967; 26: 334-340.
Johnson PM, Faulk WP. Rheumatoid factor: its nature, specificity 
and production in RA. Clin Immunol Immunopath 1976; 6 : 414-430.
Kunkel HG, Muller-Ebhard HJ, Fudenberg H, Tomasi TB. Gamma 
globulin complexes in rheumatoid arthritis and certain other 
conditions. J Clin Invest 1961; 40: 117-129.
Zvaifler NJ. The immunopathology of joint inflammation in 
rheumatoid arthritis. Adv Immunol 1973; 13: 265-336.
Kunkel HG, Ponsett DN, Pernis B. Anti-immunoglobulins and their 
idiotypes: are they part of the immune network? NY Acad Sci 1983; 
418: 324-329.
Kabat EA, Wu TT, Bilofsky H. Variable regions of immunoglobulin 
chains. Tabulations and analyses of amino acid sequence. Bethesda 
Md, National Institutes of Health 1976.
Metzger H. Structure and function of gamma-M macroglobulins. Adv 
Immunol 1970; 12: 57-116.
Kunkel HG, Agnello V, Joslin FG, Winchester RJ, Capra JD. Cross 
idiotypic specificity among monoclonal IgM proteins with anti- 
gamma-globulin activity. J Exp Med 1973; 137: 331-342.
206
93 Powell R, Agnello V. Characterisation of complement-fixing
activity of rheumatoid factors in idiopathic mixed 
cryoglobulinaemia. Clin Immunol Immunopathol 1983; 29: 146-151.
94 Capra JD, Kehoe JM. Structure of antibodies with shared idiotypy:
the complete sequence of the heavy chain variable region of two 
immunoglobulin M antigamma globulins. Proc Natl Acad Sci USA 
1974; 71; 4032-4036.
95 Egeland T, Munthe E. Rheumatoid factors. Clin Rheum Dis 1983; 9
(1): 135-160.
96 Grubb R. Agglutination of erythrocytes coated with ’incomplete’
anti-Rh by certain RA sera and some other sera. The existence of 
human serum groups. Acta Path Microbiol Scand 1956; 39: 195-197.
97 Waller MV, Vaughan JH. Use of anti-Rh sera for demonstrating
agglutination activating factor in rheumatoid arthritis. Proc Soc 
Exp Biol 1956; 92: 198-200.
98 Harboe M. Relation between Gm types and haemagglutinating
substances in rheumatoid sera. Acta Path Microbiol Scand 1960;
50: 89-105.
99 Allen JC, Kunkel HG. Hidden rheumatoid factors with specificity
for native gamma globulin. Arth Rheum 1966; 9: 758.
100 Gaarder PI, Michaelsen TE. Specificity of RF cross reacting with
human and rabbit IgG. Acta Path Microbiol Scand 1974; 82B: 733- 
741.
101 Gaarder PI, Natvig JB. Hidden RF reacting with ’non a ’ and other
antigens of native autologous IgG. J Immunol 1970; 105: 928-937.
102 Jefferis R, Nik Jaafar MI, Steinitz M. Immunogenic and antigenic
epitopes of immunoglobulins. VIII. A human monoclonal rheumatoid 
factor having specificity for a discontinuous epitope determined 
by histidine/arginine interchange as residue 435 of 
immunoglobulin G. Immunology Letters 1984; 7: 191-194.
103 Henriksen T, Melo TB, Saxebol G. Free radical formation in
proteins and protection from radiation damage. In: Free Radicals 
in Biology, Vol 2. Pryor WA, ed. New York: Academic Press 1976; 
213-256.
104 Wickens DG, Graff TL, Lunec J, Dormandy TL. Free radical mediated
aggregation of human gamma globulin. Agents Actions 1981; 11: 6- 
7.
207
105 Wickens DG, Norden AG, Lunec J, Dormandy TL. Fluorescence changes
in human gamma globulin induced by free radical activity. Biochim 
Biophys Acta 1983; 742: 607-616.
106 Lunec J, Brailsford S, Hewitt SD, Morris CJ, Blake DR. Free
radicals: are they possible mediators of IgG denaturation and 
immune complex formation in RA? Int J Immunotherapy 1987; 3 (1): 
39-43.
107 Lunec J, Blake DR, McCleary SJ, Brailsford S, Bacon PA. Self-
perpetuating mechanisms of immunoglobulin G aggregation in
rheumatoid inflammation. J Clin Invest 1985; 76 (6): 2084-2090.
108 Jose SA, Lunec J, Mageed RA, Griffiths H, Jefferis R. Immunogenic
and antigenic epitopes of immunoglobulin XX. Denaturation of 
human IgG3 by free radicals. Mol Immunol 1987; 24: 1145-50.
109 Robbins DL, Benisek WF, Benjamini E, Wistar R. Differential
reactivity of rheumatoid synovial cells and serum rheumatoid 
factors to human immunoglobulin G subclasses 1 and 3 and their 
CH3 domains in rheumatoid arthritis. Arth Rheum 1987; 30 (5): 
489-497.
110 Weiss SJ, Ward PA. Immune complex induced generation of oxygen
metabolites by human neutrophils. J Immunol 1982; 129: 309-13.
111 Johnston RB, Lehmeyer JE. Elaboration of toxic oxygen byproducts
of neutrophils in model of human immune complex disease. J Clin 
Invest 1976; 57: 836-41.
112 Ritchie DM, Boyle JA, Mclnnes JM, Jasani MK, Dalakos TG, Grieveson
P, Buchanan WW. Clinical studies with an articular index for the 
assessment of joint tenderness in patients with rheumatoid 
arthritis. QJ Med 1968; 37: 393-406.
113 Janus 0. Objective assessment of improvement in rheumatoid
arthritis. Brit Med J 1950; 2: 1244-1249.
114 Coulter S+, Coulter Electronics, Luton, Beds.
115 International committee for standardisation in haematology.
Recommendation for measurement of Erythrocyte Sedimentation Rate 
of human blood. Am J Clin Path 1977; 68: 505-7.
116 Johnson GD, Darling J. Immunofluorescence and peroxidase
techniques. In: Thompson RA, Ed. Techniques in clinical 
immunology. 2nd ed. Oxford, Blackwell, 1981; 106-137.
117
118
119
120
121
122
123
124
125
126
127
128
208
Milford-Ward A. Iiranunoprecipitation in the evaluation of proteins 
in plasma and body fluids. In: Thompson RA, Ed. Techniques in 
clinical immunology. 2nd ed. Oxford, Blackwell, 1981; 1-27.
Bird GWG, Wingham J. Agglutination and agglutination inhibition. 
In: Thompson RA (Ed). Techniques in clinical immunology. Oxford: 
Blackwell 1981; 52-74.
Boyum A. Separation of leucocytes from blood and bone marrow. IV: 
isolation of mononuclear cells and granulocytes from human blood. 
Scand J Clin Lab Invest 1968; 21 (S97): 77.
Huang W-M, Gibson SJ, Facer P, Gu J, Polak JM. Improved section 
adhesion for iochemistry using high molecular wieght polymers of 
L-lysine as a slide coating. Histochemistry 1984; 77: 275-9.
Beverly PCL, Callard RE. Distinctive functional characteristics of 
human *T’ lymphocytes defined by E resetting and monoclonal anti- 
T cell antibody. Eur J Immunol 1981; 11: 329-334.
Reinhertz EL, Kung PC, Goldstein G, Schlossmann SE. J Immunol 
1979; 123: 2894.
Reinhertz EL, Kung PC, Goldstein G, Schlossmann SE. A monoclonal 
antibody reactive with the human cytotoxic/suppressor T cell 
subset previously defined by a heteroantiserum termed TH 2. J 
Immunol 1980; 124: 1301-7.
Johnson GD, Nogueira Araujo GM de C. A simple method of reducing 
the fading of immunoflourescenee during microscopy. J Immunol 
Meth 1981; 43: 349-50.
Mageed RA, Dearlove M, Goodall DM, Jefferis R. Immunogenic and 
antigenic epitopes of immunoglobulins XVII - Monoclonal 
antibodies reactive with common and restricted idiotopes to the 
heavy chain of diuman rheumatoid factors. Rheumatol Int 1986; 6: 
179-183.
Carson DA, Fong S. A common idiotope on human rheumatoid factors 
identified by a hybridoma antibody. Mol Immunol 1983; 1081-7.
Mageed RA, Walker MR, Jefferis R. Restricted light chain subgroup 
expression on human rheumatoid factor paraproteins determined by 
monoclonal antibodies. Immunology 1986; 59: 473-478.
Mageed RAK, Goodall DM, Jefferis R. Immunogenic and antigenic 
epitopes of immunoglobulins: A highly conserved conformational 
idiotope on human rheumatoid factor paraproteins of the Wa cross­
reactive idiotype family defined by a monoclonal antibody. 
Rheumatol Int, In Press.
129
130
131
132
133
134
135
136
137
138
139
140
141
209
March RE, Santana R, Stierle HE, Holborow EJ. Rheumatoid factors 
induced by Epstein-Barr virus have different properties from 
those detected in serum. Clin Rheumatol 1983; 2(1): 102.
Steinitz M, Tamir S. Human monoclonal autoimmune antibody produced 
in vitro: rheumatoid factor generated by Epstein-Barr virus- 
transformed cell line. Eur J Immunol 1982;.12: 126-133.
Mortimer PP, Tedder RS, Hambling MH, Shafi MS, Burkhardt U Schilt. 
Antibody capture radio-immunoassay for anti-Rubella IgM. J Hyg 
Camb 1981; 86: 139-153.
Cohen BJ, Mortimer PP, Pereira MS. Diagnostic assays with 
monoclonal antibody for the human serum parvovirus-like virus 
(SPLV). J Hyg Camb 1983; 91: 113-130.
dBase III Plus, copyright Ashton Tate (UK) Ltd, Maidenhead, 1985 
and 1986.
Statgraphics: statistical graphics system, handbook. STSC inc, 
Rockville, Md, USA 1986
Hennekens CH, Buring JE. Analysis of epidemiologic studies: 
evaluating the role of chance. In: Mayrent SL (Ed). Epidemiology 
in medicine,. Boston: Little Brown and Co. 1987; 243-258.
Ferguson GA. Statistical analysis in psychology and education. 5th 
edition. McGraw-Hill 1981; 214.
Hennekens CH, Buring JE. Relative risk. In: Mayrent SL (Ed). 
Epidemiology in medicine,. Boston: Little Brown and Co. 1987; 77- 
82.
Mann HB, Whitney DR. On a test of whether one of two random 
variables is stochastically larger than the other. Ann 
Mathematical Statistics 1947; 18: 50-60..
Ferguson GA. Statistical analysis in psychology and education. 5th 
edition. McGraw-Hill 1981; 107-118.
Fiegenbaum SL, Masi AT, Kaplan SB. Prognosis in rheumatoid 
arthritis. A longitudinal study of newly diagnosed younger adult 
patients. Am J Med 1979; 66: 377-384.
Silverman GJ, Goldfien RD, Chen P, Magged R, Jefferis R, Goni F, 
Frangione B, Fong S, Carson DA. Idiotypic and subgroup analysis 
of human monoclonal rheumatoid factors: Implications for 
structural and genetic basis of autoantibodies in humans. J Clin 
Invest 1988; 82; 469-75.
210
142 Radoux V, Chen PP, Sorge JA, Carson DA. A conserved human germline
VK gene directly encodes RF light chains. J Exp Med 1986; 164: 
2119-2124.
143 Chen PP, Albrant K, Kipps TJ, Radoux V, Liu FT, Carson DA.
Isolation and characterisation of human VKIII germline genes. J 
Immunol 1987; 139: 1727-1733.
144 Cunningham-Rundles C, Cheung MKL. Cross-reactive idiotypes in
human sera. Immunol Today 1985; 6: 14-17.
145 Rajewski K, Takemori T. Genetics, expression and function of
idiotypes. Ann Rev Immunol 1983; 1: 569-607.
146 Alexander G, Williams R. Antiviral treatment in chronic infection
with hepatitis B virus. Brit Med J 1986; 292: 915-917.
147 Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA,
Arnheim N. Enzymatic amplification of beta-globin genomic 
sequences and restriction site analysis for diagnosis of sickle 
cell anaemia. Science 1985; 230: 1350-4.
148 Dinarello CA. Interleukin-1 and the pathogenesis of the acute
phase response. N Eng J Med 1984; 311: 1413-8.
149 Dinarello CA, Mier JW. Current concepts: lymphokines. N Eng J Med
1987; 940-5.
150 Marinkovic S, Jahreis GP, Wong GG, Baumann H. IL-6 modulates the
synthesis of a specific set of acute phase plasma proteins in 
vivo. J Immunol 1989; 142: 808-812.
151 Van Snick J, Van Roost E, Marcowitz B, Cambiaso CL, Masson PL.
Enhancement by IgM rheumatoid factor of in vitro ingestion by 
macrophages and in vivo clearance of aggregated IgG or antigen- 
antibody complexes. Eur J Immunol 1978; 8: 279-85.
152 Hayakawa K, Hardy RR, Honda M, Herzenberg LA, Steinberg AD. Ly-1
B-cells: functionally distinct lymphocytes that secrete IgM 
autoantibodies. Proc Natl Acad Sci 1984; 81: 2494-7.
153 Hardy RR, Hayakawa K, Shimizu M, Yamasaki K, Kishimoto T.
Rheumatoid factor secretion from human leu-l+ B cells. Science 
1987; 236: 81-3.
154 Casali P, Burastero SE, Nakamura M, Inghirami G, Notkins AL. Human
lymphocytes making rheumatoid factor and antibody to ssDNA belong 
to Leu-1+ B-cell subset. Science 1987; 236: 77-80.
211
155 Playter-Zyberk C, Maini RN, Lam K, Kennedy TD, Jannossy G. A
rheumatoid arthritis B cell subset expresses a phenotype similar 
to that in chronic lymphocytic leukemia. Arthritis Rheum 1985;
28: 971-6.
156 Hayakawa K, Hardy RR. Normal, autoimmune, and malignant CD5+ B
cells: the Ly-1 B lineage? Ann Rev Immunol 1988; 6: 197-218.
157 Portanova JP, Arndt RE, Kotzin BL. Selective production of
autoantibodies in GVH and spontaneous murine lupus. J Immunol 
1988; 140: 755-60.
158 Schlomchik MJ, Rothstein A, Wolfwicz CB, Rothstein TJ, Weigert MG.
The role of clonal selection and somatic mutation in 
autoimmunity. Nature 1987; 328: 805-11.
159 Shlomchik MJ, Aucoin AH, Pisetsky DS, Weigert MG. Structure and
function of anti-DNA autoantibodies derived from single 
autoimmune mouse. Proc Ntl Acad Sci 1987; 84: 9150-4.
160 Jerne NK. Idiotypic networks and other preconceived ideas. Immunol
Rev 1984; 79: 5-25.
161 Davidson A, Shefner R, Livneh A, Diamond B. The role of somatic
mutation of immunoglobulin genes in autoimmunity. Ann Rev Immunol 
1987; 5: 85-108.
162 Allen D,' Cumano A, Dildrop R, Kocks C, Rajewsky K, Rajewsky N,
Roes J, Sablitzky F, Siekevitz M. Timing, genetic requirements 
and functional consequences of somatic mutation during B-cell 
development. Immunol Rev 1987; 96: 5-22.
163 Carson DA, Chen PP, Fox RI, Kipps TJ, Jirik F, Goldfien RD,
Silverman G, Radoux V, Fong S. Rheumatoid factor and immune 
networks. Ann Rev Immunol 1987; 5: 109-126.
164 McKean D, Huppi K, Bell M, Staudt L, Gerhard W, Weigert M.
Generation of antibody diversity in the immune response of BALB/c 
mice to influenza virus haemagglutinin. Proc Natl Acad Sci USA 
1984; 81: 3180-4.
165 Rudikoff S, Pawlita M, Pumphrey J, Heller M. Somatic
diversification of immunoglobulins. Proc Natl Acad Sci USA 1984; 
81: 2162-2166.
166 Kishimoto T, Hirano T. Molecular regulation of B lymphocyte
response. Ann Rev Immunol 1988; 6: 485-512.
167 Splawski JB, Jelinek DF, Lipsky PE. Immunomodulatory role of IL-4
on the secretion of Ig by human B cells. J Immunol 1989; 142: 
1569-1575.
168
169
170
171
172
173
174
175
176
177
178
179
180
212
Sherris D, Stohl W, Mayer L. Characterization of lymphokines 
mediating B cell growth and differentiation from monoclonal anti- 
CD3 antibody stimulated cells. J Immunol 1989; 142: 2343-2351.
Mori J, Beattie P, Melton DW, Cohen BJ, Clewley JP. Structure and 
mapping of the DNA of human parvovirus B19. J Gen Virol 1987; 68: 
2797-2806.
Saiki RK, Bugwan TC, Horn GT, Mullis KB, Erlich HA. Analysis of 
enzymatically amplified beta-globin and HLA-DQ alpha DNA with 
allele-specific oligonucleotide probes. Nature 1986; 324: 163- 
166.
Todd JA, Bell JI, McDevitt HO. HLA-DQ beta gene contributes to 
susceptibility and resistance to insulin-dependent diabetes 
mellitus. Nature 1987; 329: 599-604.
Holoshitz J, Naparstek Y, Ben-Nun A, Cohen IR. Lines of T- 
lymphocytes induce or vaccinate against autoimmune arthritis. 
Science 1983; 219: 56-8.
Terasaki PI. Rheumatoid arthritis: Joint report. In: 
Histocompatibility testing 1980. UCLA tissue typing laboratories. 
Los Angeles, Ca. 1980; 681-686.
Denman AM. Viral aetiology of arthritis. Reports on rheumatic 
diseases 1987; 2: 7.
Rothbard J. Synthetic peptides as vaccines. Nature 1987; 330: 106- 
7.
Bodmer HC, Pemberton RM, Rothbard JB, Askonas RA. Enhanced 
recognition of a modified peptide antigen by cytotoxic T-cells 
specific for influenza nucleoprotein. Cell 1988; 52: 253-8.
Sisk WP, Berman ML. Expression of Human Parvovirus B19 structural 
protein in E Coli and detection of anti-viral antibody in human 
serum. Bio/technology 1987; 5: 1077-80.
Ozawa K, Ayub J, Yu-Shu H, Kurtzman G, Shimada T, Young N. Novel 
transcription map for the B19 (human) pathogenic Parvovirus. J 
Virol 1987; 61: 2395-2406.
Rothbard JB, Townsend A, Edwards M, Taylor W. Pattern recognition 
among T-cell epitopes. Hamatol Bluttransfus 1987; 31: 324-31.
Lanchbury JSS. Molecular genetics of the HLA-D region component of 
inherited susceptibility to rheumatoid arthritis. Brit J 
Rheumatol 1988; 27: 171-5.
213
181 Guillet JG, Lai MZ, Briner TJ, Smith JA, Gefter ML. Interactions 
of peptide antigens and Class II MHC antigens. Nature 1986; 324: 
260-2.
\ GLASGOW | 
1 UNIVERSITY f
' wlBRARY |
